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I List of abbreviations 
 
 
∆ deletion, difference 
1-DE one-dimensional gel electrophoresis 
2-DE two-dimensional gel electrophoresis 
Å Ångstrøm 
aa amino acid 
ABP actin-binding protein 
AC adenylate cyclase 
Acc.Nr. UniProtKB/ Swiss-Prot accession number 
Amp ampicillin 
BCA bicinchoninic acid 
bp base pair 
BSA bovine serum albumin 
[Ca2+]i intracellular calcium concentration 
CaM calmodulin 
CC coiled-coil motif 
cE final concentration 
CH calponin homology domain 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHL chloramphenicol 
CID collision-induced dissociation 
(Co-)IP (co-)immunoprecipitation 
CRAC calcium release-activated calcium channel 
CRP C-reactive protein 
Ctrl control (affinity column) 
CV column volume, bed volume 
Da Dalton = 1 amu (atomic mass unit) 
DAG diacylglycerol 
DMEM Dulbecco's modified Eagle's medium 
DMSO dimethyl sulfoxide 
(D)PBS (Dulbecco's) phosphate buffered saline 
DTS dense tubular system 
DTT dithiothreitol 
EDTA ethylenedinitrilo-tetraacetic acid disodium dihydrate 
ER endoplasmic reticulum 
ESI electrospray ionization 
EVH Ena/ VASP homology domain 
FA formic acid 
FAB F-actin binding region 
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FCS fetal calf serum 
FDR false discovery rate 
FPLC fast protein liquid chromatography 
FTICR Fourier-transform ion cyclotron resonance 
GAB G-actin binding region 
GP glycoprotein 
GPCR G-protein-coupled receptor 
GST glutathione-S-transferase 
HA hemagglutinin 
HEK293 immortalized human embryonic kidney cells 
HEPES N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 
hIP STIM1-specific Co-IP in human platelets 
HPLC high-performance liquid chromatography 
HRP horseradish peroxidase 
IAA iodoacetamide 
ID identification 
IEC ion exchange chromatography 
IEF isoelectric focussing 
Ig(G) immunoglobulin (G) 
IMAC immobilized metal ion affinity chromatography 
IP3 inositol 1,4,5-trisphosphate 
IPTG isopropyl β-D-1-thiogalactopyranoside 
LB medium lysogeny broth medium 
LC liquid chromatography 
LC-ESI-MS online-coupled LC- and ESI-MS systems 
LCR low complexity region 
LIM Lin-11, Isl-1 and Mec-3 motif 
m mass 
M mol per litre 
MA mass analyzer 
mAB monoclonal antibody 
MALDI matrix-assisted laser desorption/ ionization 
MBP maltose binding protein 
MCS multiple cloning site 
MDLC multidimensional liquid chromatography 
MeCN acetonitrile 
MEM Eagle’s minimum essential medium 
MES 2-N-morpholino ethanesulfonic acid 
mgf Mascot generic format 
mIP STIM1-specific Co-IP in platelets of STIM1+/+ mice 
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MLC (K)/ (P) myosin light chain (kinase)/ (phosphatase) 
MS mass spectrometry, mass spectrometer 
MS/MS tandem mass spectrometry 
MudPIT multidimensional protein identification technology 
MW molecular weight 
m/z mass-to-charge ratio 
Neo neomycin 
NP-40 Nonidet P40 substitute 
nt nucleotide 
pAB polyclonal antibody 
PAGE polyacrylamide gel electrophoresis 
PB protein band 
PCR polymerase chain reaction 
PDE phosphodiesterase 
PDZ postsynaptic density 95, discs large and zonula occludens-1 motif 
Pen penicillin 
pI isoelectric point 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PKA protein kinase A, cAMP-dependent protein kinase 
PKC Ser/ Thr protein kinase C 
PKG protein kinase G, cGMP-dependent protein kinase 
PM plasma membrane 
PMF peptide mass fingerprinting 
PRP platelet-rich plasma 
PRR proline-rich region 
pSer, pS phospho-serine 
pThr, pT  phospho-threonine 
PTM post-translational modification 
pTyr, pY phospho-tyrosine 
PVDF polyvinylidene difluoride 
RP reversed-phase, reversed-phase chromatography 
RT retention time 
(RT-)PCR (reverse transcription) polymerase chain reaction 
SAM sterile α-motif 
SC STIM1Ctail affinity column 
SDS sodium dodecylsulfate 
SEC size exclusion chromatography 
SERCA  sarcoplasmatic/ endoplasmatic reticulum Ca2+ ATPase 
sGC soluble guanylyl cyclase 
SOCE store-operated calcium entry 
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STIM1 stromal interaction molecule 1 
Strep streptomycin 
TD tetramerization domain 
TFA trifluoroacetic acid 
TM transmembrane domain 
TOF time-of-flight 
Tris tris(hydroxymethyl)aminomethane 
U units 
VASP vasodilator-stimulated phosphoprotein 
v/v volume per volume 
vWF von Willebrand factor 
wt wildtype 
w/v weight per volume 
X-gal bromo-chloro-indolyl-galacto-pyranoside 
z charge 
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II Amino acids: Residue mass and structure 
 
 
        Name                   Symbol                     Structure              Monoisotopic mass 
                                                                                                          (-H2O) [Da] 
 
 
Alanine 
 
 
 
Ala, A 
 
 
 
 
71.03711 
 
 
Arginine 
 
 
 
Arg, R 
 
 
 
156.10111 
 
 
Asparagine 
 
 
 
Asn, N 
 
 
 
114.04293 
 
 
Aspartic acid 
 
 
 
Asp, D 
 
 
 
115.02694 
 
 
Cysteine 
 
 
 
Cys, C 
 
 
 
103.00919 
 
 
Glutamic acid 
 
 
 
Glu, E 
 
 
 
129.04259 
 
 
Glutamine 
 
 
 
Gln, Q 
 
 
 
128.05858 
 
Glycine 
 
 
Gly, G 
 
 
57.02146 
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Histidine 
 
 
 
 
His, H 
 
 
 
 
137.05891 
 
 
Isoleucine 
 
 
 
Ile, I 
 
 
 
113.08406 
 
 
Leucine 
 
 
 
Leu, L 
 
 
 
113.08406 
 
 
Lysine 
 
 
 
Lys, K 
 
 
 
128.09496 
 
 
Methionine 
 
 
 
Met, M 
 
 
 
131.04049 
 
 
Phenylalanine 
 
 
 
Phe, F 
 
 
 
147.06841 
 
Proline 
 
 
Pro, P 
 
 
97.05276 
 
 
Serine 
 
 
 
Ser, S 
 
 
 
87.03203 
 
 
Threonine 
 
 
 
Thr, T 
 
 
 
101.04768 
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Tryptophan 
 
 
 
 
Trp, W 
 
 
 
 
186.07931 
 
 
 
Tyrosine 
 
 
 
 
Tyr, Y 
 
 
 
 
163.06333 
 
 
Valine 
 
 
 
Val, V 
 
 
 
99.06841 
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III Genetic code 
 
 
 
 
 
U 
 
C 
 
A 
 
G 
 
 
 
 
U 
 
Phe 
Phe 
Leu 
Leu 
 
Ser 
Ser 
Ser 
Ser 
 
Tyr 
Tyr 
Stop 
Stop 
 
Cys 
Cys 
Stop 
Trp 
 
U 
C 
A 
G 
 
 
C 
 
Leu 
Leu 
Leu 
Leu 
 
Pro 
Pro 
Pro 
Pro 
 
His 
His 
Gln 
Gln 
 
Arg 
Arg 
Arg 
Arg 
 
U 
C 
A 
G 
 
 
A 
 
Ile 
Ile 
Ile 
Met 
 
Thr 
Thr 
Thr 
Thr 
 
Asn 
Asn 
Lys 
Lys 
 
Ser 
Ser 
Arg 
Arg 
 
U 
C 
A 
G 
 
 
G 
 
Val 
Val 
Val 
Val 
 
Ala 
Ala 
Ala 
Ala 
 
Asp 
Asp 
Glu 
Glu 
 
Gly 
Gly 
Gly 
Gly 
 
U 
C 
A 
G 
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IV Summary 
 
The vasodilator-stimulated phosphoprotein VASP and the stromal interaction 
molecule STIM1 are regarded as being amongst the key players functioning in the 
processes upon platelet activation. Thereby, VASP, due to its actin filament-
remodelling activity, is closely related to platelet adhesion and shape change. The 
Ca2+-sensing molecule STIM1, on the other hand,  has been linked to CRAC entry in 
the course of platelet Ca2+-signaling, which consequently results in enhanced 
granular secretion, recruitment of further platelets and subsequent aggregation at the 
site of vessel injury. To further understand the precise mechanisms regulating the 
specific effects of these two components, we here addressed both the VASP- and 
STIM1 interactome in resting platelets by applying a differential pull down-based 
proteomics strategy. In detail, His6-tagged DNA-vector constructs of (a) phospho-
mimetic mutants of human VASP; and (b) of the cytosolic part of human STIM1 were 
heterologously expressed and IMAC purified. The resulting fusion proteins were 
intended for subsequent immobilization on Affi-Gel 10 resin to generate VASP- and 
STIM1-specific affinity supports. These affinity columns should consequently serve 
for specific interactome screenings on native lysates of resting human platelets. 
Following this strategy, however, synthesis and isolation of the intended VASP fusion 
proteins turned out to be challenging: Initially, prokaryotic translation in E.coli was 
partially inhibited, most probably as a consequence of the codon bias problem 
inherent to prokaryotic vs eukaryotic protein expression. This issue was finally 
addressed by changing to an alternate, eukaryotic expression system (i.e. stably 
transfected HEK293 cells). Nevertheless, the resulting protein yields were still too low 
to enable sufficient subsequent enrichment. In this context, the applied IMAC 
approach may have also been further limited by partial inaccessibility of the targeted 
C-terminal His6- tags, presumably caused by structural folding of the C-termini of the 
designed protein constructs. The generated stable cell lines may hence be well 
suitable to address the phospho-specific VASP interactome in the HEK293 model 
system (e.g. in Co-IP-based approaches); however, they were not adequate in the 
context of a platelet-related study as intended here. Therefore, this part of our 
analysis was finally rejected. 
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In contrast, when applying the same strategy to unravel the STIM1-specific 
interactome of resting platelets, a total of 87 non-redundant, platelet-related proteins 
were detected successfully. These components were classified in four functional 
complexes: (a) the actin-myosin complex; (b) the adhesion complex, including the  
(c) GPIb-IX-V subcomplex; and (d) the signaling-related complex. Of these, one of 
the most promising candidates - i.e. PDLIM family member CLP36, which was 
related to three of the four functional complexes - was chosen for a more detailed 
analysis (in vitro and in vivo). Deriving from these studies, α-actinin-bound CLP36 
seems to stabilize STIM1 anchoring to the F-actin cytoskeleton, hence preventing 
uncontrolled STIM1-mediated CRAC entry and consequent intravascular platelet 
activation and aggregation. There is furthermore evidence that, upon platelet 
induction, this interaction is finally reversed by limited proteolysis via the Ca2+-
dependent endoprotease calpain. Since CLP36 was also found to act as a negative 
regulator of GPVI-ITAM signaling, as indicated by functional platelet characterization 
in Clp36∆LIM mice, this cytoskeleton adaptor protein presumably plays multiple roles 
in the context of platelet inhibition. Further research on this protein candidate may 
thus help to improve our knowledge of intravascular thrombus formation and of the 
pathological mechanisms contributing to manifestation of acute ischemic diseases. 
Zusammenfassung 
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V Zusammenfassung 
 
 
Das Vasodilator-stimulierte Phosphoprotein VASP und das Stromal-
Interaktionsmolekül STIM1 zählen zu den zentralen Komponenten, die an den im 
Verlauf der Thombozytenaktivierung auftretenden Prozessen beteiligt sind. Aufgrund 
seiner Aktinfilament-remodellierenden Aktivität wird VASP hierbei in engen 
Zusammenhang mit der Adhäsion und Gestaltänderung aktivierter Thrombozyten 
gebracht. Der Ca2+-Sensor STIM1 hingegen ist in den, über CRAC-Kanäle 
mediierten, Ca2+-Flux im Zuge des thrombozytären Ca2+-Signalings eingebunden, 
was letztlich zur verstärkten granulären Sekretion, der Rekrutierung weiterer 
Thrombozyten und schließlich zur Aggregation im Bereich der Gefäßläsion führt. Um 
tieferen Einblick in die hinter diesen jeweilig spezifischen Funktionen stehenden 
regulatorischen Mechanismen zu erhalten, wurde im Rahmen der vorliegenden 
Studie eine Analyse des VASP- und des STIM1-Interaktoms in ruhenden 
Thrombozyten vorgenommen. Dies geschah unter Anwendung eines Pulldown-
basierten, differentiellen proteomischen Ansatzes. So wurden His6-getaggte DNA-
Vektorkonstrukte von (a) phospho-mimetischen humanen VASP-Mutanten; und  
(b) der zytosolischen Domänen von humanem STIM1 heterolog exprimiert und 
mittels IMAC aufgereinigt. Die so gewonnenen Fusionsproteine sollten anschließend, 
nach Immobilisierung an einer Affi-Gel 10 Matrix zur Generierung von VASP- bzw. 
STIM1-spezifischen Affinitätsmatrices, für spezifische Interaktomsscreenings in 
nativen Lysaten ruhender humaner Thrombozyten genutzt werden. 
Im Zuge dieser Vorgehensweise erwies sich die Synthese und Aufreinigung der 
VASP Fusionsproteine allerdings als schwierig: So ließ sich zunächst nur eine 
schwache Translation in E.coli feststellen, was vermutlich auf die bei prokaryotischer 
Expression von eukaryotischem Genmaterial häufig auftretende ’Codon Bias-
Problematik’ zurückzuführen war. Durch den Wechsel in ein eukaryotisches 
Expressionssystem (stabil transfizierte HEK293 Zellen) konnten diese Limitierungen 
schließlich umgangen werden. Die Expressionslevel der synthetisierten VASP 
Fusionsproteine fielen allerdings auch hier letztlich viel zu gering aus, um 
anschließend eine ausreichend hohe Anreicherung zu gewährleisten. In diesem 
Zusammenhang muss auch vermutet werden, dass die IMAC-Aufreinigung der 
Proteinkonstrukte eventuell durch partielle strukturelle Unzugänglichkeit der  
Zusammenfassung 
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C-terminalen His6-Affinitätstags als Folge C-terminaler Proteinfaltungen zusätzlich 
beeinträchtigt worden sein könnte. Die generierten stabilen Zelllinien mögen somit 
zwar durchaus dafür geeignet sein, eine phospho-spezifische VASP 
Interaktomsstudie im HEK293 Modellsystem vorzunehmen (z.B. über einen Co-IP-
basierten Ansatzes). Für die hier beabsichtigte Untersuchung humaner 
Thrombozyten erwiesen sie sich jedoch letztlich als unzulänglich. Aus diesem Grund 
muss dieser Teil der vorliegenden Studie vorerst als gescheitert angesehen werden. 
Im Falle der Analyse des thrombozytären Interaktoms von humanem STIM1 konnten 
hingegen mittels der beschriebenen Strategie insgesamt 87 nicht-redundante 
thrombozytäre Proteine erfolgreich detektiert werden. Diese Komponenten waren 
vier funktionellen Komplexen zuzuordnen: (a) dem Aktin-Myosin Komplex; (b) dem 
Adhäsionskomplex, einschließlich des (c) GPIb-IX-V Subkomplexes; und (d) dem 
Signaling-assoziierten Komplex. Einer der in diesem Zusammenhang 
vielversprechendsten Kandidaten - das zur PDLIM Familie gehörende Protein 
CLP36, welches funktionelle Assoziation zu drei der vier angesprochenen Komplexe 
zeigt - wurde schließlich einer detaillierteren Analyse (in vitro und in vivo) 
unterzogen. Auf Basis dieser Untersuchungen läßt sich schlussfolgern, dass  
α-Aktinin-gebundenes CLP36 vermutlich die Verankerung von STIM1 am F-Aktin 
Zytoskelett stabilisiert, und somit unkontrolliertem STIM1/ CRAC-vermittelten Ca2+-
Einstrom und der damit einhergehenden intravaskulären Thrombozytenaktivierung 
und -aggregation entgegenwirkt. Desweiteren bestehen Hinweise darauf, dass diese 
Interaktion in aktivierten Thrombozyten durch limitierte Proteolyse, vermittelt durch 
die Ca2+-abhängige Endoprotease Calpain, aufgehoben wird. Da CLP36 außerdem 
als Negativregulator im Zuge des GPVI-ITAM Signalings zu fungieren scheint - was 
hier anhand thrombozytärer Funktionsanalysen in Clp36∆LIM Mäusen belegt werden 
konnte - kommt diesem zytoskelettalen Adapterprotein vermutlich eine umfassendere 
Rolle im Kontext der Thrombozyteninhibierung zu. Weitere eingehendere 
Untersuchung dieses Kandidaten kann somit möglicherweise dazu beitragen, unser 
Wissen bezüglich der intravaskulären Thrombusbildung, sowie der pathologischen 
Mechanismen, die letztlich zur Ausbildung akuter ischämischer Erkrankungen führen, 
zu erweitern. 
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1 Introduction 
 
1.1 Blood platelets and hemostasis 
Blood plays an indispensable, multifaceted role, for instance in metabolic, oxygen or 
hormone transport, immune defence and temperature regulation. It is composed of 
cells of mesenchymal origin (blood cells) and carrier fluid (blood plasma). Plasma is a 
clear solution (90% water) and accounts for up to 56% of the total blood volume [1]. It 
contains amongst others sugars, lipids, vitamins, electrolytes, carrier proteins, 
hormones, enzymes, blood clotting factors, and antibodies. Blood cells, on the other 
hand, comprise erythrocytes (4-5 x 1012/ L blood), leukocytes (part of the immune 
system, 4-11 x 109/ L blood), and platelets (2-3 x 1011/ L blood) [2]. Blood platelets 
are small, anucleated discoid-shaped cellular particles (diameter 2-4 µm) originating 
from constriction of precursor megakaryocytes in the bone marrow [3]. In the intact 
vasculature, they circulate in the blood in a quiescent state for approximately seven 
days until they are degraded in the spleen and the liver. They play an essential role 
in hemostasis, i.e. the arrest of hemorrhage upon tissue trauma [4, 5]: Accordingly, 
vascular lesion first leads to rapid platelet adhesion to the zone of injury, followed by 
platelet activation. Upon subsequent recruitment and aggregation of further platelets, 
a thrombus is finally formed which loosely occludes the disrupted area. This ‘primary’ 
or ‘cellular’ hemostasis is accompanied by a series of enzymatic reactions which 
stabilize the thrombus via generation of a strong fibrin fiber mesh (secondary 
hemostasis, or humoral coagulation cascade) [6]. Simultaneously, platelet surface 
molecules and factors released from the platelets' intracellular granules (e.g. 
integrins and P-selectin) induce processes like immune response and tissue 
regeneration [7-11]. 
Many of the mediators related to physiological hemostasis are not only involved in 
platelet-related pathological events (such as atherosclerosis, coronary and peripheral 
artery disease, or cerebrovascular disease) [4, 12], but also in tumor angiogenesis, 
tumor progression and malignancy [13, 14]. Therefore, a comprehensive knowledge 
of the underlying regulatory mechanisms and signaling pathways is of high medical 
interest and offers yet unexplored possibilities to develop anti-artherosclerotic and 
anti-angiogenic agents. 
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1.1.1 Platelet morphology 
Upon activation, platelets extend their surface to efficiently occlude the lesion, 
changing their shape from discoid to a flattened, star-shaped one by formation of 
lamellipodia and filopodia. For this purpose, the plasma membrane (PM) of resting 
platelets contains numerous invaginations (i.e. the open canalicular system) serving 
both as membrane sources and guidance systems for secretory granules during the 
platelet activation process. 
Apart from typical cellular organelles, such as mitochondria, Golgi apparatus and 
lysosomes, the platelet cytoplasm contains the already mentioned secretory granules 
and the dense tubular system (DTS) which functions as an essential Ca2+-reservoir 
(see Figure 1.1 A). Platelet granules are generally subdivided into alpha, delta 
(‘dense’) and lambda granules. Alpha granules contain proteins involved in clot 
formation, including platelet factor 4, von Willebrand factor (vWF), fibrinogen, 
fibronectin, and coagulation factors V and XIII, as well as growth factors (PDGF,  
IGF-1, and TGF-β) and carrier proteins (multimerin-1) [15]. In addition, various 
glycoproteins (GP) known to increase platelet adhesion to the region of vascular 
lesion are also embedded in the alpha granule membrane, such as integrin αIIbβ3, P-
selectin or GPIb-IX-V. The content of delta granules is composed of small, soluble 
molecules (ADP, ATP, pyrophosphate, serotonin, histamine and Ca2+) which further 
contribute to platelet adhesion as well as to vasoconstriction and regulation of 
inflammation [16]. Lambda granules finally resemble lysosomes whose hydrolytic 
enzymes mediate clot resorption once the lesion has been repaired. 
One further morphological characteristic is given by the dense platelet cytoskeleton. 
The cytoplasma is traversed by a complex, rigid actin fiber mesh and a ring-shaped 
microtubuli-based structure located close to the PM region [17]. Several protein 
interactions, such as filamin - GPIb-IX-V, directly anchor the cytoskeleton to the PM. 
Moreover, the intracellular side of the PM is stabilized by a strong spectrin-based 
supporting structure [18, 19]. 
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Figure 1.1: (A) Platelet morphology: (1) plasma membrane, (2) dense tubular system,  
(3) mitochondrium, (4) actin fibers, (5) dense granule, (6) alpha granule, (7) ring-shaped microtubuli 
structure, (8) glycogen store, (9) lysosome, (10) invagination. (B) Platelet recruitment following vessel 
injury. Initially, platelets loosely adhere to exposed collagen-bound vWF via the platelet surface 
receptor GPIb-IX-V ('rolling'). Subsequent firm adhesion to subendothelial matrix proteins is mediated 
by platelet GPVI-Fc receptor gamma chain (FcRγ) and integrin α2β1. Upon granular secretion, further 
platelets are recruited and activated, which finally results in thrombus formation based on αIIbβ3-
fibrinogen interaction. 
 
1.1.2 Platelet inhibition 
To prevent uncontrolled intravascular thrombus formation under physiological 
conditions, platelet activity is tightly controlled by adequate inhibitory mechanisms. 
Accordingly, platelet antagonists such as vasodilators, prostacyclins (e.g. PGI2) and 
prostaglandins (e.g. PGE1), inhibit activation, adhesion and aggregation of resting 
platelets by enhancing the intracellular concentration of the cyclic nucleotides cAMP 
and cGMP [20]. Regarding cAMP formation, this commonly implies modulation of G-
protein-coupled receptors (GPCRs), a group of transmembrane receptors known for 
fast and amplified transduction of external stimuli via constitutively associated 
heterotrimeric G-proteins and firmly controlled subsequent signaling cascades [21]. 
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As a detailed example, both PGE1 and PGI2 bind to prostaglandin Gαs-coupled 
receptors which subsequently activate the adenylate cyclase (AC) [22]. Once 
stimulated, the AC catalyzes cAMP synthesis (Figure 1.2). Intracellular levels of 
cGMP, on the other hand, are predominantly increased by induction of the 
intracellular soluble guanylyl cyclase (sGC), e.g. as a consequence of endothelial 
release of the vasodilator nitric oxide (NO) [23]. In this context, NO (also 
'endothelium-derived relaxing factor' EDRF) furthermore inhibits phosphodiesterase 
(PDE) function and thus prevents cyclic nucleotide degradation [24]. 
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Figure 1.2: Platelet inhibitory pathways, based on Schwarz et al. [20]. Green arrows indicate 
activation, red lines inhibition. Black arrows mark subsequent signaling cascades and effects, with 
crossed-out ones symbolizing signal prevention. 
 
Generally, cyclic nucleotide-mediated platelet inhibition is executed by the cAMP- 
and cGMP-dependent protein kinases PKA and PKG [20, 25]. Though the precise 
mechanisms still have to be fully resolved, both kinases are regarded as particularly 
counteracting cytoskeleton remodelling processes occurring upon platelet activation, 
as for instance during platelet shape change. In detail, several PKA phosphorylation 
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substrates have been related to the maintenance of the cortical actin cytoskeleton: 
Accordingly, phosphorylation of GPIb inhibits collagen-induced actin polymerization 
[26], phospho-caldesmon stabilizes actin filament structures [27] and phosphorylation 
of actin binding proteins (ABP) prevents actin cytoskeleton rearrangement [28]. PKG-
mediated phosphorylation events, on the other hand, have been shown to both 
activate the myosin light chain phosphatase (MLCP) and inhibit the myosin light 
chain kinase (MLCK). This promotes dephosphorylation of myosin light chains 
(MLC), thus preserving intracellular actomyosin relaxation and consequently 
stabilizing resting platelets’ morphology [29]. Apart from the described processes, 
PKA-/ PKG-dependent platelet inhibition moreover comprises repression of (a) Ca2+-
release from intracellular stores; (b) integrin activation; and (c) granule secretion [20]. 
 
1.1.3 Platelet activation 
The complex biochemical mechanisms regulating platelet activity imply modulation of 
activating and inhibitory downstream signaling pathways, cytoskeleton reorganization 
and platelet shape change, receptor translocation to the platelet surface, as well as 
relocation and secretion of intracellular secretory granules. Initially, circulating 
platelets adhere to sites of vessel injury by a series of interactions between platelet 
tyrosine kinase-dependent adhesion receptors (PTKs) and either exposed 
subendothelial collagen or collagen-bound vWF. This is for instance illustrated by the 
contacts of platelet GPIb-IX-V with vWF, which permits platelet rolling on the 
subendothelial matrix [30] (see Figure 1.1 B). Subsequent firm platelet adhesion 
requires participation of two structurally distinct platelet-collagen receptors, the 
immune receptor homologue GPVI and integrin α2β1 [31, 32]. In this context, the 
GPVI-collagen interaction represents the main activating signal. In the further 
process, GPVI and platelet Fc receptor gamma chain (FcRγ) form a functional 
complex which, upon Src phosphorylation, induces phospholipase Cγ2 (PLCγ2) and 
phosphatidylinositol-3-kinase (PI3K)/ Akt signaling - and thus intracellular synthesis 
of second messenger molecules IP3 and diacylglycerol (DAG) [33, 34]. IP3 mediates 
cytosolic Ca2+-release from intracellular stores [21]. With regard to both cellular 
hemostasis and the subsequent coagulation cascade, Ca2+-availability plays a pivotal 
role: In platelets, for instance, Ca2+ binds to calmodulin (CaM) which in turn 
stimulates MLCK. Consequently, MLCK-mediated phosphorylation of myosin light 
chains initiates cytoskeleton shape change and thus platelet spreading [35]. For 
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further details on platelet Ca2+-signaling see also 1.3. DAG, on the other hand, 
stimulates granular secretion of e.g. PDGF, serotonin, fibrinogen and ADP via 
activation of Ser/ Thr protein kinase C (PKC). Moreover, it induces translocation of 
granular membrane glycoproteins (such as fibrinogen receptor integrin αIIbβ3) to the 
platelet surface [36]. 
Once released to the blood flow, the components of the platelet secretome - mainly 
thrombin, thromboxane A2 (TxA2) and ADP - stimulate the second step of cellular 
hemostasis, i.e. recruitment of further platelets to the site of injury. In this context, 
direct platelet-to-platelet contact is based on coordinated adhesion of GPIb-IX-V to 
vWF and activated integrin αIIbβ3 to fibrinogen, respectively. As in platelet inhibition, 
several soluble agonists act via GPCRs and the associated signaling cascades 
comprising protein kinases, phospholipases and Ras-family members [21]. Basically, 
the essential steps during agonist-induced platelet activation resemble those of 
collagen-based ones: increase of intracellular Ca2+-concentration [Ca2+]i, PKC 
activation and, finally, remodelling of the actin cytoskeleton. This is achieved by the 
complex interplay of different heterotrimeric G-protein subunits. As an example, 
binding of thrombin, TxA2 or ADP to Gαq and Gα12/13 family members subsequently 
induces phospholipase Cβ (PLCβ) as well as the Rho/ ROCK signaling pathway (for 
details see Figure 1.3) [37-39]. Simultaneously, down-regulation of inhibitory 
mechanisms takes place: Accordingly, Gαi stimulation by ADP and/ or thrombin 
inhibits the AC and hence reduces cytosolic cAMP levels [20]. The related Gßγ-
subunits, however, also activate PLC and PI3K and thus further enhance thrombus 
growing [37]. Thrombus stabilization is finally achieved both by induction of the 
coagulation cascade and by platelet receptor desensitization, which is presumably 
mediated via outside-in signaling [40]. In this context, functional implication of 
integrins and receptor kinases as well as release of growth arrest specific proteins 
from platelet alpha granules is discussed; yet the precise mechanisms still have to be 
elucidated [41, 42]. 
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Figure 1.3: GPCR-mediated platelet activation by binding of thrombin, TxA2 and ADP (based on [20, 
37-39]). Green arrows indicate activation, red lines inhibition. Black arrows mark subsequent signaling 
cascades and effects, with crossed-out ones symbolizing signal prevention. 
 
1.2 Platelet shape change and the Ena/ VASP protein family 
Platelet shape change upon activation is predominantly based on reorganization of 
the actin cytoskeleton. Having approximately two million copies per cell, actin 
monomers represent the most abundant protein in platelets [43]. Since in eukaryotic 
cells the main source of polymerization-competent globular actin (G-actin) is provided 
by profilin-actin complexes (also profilactin) [44-46], both lamellipodia and filopodia 
formation depend on the ability to recruit, process and incorporate profilactin onto the 
barbed ends of elongating actin filaments (F-actin). In this context, the role of profilin 
in filament assembly is manifold [47-49]: (a) profilin catalyzes the ADP-to-ATP 
exchange for G-actin, thus restoring the pool of ATP-actin monomers obligatory for 
polymerization; (b) profilin-bound G-actins exclusively elongate at filament barbed 
ends and not at pointed ends; and (c) profilin exhibits high affinity to proline-rich 
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regions present in several filament elongation factors, such as the Arp2/3 complex 
activator WASP, formins and proteins of the so-called Ena/ VASP family. 
The latter ones are involved in multiple actin-mediated processes related to cell 
motility and adhesion, as well as in cytoskeleton-PM anchoring to provide cellular 
shape stability and mediate tissue permeability [50]. Ena/ VASP proteins are 
consequently associated with actin bundles, stress fibers, focal adhesions (i.e. cell-
matrix interaction), cell-cell contacts, or to highly dynamic membrane structures such 
as leading edges of neuronal growth cones [51]. In addition, they colocalize with 
unipolar actin filaments of lamellipodia and particularly filopodial tips. Apart from the 
founding member VASP (‘vasodilator-stimulated phosphoprotein’), this protein family 
comprises Drosophila Ena (‘enabled’), the mammalian and the avian Ena orthologs 
(Mena and Avena, respectively) and the Ena-VASP-like protein (Evl) [50-52]. 
VASP itself is expressed in various cell types and tissues (e.g. epithelia and 
endothelia); however, it reveals highest levels in platelets where it is closely 
connected to inhibitory pathways [53]. Subsequent to platelet antagonist (e.g. NO 
and PGI2) induced increase of intracellular cAMP- and cGMP-concentration, VASP-
function in filament elongation is inhibited by PKA- and PKG-mediated 
phosphorylation [54, 55]. This model is further strengthened by studies on VASP-
deficient mice exhibiting impaired cyclic nucleotide mediated inhibition and hence 
enhanced collagen and thrombin induced platelet activation [56]. Although the 
detailed role of VASP in platelets is not yet fully understood, its participation in 
dynamic cytoskeletal processes and its response to platelet antagonists renders it an 
essential key player in regulating platelet shape change upon activation and thus 
justifies further focus on this family of filament elongation factors. 
 
1.2.1 VASP domain structure 
Ena/ VASP family members share a common domain organization consisting of 
highly conserved N-terminal and C-terminal regions, i.e. Ena/ VASP homology 
domains EVH1 and EVH2, separated by more variable low complexity regions (LCR) 
and proline-rich regions (PRR, see also Figure 1.4 A) [57]. In the following, a detailed 
functional description of the Ena/ VASP structural domains will be provided using 
human VASP (39.8 kDa, 380 aa) as an example. Accordingly, the N-terminal EVH1-
domain (in VASP aa 2-113) mediates Ena/ VASP translocation to focal adhesions, 
lamellipodia and filopodia, and binds to ligands containing an FP4 consensus 
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sequence (E/DFPPPPXD/E, i.e. a polyproline II helix) [58]. These motifs are found in 
a variety of scaffolding and focal adhesion proteins, such as zyxin, vinculin, migfilin, 
paladin or α-actinin (Figure 1.4 B) [51].  
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Figure 1.4: (A) VASP domain structure: (1) N-terminal EVH1 domain (aa 2-113), (2) central PRR-
domain (aa 118-216) consisting of regulatory-, recruiting- and loading poly-Pro-sites, (3) C-terminal 
EVH2 domain (aa 225-377) composed of the GAB- and FAB-region, followed by the VASP-TD 
domain. VASP phosphorylation sites S157, S239 and T278, which are differentially phosphorylated by 
PKA, PKG and AMPK (with thicker arrows indicating higher site preference), are highlighted in red.  
(B) VASP tetramer recruitment to sites of filament assembly, based on Ferron et al. [61]. VASP-EVH1 
domains mediate subcellular localization via interaction with scaffolding proteins which are directly or 
indirectly connected to the plasma membrane. The recruiting poly-Pro-sites sequester multiple profilin-
actin complexes thus increasing local G-actin concentration. 
 
The C-terminal EVH2 domain (aa 225-377) consists of three conserved blocks [59]: 
(a) a thymosin-like motif essential in G-actin binding (also called GAB-region, aa 225-
245); (b) an F-actin attachment site (FAB-region, aa 259-278); (c) and a coiled-coil 
motif (CC) containing a C-terminal tetramerization domain (TD, aa 343-377) which 
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mediates both VASP homo- and hetero-oligomerization with other Ena/ VASP family 
members in a bouquet-like structure [59, 60] (Figure 1.4 B). 
Finally, according to Ferron et al. [61], the central PRR-domain of VASP (aa 118-
216) can be subdivided into three distinct groups (Figure 1.4 A): The first group of 
proline residues (aa 118-135) is predicted to bind to various signaling and scaffolding 
proteins, such as Abl, Src, Nck, Crk and cortactin [61-63]. Being presumably involved 
in VASP regulation, Ferron et al. define it as ‘regulatory poly-Pro-site’ [61]. The 
second group of proline residues (aa 160-194) comprises three canonical profilin-
recognition sequences (GP5-motifs) and is thus able to bind multiple profilactin 
complexes [64]. Hence, it has been described as 'recruiting poly-Pro-site’. The third 
group of highly conserved proline residues (aa 195-216) apparently transfers 
profilactin from the PRR- to the EVH2-domain, therefore being depicted as ‘loading 
poly-Pro-site’. Both the loading poly-Pro-site and the GAB-region exhibit higher 
affinities to profilin-actin complexes than to profilin or G-actin alone [61, 65]. 
 
1.2.2 VASP-mediated remodelling of the actin-cytoskeleton 
Actin-cytoskeleton remodelling as well as generation of long, unbranched and 
crosslinked bundles of F-actin filaments e.g. during filopodia formation is assumed to 
result from three cooperative Ena/ VASP-related molecular mechanisms:  
(a) prevention of CapZ-capping of barbed ends of F-actins [66]; (b) inhibition of 
Arp2/3-mediated actin filament branching [67]; and (c) recruitment of profilin-actin 
complexes at sites of actin reorganization, which furthermore appears to enhance the 
anti-capping effect [64, 68]. In this context, based on the energetics and structural 
conditions for the interaction of profilactin and VASP, Ferron et al. [61] proposed the 
following model of VASP-mediated processive G-actin polymerization during filament 
elongation (see Figure 1.5): 
Accordingly, VASP tetramers are first recruited to the sites of actin-filament assembly 
(e.g. at the PM) by interaction of the EVH1-domain with scaffolding proteins (zyxin, 
vinculin, etc.) [69-71]. Here, activity of the recruiting poly-Pro-site increases the local 
concentration of profilactin complexes - and hence of polymerizable G-actin-
monomers. Subsequently, the loading poly-Pro-site directs the transition of attached 
profilin-actin complexes from the recruiting poly-Pro-site to the VASP EVH2-GAB-
domain, where the G-actin monomer subunits are finally added at the barbed end of 
the EVH2-FAB-tethered growing filament. Simultaneously, this transfer of G-actin 
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triggers profilin dissociation and processive stepping of the involved subunits of the 
VASP tetramer. Actin-mediated hydrolysis of ATP is generally regarded as the 
driving force behind the suggested mechanism; however, nucleotide-independent 
conformational changes due to the G- to F-actin transition are also discussed in this 
context [61]. 
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Figure 1.5: VASP-mediated filament elongation, based on Ferron et al. [61]. Blue arrows indicate 
central steps of the elongation mechanism: (1) interaction of profilin-actin complexes with VASP 
recruiting- and loading poly-Pro-sites, (2) transfer of profilactin from the loading poly-Pro-site onto the 
GAB-region, and (3) addition of the G-actin subunit at the barbed end of the growing F-actin filament 
and simultaneous profilin release. 
 
Even though VASP tetramerization, via the CC-domains, appears to be required for 
efficient filament elongation, its detailed mechanistic function is still controversial. For 
instance, it remains speculative whether each VASP subunit supports elongation of 
one filament or two subunits per filament are involved. Nevertheless, regarding actin 
bundle formation, functional tetramers may be more efficient, in particular with 
respective VASP subunits acting cooperatively, both within and between 
neighbouring tetramers. In addition, both tetramerization and tethering via the EVH1-
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domain may stabilize VASP binding to particular filaments during the processive 
stepping procedure, as it sequentially enables individual VASP subunits to release 
and advance while the remaining ones still sustain contact [61]. 
 
1.2.3 VASP phosphorylation 
Since Ena/ VASP proteins are known substrates of serine/ threonine kinases, 
differential phosphorylation is regarded crucial for: (a) subcellular trafficking of Ena/ 
VASP tetramers to the PM and to growing F-actin filaments; (b) regulation of 
profilactin recruitment and processing; and (c) dynamic specification of protein-
protein interactions, e.g. with Abl, Src or Crk [54, 72]. 
VASP itself harbours three known phosphorylation sites - S157, S239, T278 - with 
S157 being preferentially phosphorylated by PKA, S239 by PKG and T278 by AMP-
activated protein kinase AMPK [54, 73-75] (see also Figure 1.4 A). In detail, VASP 
phosphorylation at S157, which is located between the regulatory- and the recruiting 
poly-Pro-site, has been reported to inhibit binding of certain SH3-domain-containing 
proteins (e.g. Abl) to the PRR-domain [74]. On the other hand, phosphorylation of 
S239 and T278, which are located at the C-terminal ends of the EVH2-GAB- (S239) 
and -FAB-region (T278), has been implicated in modulation of actin assembling 
properties. Despite the importance of Ena/ VASP-mediated signaling dynamics, 
detailed molecular mechanisms, analyses of spatial and temporal phosphorylation 
patterns and protein-protein interactions involved in vivo have remained elusive. 
Moreover, also the presence and relevance of possible additional yet-unknown VASP 
phosphorylation sites, as for instance recently indicated by Zahedi et al. for VASP 
S238 and T249 [76], has to be illuminated. 
 
1.3 Calcium signaling in late platelet response 
Although platelet activation can be induced by various agonists and receptors, the 
majority of downstream signaling pathways culminate in one central step: the 
elevation of intracellular Ca2+-levels [77]. Cytosolic Ca2+ is a key signaling messenger 
in virtually all cells and regulates a wide variety of cellular functions from gene 
transcription to apoptosis. Accordingly, in platelets changing [Ca2+]i is related to both 
primary and secondary hemostasis events, such as platelet shape change and 
degranulation, inside-out activation of integrin aIIbß3, further aggregation, thrombus 
stabilization and, finally, induction of immune response [77-79]. 
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Generally, cytosolic Ca2+-levels can be altered by two distinct mechanisms: Ca2+-
depletion from intracellular stores and Ca2+-influx from the extracellular space. As 
mentioned in 1.1.1, the major intracellular Ca2+-pool in platelets is provided by the 
DTS [80, 81], where a high Ca2+-concentration is actively maintained via 
sarcoplasmatic/ endoplasmatic reticulum Ca2+-ATPases (SERCAs) [82, 83]. Upon 
platelet activation and subsequent PLC-mediated production of IP3, Ca2+-release into 
the cytosol is operated through IP3 receptor channels (IP3-R) localized within the DTS 
membrane [21, 84]. This fast initial mechanism has been well established for several 
years and seems to be sufficient to trigger the basic events of primary hemostasis 
without any significant delay [85]. Besides IP3, also cyclic ADP ribose, nicotinic acid 
adenine dinucleotide phosphate (NADDP) and Ca2+ itself have been reported to 
cause Ca2+-store release. 
Ca2+-depletion from intracellular stores is usually transient; however, many cellular 
functions and store refilling require persistently elevated [Ca2+]i levels based on influx 
of extracellular Ca2+, which is tightly regulated by numerous Ca2+-selective ion 
channels located within the PM [86, 87]. This amplification of an initial Ca2+-signal 
commonly occurs in response to agonist-induced store depletion itself, hence being 
also referred to as store-operated calcium entry (SOCE) [85]. In particular later 
platelet responses leading to thrombus stabilization and/ or secondary hemostasis 
can be related to SOCE-dependent Ca2+-signaling. Nevertheless, the complex 
SOCE-related molecular coupling processes, which take up to 15 sec [88], still 
remain obscure. The best characterized type of SOCE has initially been reported in 
lymphocytes and mast cells and is based on Ca2+-release-activated Ca2+-channels 
(CRAC) in the PM [89]. In this context, more recent studies identified the Ca2+-
sensitive ‘stromal interaction molecules’ [90-92] and members of the PM protein 
family ORAI [93, 94] as key players of the molecular CRAC entry machinery.  
 
1.3.1 The calcium sensor STIM1 
Stromal interaction molecules (STIMs) are single pass, type I transmembrane Ca2+-
sensitive proteins located in the ER or PM. Mammals express two isoforms (STIM1 
and STIM2), with only a small fraction of STIM1 being targeted to the PM [95, 96]. In 
2007, Grosse et al. were the first to link the STIM1 isoform (in human 77.5 kDa,  
685 aa) to SOCE signaling via a CRAC mechanism in platelets, where the protein is 
located within the DTS membrane [97]. In general, the lumen-oriented N-terminal 
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segment of STIM1 encodes a Ca2+-binding EF-hand domain (aa 63-98), and a sterile 
α-motif (SAM, aa 132-200, i.e. a putative protein interaction module mediating homo- 
and hetero-oligomerization) prior to the 21 residue transmembrane segment (aa 214-
234). The cytosolic C-terminal region contains two CC-motifs (aa 248-388) and 
finally, at the C-terminal end, a Pro/ Ser- and a Lys-rich region (aa 600-629 and  
aa 672-685, respectively) [95, 98] (see also Figure 1.6). The primary sequence-
based domains are highly conserved between homologues and across species [99]. 
Moreover, the 3D-structure of the EF-SAM motif, which forms a distinct compact 
entity, exposes a unique feature: The lumenal STIM1 segment contains a second, 
non-canonical EF-hand motif not involved in Ca2+-binding, but having stabilizing 
function instead [95]. At neutral pH, the tertiary distribution of EF-SAM residues 
exhibits a negatively charged surface; however, there is also a small patch of basic 
residues present within the SAM domain of the protein [98]. Thereby, the negative 
potential may be responsible for electrostatic guidance of Ca2+ to the binding loop of 
the canonical EF-hand motif, whereas the positive SAM portion might support 
additional biomolecular interactions, e.g. with membrane lipids. 
 
 
 
Figure 1.6: Human STIM1 domain structure: (1) N-terminal Ca2+-binding EF-hand domain (aa 63-98), 
(2) SAM motif (aa 132-200), (3) transmembrane domain (TM, aa 214-234), (4) two CC-motifs (aa 248-
388), (5) C-terminal Pro/ Ser- (aa 600-629) and Lys-rich regions (aa 672-685). The EF-SAM region 
forms a distinct entity and harbours an additional non-canonical EF-hand motif [95]. The predicted 
ORAI1 binding site is located at the end of the second CC-domain, i.e. aa 384-389. 
 
Based on recent data, CRAC activation and initiation occurs as a multi-step, STIM1-
mediated process: Under resting conditions, the STIM1 EF-hand domain is Ca2+-
loaded and the protein exists as a stable, globular monomer located in the ER/ DTS. 
Upon activation-induced store depletion, STIM1 Ca2+-binding is immediately 
abrogated [91, 92] and the EF-SAM entity is significantly destabilized, resulting in 
STIM1 transitioning from holo-Ca2+-loaded monomers to higher-order apo-Ca2+-
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depleted homotypic dimers/ oligomers in a partial unfolding-coupled process [95, 98]. 
This preliminary monomer-to-oligomer transition is reversible, as binding of Ca2+ 
restores the compact monomeric EF-SAM folding. Once oligomerized, homotypic 
STIM1 complexes translocate from a disperse DTS distribution to distinct clusters of 
DTS-PM junctions [95]. 
 
1.3.2 STIM1-ORAI1 interaction and CRAC entry 
The true identity of the mentioned CRAC channels has also remained elusive until 
very recently. As initially indicated by studies on leukocytes, primary megakaryocytes 
and platelets of respective knock-out mice, the ORAI1 protein was finally described 
as the long-sought CRAC channel moiety in platelets [94, 100, 101]. Proteins of the 
ORAI family (ORAI1, ORAI2 and ORAI3; 28-33 kDa) contain four transmembrane 
segments - with both the N- and the C-terminal end facing the cytosol - and reveal 
high levels of glycosylation [102, 103]. They are assumed to function as homo-
tetramers [104, 105]. 
ORAI1 tetramers are teardrop shaped and estimated to form the CRAC channel pore 
[94, 101, 106]. Accordingly, subsequent to Ca2+-store depletion, ORAI1 is recruited to 
the same DTS-PM junctions as STIM1 dimers, creating sites of direct STIM1-ORAI1 
heterotypic interaction ('punctae') [107-109] (Figure 1.7; predicted ORAI1 binding site 
in STIM1: aa 384-389). The minimal CRAC complex hence presumably consists of 
one STIM1 dimer and the ORAI1 tetramer channel pore [110, 111]. Following STIM1-
ORAI1 coupling, the newly assembled CRAC channel is finally activated and the 
consequent influx of Ca2+ persistently enhances [Ca2+]i for further intracellular 
signaling events and Ca2+-store refilling. Still, numerous questions remain 
unanswered regarding the proposed STIM1-mediated CRAC initiation mechanism: 
From a structural point of view, how does partial unfolding of STIM1 by Ca2+-
depletion lead to EF-SAM oligomerization? How does this oligomerization promote 
homotypic interactions of cytoplasmic STIM1 domains, resulting in translocation of 
the protein complex to DTS-PM junctions? Moreover and more importantly, how does 
oligomerized STIM1 couple to and induce ORAI1-composed Ca2+-channels? Does 
the STIM1-ORAI1 interaction occur directly or are there additional factors involved? 
Last but not least, is the discussed model also relevant in platelets in vivo? 
One possibility to particularly address the latter issues, and thus further enhance our 
understanding of the molecular machinery regulating CRAC entry, might be given by 
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elucidating the protein-protein interactions of the cytosolic STIM1 domains in 
platelets. 
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Figure 1.7: Scheme of STIM1-ORAI1 mediated CRAC entry in platelets, based on Stathopulos et al. 
[95]. Under resting conditions, DTS-localized STIM1 monomers are Ca2+-loaded and maintain a well-
folded lumenal EF-SAM region. Activation-induced store release deprives Ca2+ from the STIM1 EF-
hand domain, with EF-SAM entities undergoing partial unfolding-coupled oligomerization. The 
resulting STIM1 dimers translocate to the PM to interact with activated ORAI1 tetramers thus forming 
the CRAC channel pore for prolonged Ca2+-influx. 
 
1.4 Protein interaction studies 
Protein-protein interactions are the basis of many processes in living cells and 
regulate the majority of biological functions, e.g. during signal transduction, protein 
activation/ inactivation as well as structural maintenance, biosynthesis and transport 
of nutrients and metabolites. Such interactions might occur persistently in form of 
protein complexes or transiently as for instance during protein modification. 
Nowadays, a multitude of techniques and strategies is available to investigate this 
decisive issue of systems biology, with each individual one having distinct 
advantages and disadvantages with regard to sensitivity and specificity. Thus, the 
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following sections provide a brief excerpt of those biochemical methods selected for 
the purpose of this recent study. 
 
1.4.1 Co-immunoprecipitation of protein complexes 
Immunoprecipitation (IP) of intact protein complexes (i.e. antigen and associated 
ligands) is called co-immunoprecipitation (Co-IP) and considered to be the gold 
standard for protein-protein interaction assays [112, 113]. By targeting a protein 
believed to participate in a larger protein complex with a specific antibody in a Co-IP 
approach, the entire protein complex can be co-isolated as well, thus enabling 
subsequent identification of further suspected constituents. Prerequisites are 
maintenance of native experimental conditions and stable binding between the 
complex members [114]. Being solely capable of verifying interactions between 
suspected interaction partners, this method strongly depends on the availability of 
suitable antibodies (both for the IP and for subsequent ID via Western blotting) and 
did originally not provide screening approaches. However, implementation of protein 
mass spectrometry (MS) (see 1.5.2) instead of Western blotting partially overcomes 
the latter limitation since it allows a non-targeted analysis of the whole immuno-
precipitate. 
IP and Co-IP experiments can be performed both directly and indirectly. During a 
direct approach, the respective antibodies are first immobilized on a solid support, 
such as agarose or sepharose resins [115, 116]. The resulting antibody-bead 
complexes are subsequently added to the sample mixture and the targeted proteins 
are selectively captured via specific antibody-antigen interaction. When performing 
an indirect (Co-)IP approach, free antibodies are directly incubated with the sample 
protein mixture [113]. Once associated, antibody-target protein complexes are finally 
precipitated by adding a solid support coated with the bacterial surface proteins A or 
G which bind the Fc-regions of most IgG species and subclasses. Random 
orientation of the coupled antibodies on the resin, as it frequently occurs in direct 
(Co-)IP approaches, is a priori prevented [117]. Thus providing a higher degree of 
antibody mobility, this method is particularly useful in case of low target protein 
concentration as well as low antibody-epitope affinity. 
Despite the applied (Co-)IP method, the major technical obstacle is the availability of 
target protein-specific antibodies - which might be circumvented with the aid of 
protein tags. If the protein of interest is expressed recombinantly, additional 
Introduction 
   
35 
oligopeptide sequences can be appended to its native aa-sequence, usually at the  
N- or C- terminal end [118]. These 'fusion tags' assist during protein identification as 
well as artificial modification and purification. With respect to Co-IPs, several types of 
protein tags are feasible: (a) epitope tags, e.g. the hemagglutinin tag (HA) and the 
V5-tag; (b) affinity tags, such as the glutathione-S-transferase tag (GST) and poly- 
histidine tags (His-tag) (see also 1.4.2); and (c) chromatography tags as for instance 
the polyanionic FLAG-tag [119, 120]. For each of these oligopeptides, high-affinity 
antibodies can be efficiently generated and used to exclusively target any 
recombinant protein carrying the respective tag. However, tag addition as well as 
expression in producer cell lines might affect native protein function and interaction 
behaviour to some extent. This has to be considered when evaluating the biological 
relevance of the obtained data. For this reason, protein tags are often specifically 
designed to enable their subsequent removal by chemical agents or by specific 
proteolysis [120]. Moreover, for further verification of Co-IP data, a counter-IP can be 
performed - meaning a targeted Co-IP of questionable protein interaction partners 
followed by specific screening of the obtained interactome for the original protein of 
interest. True interactions are likely to Co-IP in either way. 
 
1.4.2 Affinity purification of individual proteins and protein complexes 
Affinity chromatography generally enables isolation and concentration of a specific 
subset of molecules based on highly specific and reversible interactions, such as 
receptor/ ligand- or antigen/ antibody-binding. This method is widely applicable, 
however, it is most commonly used for the purification of either modified (e.g. 
glycosylated) or recombinant proteins carrying an affinity tag [121-124]. Depending 
on the stringency of chromatographic conditions, targeted proteins can be isolated 
together with associated components. Hence affinity chromatography approaches 
are also suitable for protein complex and interaction studies. 
The stationary phase typically consists of an agarose gel matrix adequately modified 
with the corresponding ligand onto which the initial sample solution (usually crude 
cell/ tissue lysates or blood serum) is directly applied in a batch or a column setup 
[122]. During the affinity purification process, the targeted proteins are trapped on the 
stationary phase by exploiting the predefined interaction properties. Non-bound 
sample molecules either pass the matrix directly without significant retardation or are 
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removed by subsequent washing of the resin. The trapped proteins are finally 
recovered from the immobilized ligand by specific elution. 
For large scale protein purification, fusion tag-targeted approaches are commonly 
preferred. As tag-ligand chemistry is usually well-characterized, tagged fusion 
proteins are easy to manipulate and can often be isolated from crude sample 
mixtures in a single-step affinity purification approach based on an immobilized 
version of their specific ligands. Such protein tags include the maltose binding protein 
(MBP-tag), the GST-tag, as well as the His-tag which will be described in more detail 
in the following [125-127]. Accordingly, His-tags are short sequences of four (His4-
tag) to nine (polyHis-tag) histidine residues and are among the most common fusion 
tags [125]. As histidines have high affinity for metal ions by forming specific 
coordinated complexes, His-tagged proteins can be trapped on a matrix containing 
immobilized (e.g. via chelators) metal ions, such as cobalt, nickel or copper. The 
respective technique is consequently described as ‘immobilized metal ion affinity 
chromatography’ (IMAC) [128, 129]. Subsequent elution strategies include change of 
pH (as protonated His residues dissociate from the IMAC resin) as well as addition of 
either metal chelating agents (e.g. EDTA) or competitive molecules such as 
imidazole. 
 
1.4.3 Pull down assays 
Regarding the study of putative protein interactions, all techniques described so far 
follow the same principle: A protein of interest is isolated based on specific affinities 
and additional interacting components are co-purified simultaneously - yet indirectly. 
Pull down assays, however, offer an alternative affinity purification technique where 
random proteins (meaning without further modification or specification) themselves 
may be used as a ‘stationary  phase’ to directly screen for their individual interactome 
[130, 131]. Accordingly, the protein of interest (i.e. ‘the bait’) is first purified and 
subsequently immobilized on a solid-phase material. The thus generated 'bait 
support' is then incubated with the sample mixture and used for a targeted 'pull down' 
of putative bait-interaction partners (i.e. ‘the prey’). In this context, activated solid-
phase supports, such as Affi-Gel 10 (BioRad) or SulfoLink (Pierce), allow for direct 
covalent immobilization of almost any bait molecule to beaded agarose or sepharose. 
The most convenient conjugation chemistries applied are those directed towards 
primary amines (-NH2) and sulfhydryl groups (-SH) of cysteine residues. For this 
Introduction 
   
37 
purpose, a terminal cysteine residue is frequently added at either the N- or the  
C-terminus of synthetically produced bait peptides. Additional functional groups 
targeted for covalent linking are hydroxyls, carboxylic acids and carbohydrate 
moieties [115, 116]. To preserve proper structural folding, incubation of both bait and 
prey material has to be performed under native conditions throughout the whole 
procedure. For this reason, the application of this technique is moreover commonly 
limited to analysis of non-membrane bait proteins. 
 
1.4.4 Size exclusion chromatography in protein purification 
In size exclusion chromatography (SEC), dissolved analytes are separated by their 
molecular hydrodynamic volume or size, respectively [132]. Being considered a low 
resolution chromatography, this technique is routinely applied under low pressure 
conditions for the final ‘polishing’ and desalting of crude protein purifications. The 
underlying principle is that analytes of different sizes will pass with different retention 
times through a chemically inert stationary phase consisting of porous particles of a 
defined pore size. During the procedure, small-sized molecules penetrate into the 
pores of the stationary phase and thus traverse a larger volume (i.e. the respective 
pore volume plus the interparticle volume) than comparatively larger sample 
components. As a consequence, high-molecular-weight analytes elute prior to low-
molecular-weight material. Equally sized molecules, however, theoretically elute 
together. Generally, the so-called exclusion limit defines the upper end of separation, 
i.e. when sample components are too large to traverse the stationary phase and thus 
elute in the void volume [132, 133]. The permeation limit, on the other hand, 
describes the other extreme: All analytes below this molecular weight value penetrate 
the entire pore volume and finally elute in one single fraction. As the mobile phase is 
usually the same solvent used to dissolve the sample, even individual biological 
activities of e.g. purified proteins can be maintained [132, 133]. 
 
1.5 Protein identification by mass spectrometry 
In the post-genomics era, large-scale proteomic and functional studies aim at a 
global view on the total protein content expressed by a cell type, tissue or organism. 
However, the proteome of a given biological system is highly dynamic and 
multifaceted. Therefore, besides protein identification, such approaches also have to 
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consider post-translational modifications (PTMs), alternative splice- and isoforms of 
proteins, quantitative aspects and protein-protein interactions [134]. 
Generally, proteomic workflows comprise adequate sample preparation (including 
cell lysis), specific enrichment or purification strategies (as proteome datasets are 
often biased towards high abundant proteins), followed by protein separation and 
fractionation often based on techniques like gel electrophoresis or (multidimensional) 
liquid chromatography.  Protein/ peptide sequencing, identification and 
characterization (including e.g. PTM annotation) is finally performed via mass 
spectrometric measurements and subsequent computational data analysis using 
distinct search algorithms (most commonly Mascot [135]), databases (e.g. 
UniProtKB/ Swiss-Prot at www.ebi.ac.uk/uniprot) and further bioinformatic tools. 
Continual progress in sample preparation and separation as well as in sensitivity, 
scanspeed and resolution of mass spectrometers has enhanced the potential of this 
strategy decisively. For instance, both PTMs as well as (semi-)quantitative tasks are 
nowadays efficiently addressable. MS-based proteomics consequently holds the key 
to a refined knowledge in fundamental systems biology – including cellular 
mechanisms related to platelet regulation and function [136]. Hence the following 
sections will outline proteomic workflows in general and provide an insight into those 
MS methods used in the context of this work. 
 
1.5.1 Preparing protein samples for MS analysis 
1.5.1.1 Cell lysis 
Sample preparation for proteomic research encompasses as a first step protein 
extraction from respective biological material (e.g. by cell disruption), followed by 
specific protein enrichment and removal of interfering or contaminating lysate 
components. For cell lysis, one distinguishes between mechanical (also 'physical') 
and non-mechanical cell disruption strategies [137]. 
Regarding mechanical cell lysis, high-pressure- (also 'high shear'-) homogenization 
as well as sonication have been applied within the current study. High-shear 
mechanical processors are often referred to as the method of choice for large-scale 
approaches and have proven to be especially suitable for bacteria and mycelia [137]. 
In a French press, the cell suspension is e.g. pressed through a narrow valve or 
channel, which consequently disrupts cell membranes by strong liquid shear and 
highly focused turbulences at the entrance orifice, as well as by the sudden pressure 
Introduction 
   
39 
drop to atmospheric value as soon as the lysate passes the exit orifice [137, 138]. 
Sonication (also ‘ultrasonic treatment’ or 'sonoporation') on the other hand, which is 
best suited for volumes less than 100 mL, utilizes pulsed, high frequency sound 
waves to lyse cells with less resistant cell walls, such as certain bacteria and fungi as 
well as animal cells and tissue in laboratory scale [138]. The resulting pressure 
waves confer mechanical energy to the liquid, leading to streaming and the formation 
and sudden collapse of low-pressure vapor cavities (i.e. cavitation process). As a 
consequence, intensive shock waves spread out through the suspension with 
sufficient energy to cause agitation and disruption of cellular barriers by shearing and 
breaking of covalent bonds. However, one general negative side effect of any 
physical cell disruption technique is given by the accompanying harsh conditions, in 
particular sample heating. Hence to avoid unintended protein denaturation and 
aggregation, the whole equipment has to be constantly cooled and repetition cycles 
should be kept at a minimum. 
In contrast, non-mechanical lysis of cell walls and plasma membranes provides a 
mild and efficient alternative. Such strategies include enzymatic digestion of 
bacterial, yeast or plant cell walls by glycanases and proteases [139], plasmolysis by 
osmotic shock in hypotonic buffers, as well as chemical permeabilization of the 
plasma membrane phospholipid bilayer by organic solvents (e.g. chloroform, 
benzene, ether, methanol and toluene) or chaotropic agents (such as urea and 
guanidine) [140, 141], as well as by detergents (for instance digitonin, Nonidet P-40, 
and Triton X-100) [137, 142]. Depending on the type of detergent, cell lysis might 
occur (a) denaturing when using strong solubilizing ionic agents; or (b) non-
denaturing in case of non-ionic and zwitterionic compounds. The latter ones, such as 
Triton X-100 or CHAPS, are consequently preferred when studying native protein 
interactions and functions [142]. 
Subsequent to cell disruption, sample complexity has to be further reduced prior to 
MS analysis. Final enrichment and purification of the protein fraction of interest can 
be performed in a targeted approach as described in 1.4.1 - 1.4.3, as well as by 
either overall protein precipitation or specific sample separation - with gel 
electrophoresis and liquid chromatography being widely applied techniques in this 
context. 
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1.5.1.2 Separation of protein samples by gel electrophoresis 
Electrophoresis, i.e. ion migration in an electric field, is a frequently applied technique 
for the separation of complex mixtures, including protein samples. In gel 
electrophoresis, this process occurs e.g. within a polyacrylamide or agarose gel 
matrix; molecular segregation hence depends on both electrophoretic mobility of the 
analyte ions and gel filtration effects specified by the size of the gel pores, which 
results in retardation of larger molecules in relation to smaller ones. 
In polyacrylamide gel electrophoresis (PAGE) - a technique commonly applied for 
protein separation - gels are generated by co-polymerizing acrylamide monomers via 
crosslinking reagents such as N,N’-methylenebisacrylamide [143]. Prior to PAGE, 
protein samples have to be efficiently solubilized. In addition, by forming complexes 
with the anionic detergent sodium dodecylsulfate (SDS), proteins are denatured (see 
also 1.5.1.1) and their endogenous net charges are negatively masked [143, 144]. 
Hence, upon application of an electric field, the protein mixture starts migrating 
towards the anode and the individual components are separated into series of 
discrete bands following the order of their molecular masses (1D-SDS-PAGE). To 
increase sample resolution, two orthogonal separation modes, such as isoelectric 
focussing (IEF) and SDS-PAGE, can be combined (i.e. two-dimensional gel 
electrophoresis, 2-DE) [145, 146]. Subsequent to 1-DE and 2-DE, separated proteins 
can be detected via gel staining (e.g. Coomassie blue- and silver staining) [147] or 
Western blotting, and distinct proteins of interest can furthermore be excised, 
proteolytically processed and extracted for MS-based characterization. 
 
1.5.1.3 Protein digestion and denaturation 
Due to their large molecular weight (MW), intact proteins are difficult to analyze by 
means of mass spectrometry and thus are commonly cleaved into peptide fragments 
prior to MS analysis. Such cleavage can be performed either in-gel or in-solution via 
usage of proteolytic enzymes which specifically recognize and hydrolyse peptide 
bonds between distinct amino acids. One of the most frequently applied proteases in 
proteome studies is the highly effective serine protease trypsin [148]. It cleaves 
peptide bonds C-terminally of arginine and lysine residues (except these amino acids 
are followed by proline [149]) and thus creates fragments of approximately 10-17 aa 
with defined C-terminal ends. Tryptic digestion is regularly performed over night at 
37°C in a protease-to-protein ratio of 1:20 - 1:100. However, since complex protein 
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structures (caused by intra- and intermolecular ion bonds, hydrogen bridges, 
hydrophobic interactions and disulfide bonds) often disturb proteolytic cleavage, 
initial denaturation is mandatory. For instance chaotropes (commonly urea or 
thiourea) help to undo hydrogen bridges. Detergents, on the other hand, are used in 
particular when hydrophobic proteins are to be solubilized as they prevent protein 
precipitation by conferring a hydrophilic character [142, 144]. Regarding disulfide 
bonds, a common derivatisation procedure is given by dithiothreitol (DTT)-mediated 
chemical reduction. In order to avoid reorganization of the resulting free cysteines, 
these sidechains are subsequently irreversibly modified by alkylation, e.g. via 
iodoacetic acid or iodoacetamide (IAA) [150]. 
 
1.5.1.4 Separation of proteome samples by liquid chromatography 
Liquid chromatography (LC) offers the possibility of sample fractionation and 
concentration as well as removal of contaminations, such as salts, buffers and 
detergents. In principle, dissolved analytes (i.e. in a mobile phase) are applied to a 
stationary phase where they are retained based on their individual affinities towards 
the respective matrix material [151]. Unbound or unspecific remnants and 
contaminations are subsequently removed and the trapped molecules are finally 
released by suitable elution profiles. 
Nowadays, high-performance LC (HPLC, also high-pressure LC) - an automated, fast 
and very sensitive high-throughput LC setup - is regularly used in proteomic studies 
[152]. Here, the analytes are automatically applied to the HPLC system, e.g. via an 
autosampler. For the generation of solvent gradients particularly necessary for 
continuous analyte elution, at least a binary solvent system is regularly implied in 
proteomic HPLC setups. In proteome research, HPLC approaches typically utilize a 
precolumn concentration setup for fast sample loading and desalting [153], coupled 
to the main separation column. Since reduction of the inner diameter of the 
separation column results in enhanced sensitivity [152], optimal HPLC separation is 
commonly achieved with small columns densely packed with 2-5 µm particle size 
resins. Following the column unit, an UV-detector enables constant monitoring of the 
chromatographic separation. Accordingly, the UV-absorbance of peptide bonds is 
regularly determined at 214 nm, the one of aromatic side chains of Phe, Tyr or Trp 
residues at 254 and 280 nm, respectively [154]. 
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Of the numerous chromatographic procedures, two have to be particularly mentioned 
with regard to protein mass spectrometry: ion exchange chromatography (IEC) and 
reversed-phase chromatography (RP). The competitive interaction of charged 
molecules presents the basic principle of IEC. Here, the stationary phase contains 
ionic functional groups which selectively interact with analyte counter ions [155, 156]. 
In contrast to IEC, which is often applied for pre-fractionation, RP enables separation 
of organic substances according to their hydrophobicity [152, 157]. The RP stationary 
phase is commonly substituted with long chains of alkyl residues, thus providing an 
organic, non-polar matrix. Depending on the hydrophobic characteristics of the 
analyte, C1 up to C30 RP materials are used (commonly C4 or C8 for hydrophobic 
proteins and C18 for peptides) [158]. For improved separation, the mobile phase is 
composed of an aqueous buffer solution (including low amounts of ion pair reagents 
such as formic acid or trifluoroacetic acid) and an organic modifier. Due to low 
viscosity, low chemical reactivity, absence of UV-absorbance above 200 nm and a 
medium polarity enabling both miscibility with water and solubility of ionic as well as 
non-polar compounds, acetonitrile (MeCN) is most frequently applied in this context 
[156]. During the chromatographic procedure, polar sample components elute first 
from the column while non-polar molecules (e.g. peptides) are stronger retained as a 
result of hydrophobic interactions with the stationary phase. The bound analytes are 
finally eluted by gradually increasing the organic content of the mobile phase, with 
non-polar molecules consequently having longer retention times (RTs) than more 
polar ones. 
Nowadays, RP accounts for the majority of LC, in particular in proteome research 
where it enables efficient separation of complex protein and peptide mixtures and 
simultaneously provides suitable conditions for subsequent MS analysis [152]. In 
recent years, multidimensional LC-MS (MDLC-MS) is increasingly emerging, with 
MudPIT (i.e. multidimensional protein identification technology) being one of the most 
prominent techniques in this context [159, 160]. Such approaches enable separation 
and identification of highly complex peptide mixtures. 
 
1.5.2 Mass spectrometric analysis 
Mass spectrometers are composed of three functional units: Firstly, the ion source 
where charged analyte ions are generated, desolvatized and transferred into the 
mass analyzer. In proteomics, which requires gentle and reliable ionization of large 
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biomolecules, either electrospray ionization (ESI) [161, 162] or matrix-assisted laser 
desorption/ ionization (MALDI) [163, 164] are generally applied. The resulting analyte 
ions are subsequently stored, separated or further fragmented in the mass analyzer 
unit. Such MS analyzers include quadrupole systems (e.g. triple-quadrupoles, see 
1.5.2.2), electric ion traps, as well as time-of-flight- (TOF), Fourier-transform ion 
cyclotron resonance- (FTICR, also FTMS) and Orbitrap instruments [165-167]. Hybrid 
instruments, such as linear ion traps (Qtrap, LTQ), LTQ-Orbitraps or quadrupole-TOF 
analyzers (QTOF), combine certain advantages [168, 169]. Finally, the MS detector 
unit traces the current induced by analyte ions and continuously records respective 
ion signal intensities. Since the amount of ions delivered by the mass analyzer is 
usually relatively small, some types of electron multipliers are applied for further 
signal amplification by secondary electron emission [170, 171]. Deriving from the 
analyzer-detector interplay, the total of ion signal intensities is displayed as a function 
of m/z (m: mass, z: charge) throughout the whole scanning period - hence generating 
a typical mass spectrum. Nowadays, there are multiple instrumental MS setups 
commercially available, with each single one having individual specificities and 
distinct fields of application. The following sections, however, will only focus on MS 
units which have been of particular relevance in the context of this work. 
 
1.5.2.1 Electrospray ionization and LC-ESI-MS 
Electrospray means the dispersion of a liquid into many small, charged droplets 
within an electrostatic field [172]. During ESI, peptide ions are desolvatized - i.e. 
transferred from solution into gas phase - at atmospheric pressure. In detail, the 
sample solution is injected to the MS ion source, e.g. via a fused silica capillary held 
at a voltage of several kV depending on the source design (Figure 1.8). Upon 
entering the electrostatic field, charged droplets are generated and continuously 
reduced in volume by constant solvent evaporation [173]. When reaching the 
Rayleigh limit, the charge accumulation on the droplet’s surface culminates in so-
called Coulomb explosions, leading to formation of microdroplets. According to both 
the ‘charged residue model’ (established by Dole et al., 1968) [174] and the ‘single 
ion in droplet theory’ by Friedrich Röllgen et al. (1989) [175], numerous subsequent 
Coulomb explosions finally produce droplets having a radius of approximately one 
nanometer and containing only a single analyte ion. Upon collision with nitrogen 
molecules infused at the interface between the source region and the mass analyzer, 
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these distinct analyte ions are finally completely desolvatized. Another theory, the 
‘ion evaporation model’, has been established by Iribane and Thomson in 1976 [176]. 
Accordingly, the Coulomb explosions generate bigger microdroplets (radius 
approximately eight nanometers) containing several molecule ions and thus being 
highly charged. At these conditions, free molecule ions are constantly emitted into 
the gas phase. Although the amount of charges decreases during this process, the 
ion emission still persists since the microdroplet volume is simultaneously reduced by 
continuous solvent evaporation - until the analyte ions, both singly and multiply 
charged, are completely desolvatized. 
 
 
 
Figure 1.8: ESI ionization. Upon application of an electric field, charged sample droplets are generated 
and accelerated towards the mass analyzer interface. During this process, constant solvent 
evaporation culminates in Coulomb explosions and thus in generation of first multiply charged 
microdroplets and finally in completely desolvatized analyte ions. 
 
In either case, for adequate sample desolvatisation organic liquids (ethanol, MeCN, 
etc.) proved to be advantageous since the correspondingly high vapor pressure 
accelerates solvent evaporation during the ESI process [177]. Moreover, peptide 
protonation (as required for MS measurement in positive ion mode) is promoted by 
addition of weak organic acids, commonly formic acid (FA) at a concentration of 0.01-
0.2%. Additional components like salts, detergents or strong ion-pairing agents such 
as trifluoroacetic acid (TFA) [178], however, may disturb ESI-MS either by affecting 
the ionization process (e.g. prevention of free analyte formation due to detergent-
peptide interactions) or by subsequently contributing to strong ion signals 
themselves. As a consequence, when using appropriate conditions HPLC-based 
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sample purification/ separation and ESI-MS can efficiently be combined in an online 
LC-ESI-MS setup [179]. In this context, to maintain stable ionization, the applied 
voltage and the flow rate, as well as sample conductivity and liquid surface tension 
have to be balanced adequately. The challenge is to improve both the ESI ionization 
process and the sensitivity of detection by using small separation columns and low 
flow rates (i.e. nano-LC) [152]. Hence, columns having an inner diameter of  
75-100 µm are most frequently utilized in proteomic applications nowadays. 
 
1.5.2.2 Quadrupoles and ion traps 
From the MS ion source, peptide ions are directed towards the mass analyzer for m/z 
determination. Typical ESI mass analyzer used in the context of this work were 
quadrupoles and ion trap instruments. Quadrupoles are composed of four parallel 
metal electrodes (circular or hyperbolic rods) to which an electric field - i.e. a 
superimposition of a constant and an alternating current - is applied. In detail, 
opposite electrodes are in-phase and have the same polarity; juxta-positioned 
electrodes possess reversed polarity and a phase difference of 180° [180]. Once 
injected, the analyte ions are guided to traverse these oscillating quadrupole fields. 
Thereby, depending on the applied voltages, exclusively ions of a defined m/z ratio 
travel on stable trajectories and will reach the detector unit. All other ions are either 
deflected or absorbed upon collision with the electrodes. This allows for selected 
scanning of a whole range of ions of particular m/z values. Modern quadrupoles are 
thus able to address m/z values up to 4,000 with a mass resolution between 500 and 
5,000 [180]. Often linear arrangements of three quadrupoles Q1-Q3 (i.e. triple-
quadrupole instrument) are applied (Figure 1.9). 
 
 
 
Figure 1.9: Triple-quadrupole instrument. Q1 and Q3 function as mass filters for precursor- and 
fragment ion selection, respectively. Q2 acts as collision cell for CID fragmentation of selected 
precursor ions. 
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In this context, Q1 and Q3 commonly function as mass filters and Q2 acts as collision 
cell where precursor ions selected in Q1 are fragmented by colliding with intra-
systemic nitrogen, helium or argon gas molecules (‘collision-induced dissociation’, 
CID) [181]. Thus generated fragment ions are then transferred to Q3 and are either 
completely or selectively conveyed to the MS detector unit (tandem MS, MS² or 
MS/MS). In contrast to MS survey scans (m/z ratios of all precursor ions) MS/MS 
fragmentation of isolated precursor ions consequently delivers profound sequence 
information. 
Whereas quadrupole systems selectively filter for ions of certain m/z values, ion traps 
have specifically been developed to accumulate and store ions of a defined mass 
range prior to successive m/z determination. Classical electric ion traps consist of a 
circular electrode (‘ring electrode’), to which a radio frequency voltage is applied, and 
two endcap electrodes held at ground (or auxiliary) potential [182] (Figure 1.10). 
Analyte ions are injected and finally ejected via small orifices located in the center of 
each endcap. Functionally, electric ion traps are based on the same principles as 
quadrupoles; however, in contrast to quadrupoles, upon application of an adequate 
alternating current a three-dimensional quadrupolar field is generated inside the trap 
[183]. As soon as analyte ions enter the trap, they are first decelerated by collision 
with helium gas ('collisional cooling') and finally caught in the center of the ion trap. 
Here, they are maintained on stable trajectories and successively ejected towards 
the detector with the aid of multipolar electric fields. Modern electric ion traps provide 
mass resolutions up to 20,000 and cover m/z values of up to 6,000 [184]. Apart from 
3D electric ion traps, linear ion traps are increasingly utilized in proteomic research - 
either as stand-alone device or in hybrid instruments. Here, analyte ions are 
maintained in a trapping field generated by a set of quadrupole rods [185, 186]. 
Similar to triple-quadrupole systems, ion traps also enable distinct peptide 
fragmentation: The selected precursor ions are first isolated (ions of diverging m/z 
values are ejected from the trap) and subsequently excited by increasing the applied 
voltages. This finally culminates in controlled collision with helium gas molecules and 
thus in CID fragmentation. Once generated fragments can either be ejected for 
detection (MS²) or selectively subjected to further fragmentation cycles (i.e. MS³ - 
MSn) to gain supplemental structural information. 
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Figure 1.10: Electric ion trap, consisting of a ring- and two endcap electrodes. Analyte ions entering 
the system through a small orifice are stored, fragmented and selectively ejected towards the MS 
detector via modulation of three-dimensional quadrupolar electric fields generated inside the He-filled 
trap. 
 
1.5.2.3 Interpretation of mass spectrometric datasets 
During the MS/MS fragmentation process, peptides predominantly dissociate at the 
peptide bonds, which generates both charged and neutral fragments. In case of the 
charge remaining at the N-terminal fragment side, the respective ions are called a-, 
b- and c-ions (following the Roepstorff-Fohlmann-Biemann nomenclature) [187, 188]; 
if it remains at the C-terminal side, they are called x-, y-, z-ions. Once assigned to the 
[a,b,c]- or [x,y,z]-series, the primary aa-sequence of the original molecule can 
theoretically be concluded based on the individual molecular masses of all 
successive fragments of a distinct precursor peptide (i.e. de-novo sequencing) [189]. 
In addition, as mentioned in 1.5.2.2, MSn approaches also provide specific 
supplemental information e.g. on PTMs. 
The generated data might be analyzed manually; however, usage of advanced 
proteomic informatics tools vastly reduces the time required for large datasets 
derived from LC-ESI-MS/MS experiments. Using search algorithms like Mascot [135], 
SEQUEST [190], OMSSA [191], Phenyx [192] or X!Tandem [193], experimental MS 
spectra are automatically compared to in silico predicted ones provided by adequate 
proteomic databases. Databases frequently applied in this context are the 
International Protein Index (IPI, www.ebi.ac.uk) or the UniProtKB/ Swiss-Prot 
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(www.ebi.ac.uk/uniprot) database. Potentially matching sequences are subsequently 
summarized in identification lists [194, 195]. This process regularly implies profound 
statistical validation including determination of thresholds or evaluation of false 
discovery rates (FDR) [196-198]. The likelihood of matching peptides being random 
hits is calculated and displayed as scores (e.g. high Mascot scores relate to ‘true’ 
hits); respective cut-off scores have to be defined depending on the applied 
algorithm. In addition, search parameter settings commonly specify: (a) the applied 
protease; (b) the number of allowed missed cleavage sites; (c) modifications (e.g. 
carbamidomethylation, methionine oxidation and phosphorylation sites); (d) MS and 
MS/MS mass tolerances; as well as (e) charge and expected fragment ion series. 
The total amount of identified peptides is finally assembled to proteins which are 
subsequently ranked based on their individual overall identification score. Most often, 
consistent protein annotation relies on assignment of at least two distinct peptides, 
thereby excluding so-called 'one-hit wonders'. Determination of isoforms moreover 
requires reliable identification of at least one unique peptide for the putative isoform. 
However, for final protein characterization - including PTM annotation as well as 
structural and quantitative evaluations - and adequate integration in complex 
biological interaction networks (i.e. systems biology), more sophisticated 
computational strategies are required. Valuable protein-specific information is 
provided by online databases such as UniProtKB/ Swiss-Prot (e.g. on protein domain 
structure, putative modification sites, isoforms, homologies and reported function), as 
well as by sequence- and structural alignment tools as for instance SMART 
(http://smart.embl-heidelberg.de), PFAM (http://pfam.sanger.ac.uk) or the RCSB 
protein database (www.rcsb.org/pdb/home/home.do). Finally, bioinformatics tools like 
STRING 8.3 (http://string-db.org) also include data derived from other -omics 
approaches (i.e. genomics, transcriptomics, metabolomics, lipidomics), thus helping 
to deduce a scheme of known and predicted interaction pathways related to the 
identified protein. 
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2 Objective 
 
Following platelet recruitment to sites of vessel injury, elevation of intracellular Ca2+-
levels and platelet shape change provide the basis for later-occurring events of 
cellular hemostasis. Therefore, numerous studies have focused on gaining insight 
into related signaling pathways and the underlying protein-protein interactions. The 
actin filament-remodelling protein VASP and the Ca2+-sensing molecule STIM1 are 
regarded as being amongst the key players involved during this stage of platelet 
response. Although these two proteins have clearly been linked to cytoskeleton 
shape change and platelet CRAC entry, their precise regulatory and functional 
mechanisms are still far from being fully understood. Therefore, it is the overall aim of 
this work to specifically address the VASP and STIM1 interactome in resting 
platelets. 
First, inspired by Benz et al. [199], a differential proteomics strategy should be 
developed to analyze protein binding of VASP in a phosphorylation-dependent 
manner. For this purpose, affinity-tagged phospho-mimetic mutants of human VASP 
will be overexpressed, purified and immobilized on an affinity support. The resulting 
bait matrices should consequently serve to perform differential phospho-specific 
interactome studies in native platelet lysates of human origin. In parallel, the 
interactome of STIM1 will be examined in a similar pull down-based approach: Here, 
affinity-tagged truncated STIM1 constructs (cytosolic portion) should be used as bait 
and native lysates of resting human platelets as prey material. 
Differential analysis and component identification of all interactome samples will 
finally be achieved by 1D-SDS-PAGE and subsequent nano-LC-ESI-MS/MS. 
Putative protein interaction partners will moreover be specifically confirmed by 
independent methods, such as Co-IP and Western blotting. In this context, particular 
interest focuses on hitherto unknown VASP- and STIM1 binding partners as these 
candidates may help to deduce signaling pathways possibly involved in platelet 
activation and shape change  - and thus in the regulation of thrombotic events. 
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3 Materials and Methods 
 
3.1 Table 3.1: Chemicals, media and enzymes 
Reagent Manufacturer 
Acetic acid Merck KGaA, Darmstadt, Germany 
Acetonitrile, ULC/ MS Merck KGaA, Darmstadt, Germany 
N-Acetyl-β-D-glucosamine Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Affi-Gel 10 BioRad Lab GmbH, München, Germany 
Agarose Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ammonium bicarbonate Merck KGaA, Darmstadt, Germany 
Ammonium sulfate Merck KGaA, Darmstadt, Germany 
Ampicillin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bacto agar Becton Dickinson GmbH, Heidelberg, Germany 
Bacto tryptone Becton Dickinson GmbH, Heidelberg, Germany 
Bacto yeast extract Becton Dickinson GmbH, Heidelberg, Germany 
BamHI restriction enzyme New England BioLabs GmbH, Frankfurt, Germany 
Benzonase endonuclease Merck KGaA, Darmstadt, Germany 
Boric acid Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bovine serum albumin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bromo-chloro-indolyl-galacto-pyranoside Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bromophenol blue sodium salt Merck KGaA, Darmstadt, Germany 
Calcium chloride Merck KGaA, Darmstadt, Germany 
Calpain-1 (µ-calpain), human Merck KGaA, Darmstadt, Germany 
Calpain-2 (m-calpain), rat Merck KGaA, Darmstadt, Germany 
Chloramphenicol Applichem GmbH, Darmstadt, Germany 
3-[(3-Cholamidopropyl)dimethylammonio]-1-propane-
sulfonate 
Merck KGaA, Darmstadt, Germany 
Citric acid Merck KGaA, Darmstadt, Germany 
Cloned Pfu DNA polymerase AD Agilent Technologies Dtl. GmbH, Böblingen, Germany 
Cloned Pfu reaction buffer AD (10x) Agilent Technologies Dtl. GmbH, Böblingen, Germany 
CLP36 protein (PDLIM1), human Abnova Corporation, Jhongli City, Taiwan 
Complete Mini Protease Inhibitor Roche Diagnostics, Mannheim, Germany 
Complete Mini Protease Inhibitor, EDTA-free Roche Diagnostics, Mannheim, Germany 
Complete Protease Inhibitor Roche Diagnostics, Mannheim, Germany 
Coomassie G-250 Merck KGaA, Darmstadt, Germany 
Dimethyl sulfoxide Applichem GmbH, Darmstadt, Germany 
Dithiothreitol Merck KGaA, Darmstadt, Germany 
DNA Ladder (123 bp) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
DNA Loading Buffer MBI Fermentas GmbH, St. Leon-Rot, Germany 
dNTP-Mix  MBI Fermentas GmbH, St. Leon-Rot, Germany 
Dulbecco's modified Eagle's medium PAA Laboratories GmbH, Cölbe, Germany 
Dulbecco's phosphate buffered saline PAA Laboratories GmbH, Cölbe, Germany 
Eagle’s minimum essential medium PAA Laboratories GmbH, Cölbe, Germany  
EcoRI  restriction enzyme New England BioLabs GmbH, Frankfurt, Germany 
Ethanol (96%) (v/v) Carl Roth GmbH, Karlsruhe, Germany 
Ethanol (for DNA preparation) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ethanolamine Merck KGaA, Darmstadt, Germany 
Ethylenedinitrilo-tetraacetic acid disodium dihydrate Merck KGaA, Darmstadt, Germany 
ExGen 500 in vitro transfection reagent MBI Fermentas GmbH, St. Leon-Rot, Germany 
Fetal calf serum PAA Laboratories GmbH, Cölbe, Germany  
Formaldehyde solution (37%) (v/v) Carl Roth GmbH, Karlsruhe, Germany 
Formic acid, ULC/ MS Merck KGaA, Darmstadt, Germany 
GelRed Nucleic Acid Gel Stain VWR International GmbH, Nürnberg, Germany 
GeneRuler 1kb DNA Ladder MBI Fermentas GmbH, St. Leon-Rot, Germany 
Geneticin (G418) Applichem GmbH, Darmstadt, Germany 
D-Glucose Merck KGaA, Darmstadt, Germany 
L-Glutamine Invitrogen GmbH, Karlsruhe, Germany 
Glycerol (87%) (v/v) Merck KGaA, Darmstadt, Germany 
Glycine Applichem GmbH, Darmstadt, Germany 
Hexamminecobalt (III) chloride Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrochloric acid (37%) (v/v) Merck KGaA, Darmstadt, Germany 
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N-2-Hydroxyethylpiperazine-N-2-ethanesulfonic acid Applichem GmbH, Darmstadt, Germany 
Igepal CA-630 Sigma, Deisenhofen, Germany 
Imidazole Merck KGaA, Darmstadt, Germany 
Iodoacetamide Merck KGaA, Darmstadt, Germany 
Isopropyl β-D-1-thiogalactopyranoside MBI Fermentas GmbH, St. Leon-Rot, Germany 
L-Lysine hydrochloride Merck KGaA, Darmstadt, Germany 
Magnesium chloride, anhydrous Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Manganese chloride Merck KGaA, Darmstadt, Germany 
Mark 12 MW Standard Invitrogen GmbH, Karlsruhe, Germany 
β-Mercaptoethanol Biomol GmbH, Hamburg, Germany 
Methanol, Rotipuran Carl Roth GmbH, Karlsruhe, Germany 
Monosodium phosphate Merck KGaA, Darmstadt, Germany 
2-N-Morpholino ethanesulfonic acid Carl Roth GmbH, Karlsruhe, Germany 
NEB BSA solution New England BioLabs GmbH, Frankfurt, Germany 
NEBuffer 3 (10x)  New England BioLabs GmbH, Frankfurt, Germany 
Ni-NTA agarose Qiagen GmbH, Hilden, Germany 
Nicotinamide Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Nonfat dried milk powder Applichem GmbH, Darmstadt, Germany 
Nonidet P40 substitute Fluka GmbH, Steinheim, Germany 
NuPAGE LDS Sample Buffer (4x) Invitrogen GmbH, Karlsruhe, Germany 
NuPAGE MOPS SDS Running Buffer (20x) Invitrogen GmbH, Karlsruhe, Germany 
NuPAGE Transfer Buffer (20x) Invitrogen GmbH, Karlsruhe, Germany 
Ortho-phosphoric acid (89%) (v/v) VWR International GmbH, Nürnberg, Germany 
Overnight Express Instant TB Medium Merck KGaA, Darmstadt, Germany 
PageRuler Prestained Protein Ladder  MBI Fermentas GmbH, St. Leon-Rot, Germany 
Penicillin PAA Laboratories GmbH, Cölbe, Germany 
PhosSTOP Phosphatase Inhibitor Roche Diagnostics, Mannheim, Germany 
Ponceau S Merck KGaA, Darmstadt, Germany 
Potassium chloride Merck KGaA, Darmstadt, Germany 
Potassium dihydrogen phosphate Merck KGaA, Darmstadt, Germany 
Potassium hydroxide Merck KGaA, Darmstadt, Germany 
2-Propanol Merck KGaA, Darmstadt, Germany 
Quick Ligation Reaction Buffer New England BioLabs GmbH, Frankfurt, Germany 
Rubidium chloride Merck KGaA, Darmstadt, Germany 
See Blue Plus2 Prestained Protein Standard Invitrogen GmbH, Karlsruhe, Germany 
Silver nitrate Carl Roth GmbH, Karlsruhe, Germany 
Sodium acetate Merck KGaA, Darmstadt, Germany 
Sodium azide Merck KGaA, Darmstadt, Germany 
Sodium carbonate, anhydrous Applichem GmbH, Darmstadt, Germany 
Sodium chloride Merck KGaA, Darmstadt, Germany 
Sodium citrate Merck KGaA, Darmstadt, Germany 
Sodium dihydrogen phosphate monohydrate Merck KGaA, Darmstadt, Germany 
Sodium dodecylsulfate Applichem GmbH, Darmstadt, Germany 
Sodium hydrogene carbonate Merck KGaA, Darmstadt, Germany 
di-Sodium hydrogen phosphate dihydrate Merck KGaA, Darmstadt, Germany 
Sodium hydroxide VWR International GmbH, Nürnberg, Germany 
Sodium thiosulfate pentahydrate Merck KGaA, Darmstadt, Germany 
Streptomycin PAA Laboratories GmbH, Cölbe, Germany 
Taq-Polymerase MBI Fermentas GmbH, St. Leon-Rot, Germany 
Trifluoroacetic acid, ULC/ MS Merck KGaA, Darmstadt, Germany 
Tris-hydroxymethyl-aminomethane, base Applichem GmbH, Darmstadt, Germany 
Triton X-100 Roche Diagnostics GmbH, Mannheim, Germany 
Trypsin Gold, modified, seq. grade Promega GmbH, Mannheim, Germany 
Tween 20 Sigma-Aldrich, Steinheim, Germany 
Urea Applichem GmbH, Darmstadt, Germany 
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3.2 Table 3.2: Kits 
Kit Manufacturer 
BCA Protein Assay Kit Thermo Fisher Scientific, Bonn, Germany 
β-Gal Staining Kit Invitrogen GmbH, Karlsruhe, Germany 
GenomeLab DTCS Quick Start Kit Beckman Coulter GmbH, Krefeld, Germany 
MinElute Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
Ni-NTA Spin Kit Qiagen GmbH, Hilden, Germany 
NucleoBond Xtra Maxi EF Kit Macherey-Nagel, Düren, Germany 
NucleoSpin Plasmid Kit Macherey-Nagel, Düren, Germany 
QIAquick PCR Purification Kit  Qiagen GmbH, Hilden, Germany 
Quick Ligation Kit New England BioLabs GmbH, Frankfurt, Germany 
StrataClone PCR Cloning Kit Stratagene GmbH, Heidelberg, Germany 
 
3.3 Table 3.3: Additional material 
C18 trapping column: inner diameter 100 µm, length 2 cm, packed in-house with Synergi 
Hydro RP, particle size 4 µm, pore size 80 Å, Phenomenex, Aschaffenburg, Germany 
Econo Chromatography Column (2.5 x 20 cm), BioRad Lab GmbH, München, Germany 
Gravity flow column (5/ 10/ 20 mL), Qiagen GmbH, Hilden, Germany 
RP main column: inner diameter 75 µm, length 30 cm, packed in-house with Synergi 
Hydro RP, particle size 2 µm, pore size 80 Å, Phenomenex, Aschaffenburg, Germany 
Chromatography 
Superdex HiLoad 26/ 60 FPLC separation column (200 pep grade), Amersham 
Biosciences, Freiburg, Germany 
15/ 50 mL Falcon tubes, Becton Dickinson GmbH, Heidelberg, Germany 
0.2 mL Multiply PCR microtube strips, Sarstedt AG & Co, Nümbrecht, Germany 
12 cm Petri plates, Sarstedt AG & Co, Nümbrecht, Germany 
6-well Petri plates, Sarstedt AG & Co, Nümbrecht, Germany 
0.5 mL Protein LoBind tubes, Eppendorf AG, Hamburg, Germany 
0.5/ 1.5/ 2 mL Reaction tubes, Eppendorf AG, Hamburg, Germany 
Reaction tubes and 
Vessels 
25/ 75 cm² Tissue culture flasks, Sarstedt AG & Co, Nümbrecht, Germany 
CL-X Posure Film, Thermo Fisher Scientific, Bonn, Germany 
Hybond-ECL Nitrocellulose Membranes, Amersham Biosciences, Freiburg, Germany 
Immobilon-PSQ PVDF Transfer Membrane, Millipore GmbH, Schwalbach, Germany 
NuPAGE precast Bis-Tris gels (10/ 12/ 4-12%), Invitrogen GmbH, Karlsruhe, Germany 
SuperSignal West Pico Chemiluminescence Substrate, Thermo Fisher Scientific, Bonn, 
Germany 
XCell II Blot Modul, Invitrogen GmbH, Karlsruhe, Germany 
SDS-PAGE and 
Western blot 
XCell SureLock Mini Cell, Invitrogen GmbH, Karlsruhe, Germany 
 
3.4 Table 3.4: Instruments 
SLM Aminco French Pressure Cell Press, Heinemann, Schwäbisch Gmünd, Germany 
Sonopuls UW 2070, Bandelin Electronic GmbH & Co KG, Berlin, Germany 
Cell lysis 
Sonorex RK 52 ultrasonic bath, Bandelin Electronic GmbH & Co KG, Berlin, Germany 
Allegra 21R centrifuge, F2402H rotor, Beckman Coulter GmbH, Krefeld, Germany 
Avanti J-20XP, Beckman Coulter GmbH, Krefeld, Germany 
Centrifuge 5415R, Eppendorf AG, Hamburg, Germany 
Centrifuge 5804R, Eppendorf AG, Hamburg, Germany 
Centrifuge 5810R, A-4-62 and A-4-81 rotor, Eppendorf AG, Hamburg, Germany 
Multifuge 3S-R, Heraeus, Kendro Lab Products, Osterode, Germany 
Optima Ultracentrifuge, TLA 100.4 rotor, Beckman Coulter GmbH, Krefeld, Germany 
Speed Vac Plus SC 110A, Thermo Savant Labsystems, Egelsbach, Germany 
Speed Vac SPD 111V, Thermo Savant Labsystems, Egelsbach, Germany 
Speed Vac SPD131DDA (Thermo Fisher Scientific, Dreieich, Germany) 
Centrifuges 
Ultracentrifuge L7, SW41 rotor, Beckman Coulter GmbH, Krefeld, Germany 
ÄKTA FPLC System, Amersham Biosciences, Freiburg, Germany 
Famos, Switchos, Ultimate nano-HPLC system, Dionex, Idstein, Germany 
Fraction Collector 2110, BioRad Lab GmbH, München, Germany 
Chromatography 
Ultimate 3000 HPLC System, Dionex, Idstein, Germany 
Certomat, B. Braun Melsungen AG, Melsungen, Germany Incubation 
CO2 incubator MCO 18AIC(UV), SANYO Sales & Marketing Europe GmbH, München, 
Germany 
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Grant-bio rotor PTR-30, Grant Instruments Ltd., Shepreth, England 
IKA HS 260 basic shaker, IKA Werke GmbH & Co. KG, Staufen, Germany 
Thermomixer comfort, Eppendorf AG, Hamburg, Germany 
LTQ-FT Ultra, Thermo Fisher Scientific, Dreieich, Germany 
LTQ XL, Thermo Fisher Scientific, Dreieich, Germany 
QStar Elite, Applied Biosystems, Darmstadt, Germany 
Mass 
spectrometers 
Qtrap 4000, Applied Biosystems, Darmstadt, Germany 
Gel chamber class II 40-1214, PEQLAB Biotechnologie GmbH, Erlangen, Germany 
Genetic Analysis System CEQ 8000, Beckman Coulter GmbH, Krefeld, Germany 
Spectrophotometer UV-1601, Shimadzu Deutschland GmbH, Duisburg, Germany 
Thermocycler T1, Biometra GmbH, Göttingen, Germany 
Transilluminator TFX-35M UV, Gibco BRL Life Technologies, Eggenstein, Germany 
PCR, cloning and 
DNA sequencing 
Video camera (Hama objective M49 IV), INTAS Science Imaging Instruments GmbH, 
Göttingen, Germany 
Scanner Power Look 2100 XL, Umax Systems GmbH, Willich, Germany 
Electrophoresis Power Supply EPS 1001, Amersham GE Healthcare, Freiburg, Germany 
Electrophoresis Power Supply EPS 3501 XL, Amersham GE Healthcare, Freiburg, 
Germany 
Fusion FX7 CCD Imaging System, Vilbert Lourmat Deutschland GmbH, Eberhardzell, 
Germany 
PowerPac 3000 power supply, BioRad Lab GmbH, München, Germany 
PowerPac Basic power supply, BioRad Lab GmbH, München, Germany 
SDS-PAGE and 
Western blot 
Processor X-OMAT 1000, Eastman Kodak Company, Rochester, NY, USA 
 
3.5 Software and databases 
Analyst 1.4 (MDS AB Sciex) 
Analyst QS 2.0 (MDS AB Sciex) 
CEQ 8000 software, version 9.0 (Beckman Coulter Inc.) 
Chromeleon 6.8.SR8 (Dionex Softron) 
Fusion software, version 15.12 (Vilbert Lourmat GmbH) 
GATC Viewer 1.00 (GATC Biotech AG) 
Mascot Daemon 2.2.0.2, server version 2.2.0.4 (Matrix Sciences Ltd.) 
Silverfast Ai6.0.2r.36 scanning software (Lasersoft Imaging AG) 
Xcalibur 2.1.0 build 1139 (Thermo Fisher Scientific) 
 
3.6 Cellular material 
3.6.1 Table 3.5: Escherichia coli strains (E.coli) 
E.coli strain Characteristics 
E.coli BL21 - IPTG-inducible T7 RNA polymerase gene 
- Suitable for high-level expression of non-toxic genes 
- Tetracycline and CHL resistance 
E.coli BL21-CodonPlus-RP - Similar to E.coli BL21 
- Addresses codon bias problem of GC-rich genomes by expressing tRNAs for  
  AGA, AGG and CCC 
E.coli DH5α - Reduced endogenous nuclease activity due to RecA- and endonuclease I  
  deficiency 
- Applied for molecular cloning and plasmid DNA production 
E.coli Rosetta - IPTG-inducible T7 RNA polymerase gene 
- Suitable for high-level expression of non-toxic genes 
- Mutated lac permease gene (lacZY) for uniform IPTG entry and regulatable  
  induction levels 
- Addresses codon bias problem by expressing tRNAs for AGG, AGA, AUA,  
  CUA, CCC, GGA on CHL resistance factor 
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Except for E.coli BL21-CodonPlus-RP (Stratagene GmbH, Heidelberg, Germany), all 
E.coli strains were kindly provided by Prof. Dr. Thomas Renné (Department of 
Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden) and Prof. 
Dr. Ulrich Walter (Institute of Clinical Biochemistry and Pathobiochemistry, Center of 
Inner Medicine, Würzburg, Germany). They were stored at -80°C in glycerol stocks 
until further usage. 
 
3.6.2 HEK293 cells 
HEK293 cells were kindly provided by Dr. Raffael Kettler (Leibniz-Institute for 
Analytical Sciences - ISAS - e.V., Dortmund, Germany) and were cultivated in tissue 
culture flasks in HEK293 complete medium at 37°C and 5% CO2. Having grown to a 
confluence of 80-90% (determined microscopically) within 5-7 days of incubation, 
cells were washed twice with DPBS and harvested by stringently rinsing the flasks 
with DPBS. Upon centrifugation at 200 x g at 4°C for 7 min, the resulting cell pellets 
were (a) either processed further; or (b) stored at -80°C for subsequent treatment, or 
(c) passaged at a ratio of 1:10 for continued cell culture and spreading. Cell culture 
medium was exchanged twice a week. For long-time preservation, harvested cell 
pellets of confluent 25 cm² tissue culture flasks were suspended in HEK293 
cryomedium (800 µL per pellet) and stored at -196°C.  
 
HEK293 complete medium 
DMEM, 1% (v/v) MEM, 10% (v/v) FCS, 1% (v/v) Pen/ Strep 
 
HEK293 cryomedium 
HEK293 complete medium, 36% (v/v) FCS, 9% (v/v) DMSO 
 
3.6.3 Platelet purification 
A total of 200 mL human blood from healthy donors was collected in 50 mL tubes 
(each containing 10 mL of anti-coagulation buffer) and centrifuged for 20 min at  
300 x g at 20°C. The upper phase (i.e. platelet-rich plasma, PRP) was subsequently 
cleared from remaining leukocytes and erythrocytes by two additional 20 min 
centrifugation steps (20°C) at 300 and 400 x g, respectively. Upon discard of the final 
supernatant, residual plasma proteins were removed from the obtained platelet pellet 
by resuspending twice with 20 mL washing buffer, followed by 20 min centrifugation 
at 400 x g (20°C). Finally, the resulting platelet pellet was aliquoted à 100 µL, flash 
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frozen in liquid nitrogen and stored at -80°C until further use. The same protocol was 
applied for platelet enrichment out of 500 mL fresh, leukocyte-depleted apheresis 
concentrates from healthy donors which were kindly provided by the Department of 
Transfusion Medicine, University of Würzburg, Germany. 
In addition, all purified mouse platelets (C57Bl6-Sv129 mixed background) used in 
this study were kindly provided by Dr. Attila Braun (Rudolf-Virchow-Center, 
Würzburg, Germany). 
 
Anti-coagulation buffer, pH 6.5 
100 mM sodium citrate, 7 mM citric acid, 140 mM glucose, 15 mM EDTA 
 
Tyrode's buffer (10x) 
1.45 M NaCl, 50 mM KCl, 10 mM MgCl2 
 
Washing buffer, pH 6.4 
50 mL anti-coagulation buffer, 50 mL Tyrode's buffer (10x), 400 mL water 
 
3.7 Vector constructs 
Table 3.6: Original vectors 
Original vector Characteristics 
pcDNA3.1/V5-HisA 
(Invitrogen GmbH, Karlsruhe, Germany) 
 
- 5,500 bp, MCS nt 902-999 
- CMV-, SV40- and T7 promoter 
- Amp resistance, Neo resistance 
- C-terminal V5-tag, C-terminal His6-tag 
pcDNA3.1/V5-His lacZ 
(Invitrogen GmbH, Karlsruhe, Germany) 
 
- See pcDNA3.1/V5-HisA 
- 8,500 bp 
- Control vector, encodes β-galactosidase 
- Calculated MW of fusion protein 121 kDa 
pGEX 6p1 
(GE Healthcare, München, Germany) 
 
- 4,900 bp, MCS nt 945-981 
- IPTG-inducible, Tac promoter 
- Amp resistance 
- N-terminal GST-tag 
pQE-30 
(Qiagen GmbH, Hilden, Germany) 
 
- 3,500 bp, MCS nt 145-192 
- IPTG-inducible, T5 promoter 
- Amp resistance 
- N-terminal His6-tag 
 
Table 3.7: Recombinant vector constructs 
Recombinant vector construct Insert characteristics 
STIM1Ctail 
(in pGEX 6p1) 
- STIM1 cytoplasmic region (aa 484-685) 
- Insertion sites BamHI, XhoI 
- N-terminal GST-tag, C-terminal His6-tag 
- Calculated MW of fusion protein 49 kDa 
VASP-AAA ('non-phospho VASP') 
(in pQE-30) 
 
- Human full length VASP, site-directed mutagenesis of S157A,   
  S239A and T278A 
- Insertion sites BamHI, Sal I 
- N-terminal His6-tag 
- Calculated MW of fusion protein 41 kDa 
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VASP-DDE ('phospho-VASP') 
(in pQE-30) 
- Human full length VASP, site-directed mutagenesis of S157D,  
  S239D and T278E 
- Insertion sites BamHI, Sal I 
- N-terminal His6-tag 
- Calculated MW of fusion protein 41 kDa 
VASP-DDE∆FAB∆TD, VASP-AAA∆FAB∆TD 
(in pcDNA3.1/V5-HisA) 
 
- VASP-DDE/ -AAA, deletion of VASP-FAB and -TD domains 
  (∆aa 259-380) 
- Insertion sites BamHI, EcoRI 
- C-terminal V5-tag, C-terminal His6-tag 
- Calculated MW of fusion proteins 29 kDa 
VASP-DDE∆TD, VASP-AAA∆TD 
(in pcDNA3.1/V5-HisA) 
 
- VASP-DDE/ -AAA, deletion of VASP-TD domain (∆aa 343-380) 
- Insertion sites BamHI, EcoRI 
- C-terminal V5-tag, C-terminal His6-tag 
- Calculated MW of fusion proteins 38 kDa 
 
The phosphomimetic human VASP constructs ‘VASP-AAA’ and ‘VASP-DDE’ were 
kindly provided by Prof. Dr. Thomas Renné (Department of Molecular Medicine and 
Surgery, Karolinska Institute, Stockholm, Sweden); the STIM1 expression construct 
‘STIM1Ctail’ by Prof. Dr. Bernhard Nieswandt and Dr. Attila Braun (Rudolf-Virchow-
Center, Würzburg, Germany). Prof. Dr. Thomas Renné also provided an MBP fusion 
tag vector as positive E.coli transformation- and expression control (MW of fusion 
protein ~ 40 kDa). VASP deletion constructs 'VASP-AAA∆TD', 'VASP-DDE∆TD', 
'VASP-AAA∆FAB∆TD' and 'VASP-DDE∆FAB∆TD' were generated as described in 
3.7.1. For detailed vector maps, as well as full length nt- and aa-sequences, see 7.1-
7.3. 
 
3.7.1 Generation of VASP deletion constructs 
3.7.1.1 VASP mutagenesis primers 
For deletion of VASP subdomains, the following oligonucleotides were chosen as 
PCR primers (Table 3.8): 
 
Primer nt sequence (5’-to-3’) Details  
VASP-Fwd AGTGGATCCATGAGC 
GAGACGGTCATCTG 
- VASP forward primer (29 nt) 
- Melting temperature 69.5°C  
- Confers BamHI restriction site to the 5'-end of the VASP sequence 
VASP-Rev I TCGAGGTCACTAAT 
GAGCCTTAAGCTG 
- VASP reverse primer (27 nt) 
- Melting temperature 65.0°C 
- Deletes VASP-TD domain (nt 1027-1143)   
- Confers EcoRI-restriction site to the 3'-end of the VASP-sequence 
VASP-Rev II CTCTCACCAGCTT 
CGCTTAAGCTG 
- VASP reverse primer (24 nt) 
- Melting temperature 64.4°C 
- Deletes VASP-TD and -FAB domains  (nt 775-1143) 
- Confers EcoRI-restriction site to the 3'-end of the VASP-sequence 
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3.7.1.2 VASP deletion PCR 
Using the VASP pQE-30 vector constructs ‘VASP-AAA/ -DDE’ as DNA templates, 
VASP deletion PCRs were prepared in 0.2 mL PCR reaction tubes and performed in 
a T1 Thermocycler as outlined in the following (Table 3.9): 
 
Component Stock  In 25 µL reaction volume Temp.  Time 
 DNA template 0.1 µg/ µL 500 ng 96°C 2 min 
Pfu DNA polymerase 2.5 U/ µL 1.25 U 96°C 30 sec 
Primer 100 pmol/ µL 5 pmol per primer* 64°C 30 sec 
Pfu reaction buffer 10x 2.5 µL 72°C 2 min 
 
33 cycles 
dNTP-Mix 10 mM 0.5 µL 72°C 20 min 
DMSO - 5% (v/v) 
 
12°C ∞ 
 
* a) for deletion of VASP-TD domain:  VASP-Fwd + VASP-Rev I 
   b) for deletion of VASP-FAB and -TD domains: VASP-Fwd + VASP-Rev II 
 
The resulting VASP-PCR products were separated by agarose gel electrophoresis, 
purified using the QIAquick PCR Purification Kit according to the manufacturer’s 
instructions and stored at -20°C. 
 
3.7.1.3 Agarose gel electrophoresis 
1% (w/v) agarose was dissolved in 100 mL TBE buffer by heating. Having cooled 
down to 50-60°C, the gel solution was supplemented with 4 µL GelRed Nucleic Acid 
Gel Stain and poured into a gel chamber. For analysis, 2-5 µL DNA samples were 
mixed 2:1 with DNA Loading Buffer, loaded into the gel slots and subjected to a 
voltage of 109 V for 45 min. DNA bands were finally visualized by exposing the gel to 
UV light on a TFX-35M UV transilluminator and pictures were taken with an INTAS 
video camera system. 
 
10x TBE buffer 
0.89 M Tris base, 0.89 M boric acid, 20 mM EDTA 
 
3.7.1.4 PCR cloning in StrataClone SoloPack competent E.coli 
For enhanced amplification prior to enzymatic restriction, a StrataClone PCR Cloning 
Kit was used according to the manufacturer’s instructions. Purified VASP-PCR 
products were first incubated with 1 U Taq-Polymerase and 0.5 µL  
of the 10 mM dNTP-Mix at 72°C for 10 min to allow for generation of poly-A sticky 
ends, then cooled down to 4°C and subsequently integrated into a pSC-A-amp/kan 
vector (4.3 kb). Finally, 2 µL of the recombinant vector constructs were transformed 
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into 50 µL StrataClone SoloPack competent E.coli cells. Transformed cells were 
seeded on 12 cm LB-Amp agar Petri plates (pre-treated by plating of 40 µL 2% (w/v) 
X-gal solution for subsequent blue-white screening) and incubated overnight at 37°C. 
 
LB-Amp agar solution (1L) 
15 g Bacto agar, 10 g Bacto tryptone, 5 g Bacto yeast extract, 5 g NaCl, 100 mg Amp 
 
3.7.1.5 Colony picking and plasmid preparation 
Insert-positive clones were picked and proliferated in LB-Amp medium (2 mL for 
subsequent miniprep and 200 mL for maxiprep) overnight at 37°C and 200 rpm. The 
next day, plasmid preparation was performed using a NucleoSpin Plasmid Kit for 
miniprep and a NucleoBond Xtra Maxi EF Kit for maxiprep. DNA concentrations were 
evaluated by measuring the OD260 via an UV-1601 spectrophotometer. 
 
LB-Amp medium (1L) 
10 g Bacto tryptone, 5 g Bacto yeast extract, 5 g NaCl, 100 mg Amp 
 
3.7.1.6 BamHI/ EcoRI restriction digest 
BamHI/ EcoRI restriction digest of (a) purified pSC-A-amp/kan vectors containing the 
VASP-inserts ('source'); and (b) of the pcDNA3.1/V5-HisA vector ('target') was 
performed at 37°C overnight (Table 3.10). 
 
Component Stock  In 30 µL reaction volume 
DNA template Source: 2-3 µg/ µL 
Target: 4 µg/ µL 
4-6 µg 
6 µg 
BamHI 20 U/ µL 10 U 
EcoRI 20 U/ µL 10 U 
BSA solution 100 µg/ mL 33 ng 
NEBuffer 3 10x 3 µL 
 
The whole reaction volume was subsequently separated by agarose gel 
electrophoresis and further purified using the QIAquick PCR Purification Kit for the 
VASP-inserts and the MinElute Gel Extraction Kit for linearized pcDNA3.1/V5-HisA 
vector according to the manufacturer’s instructions. Purified DNA samples were 
quantified by OD260 measurement and stored at -20°C. 
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3.7.1.7 Ligation and transformation in E.coli DH5α 
Integration and ligation of the isolated VASP-inserts into linearized pcDNA3.1/V5-
HisA vector was performed according to the Quick Ligation Kit protocol (Table 3.11). 
 
Component Stock  In 20 µL reaction volume 
Digested vector 2-3 µg/ µL ~ 3 µg (1 µL) 
Digested insert 2-3 µg/ µL ~ 9-12 µg (4.5 µL) 
Quick Ligation Reaction Buffer  10 µL 
 
The whole reaction volume was subsequently transformed into 50 µL competent 
E.coli DH5α. In detail, the transformation reaction was first cooled on ice for 30 min, 
heat-shocked at 42°C for 45 sec, again chilled on ice for 2 min and finally incubated 
in 800 µL SOC medium at 37°C for 1 hour. Upon reducing the total volume to 100 µL 
in a Speed Vac Plus SC 110A (1,000 rpm for 5 min), transformed cells were seeded 
on 12 cm LB-Amp agar Petri plates overnight at 37°C. 
 
SOC medium (1L), pH 7.0 
20 g Bacto tryptone, 5 g Bacto yeast extract, 0.5 g NaCl, 2.5 mL 1 M KCl, 20 mL 1 M glucose 
 
3.7.1.8 VASP constructs - plasmid preparation and controls 
Colony picking of insert-positive clones and maxiprep plasmid preparations were 
performed as described in 3.7.1.5. Isolated recombinant plasmids were stored at  
-80°C. Correctness of vector recombination was validated (a) by VASP control PCRs 
using VASP primers VASP-Fwd/ -Rev I or -Rev II as described in 3.7.1.2; (b) by 
BamHI/ EcoRI control digests (see 3.7.1.6); and (c) by nucleotide sequencing. 
In detail, VASP construct minipreps were sequenced using the GenomeLab DTCS 
Quick Start Kit (‘Q-Kit’). Accordingly, 50-100 fmol of DNA template (i.e. 1 µL of a  
50-µL plasmid miniprep in 5 µL water) was first denatured at 96°C for 2 min and then 
briefly chilled on ice. Upon addition of 3 µL Q-Kit solution and 5 pmol sequencing 
primer (either T7-Fwd or BGH-Rev, see below), the sequencing reaction was 
executed in a T1 Thermocycler under the following conditions (Table 3.12): 
 
Primer nt sequence (5’-to-3’) Details Temp. Time 
98°C 40 sec 
96°C 20 sec 
T7-Fwd TAATACGACT 
CACTATAGGG 
- Forward sequencing primer  
- Melting temperature 48.0°C 
- Stock: 5 pmol/ µL 50°C 20 sec 
65°C 2 min 
 
30 cycles 
12°C ∞ 
BGH-Rev TAGAAGGCA 
CAGTCGAGG 
- Reverse sequencing primer 
- Melting temperature 54.8°C 
- Stock: 5 pmol/ µL 
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The reaction was finally stopped by addition of 15 µL stop solution. To remove salt 
and free ddNTPs, the DNA was subsequently precipitated with 60 µL absolute 
ethanol (-20°C) and centrifuged at maximum speed in an Allegra 21R centrifuge 
(rotor F2402H) at 4°C for 5 min. The obtained DNA pellet was washed with 180 µL 
70% (v/v) ethanol (25°C), followed by 5 min centrifugation as before. The resulting 
pellet was dried for 30 min at 25°C in the dark, dissolved in 35 µL Q-Kit sample 
loading solution and either stored at -20°C or directly analyzed in a CEQ 8000 
Genetic Analysis System using the CEQ 8000 software. In addition, final full-length 
sequencing of VASP construct maxipreps was provided by GATC Biotech (Konstanz, 
Germany); the delivered nucleotide sequences were analyzed via the GATC Viewer 
software. 
 
Stop solution (per 10 µL sequencing reaction) 
2 µL 100 mM EDTA (pH 8.0), 2 µL 3 M sodium acetate (pH 5.2), 1 µL glycogen solution (stock: 20 µg/ µL, 
provided by the Q-Kit), 10 µL water 
 
3.8 Protein expression 
3.8.1 Transformation of VASP-AAA, VASP-DDE and STIM1Ctail in E.coli 
For rapid transformation, 50 µL of competent E.coli BL21 were seeded on 12 cm LB-
Amp agar Petri plates pre-treated by plating of 34 µg/ mL CHL and incubated 
overnight at 37°C. The next day, colonies were picked and suspended in 200 µL 
transformation buffer. Upon addition of 1 µg plasmid DNA, the reaction was first 
chilled on ice for 10 min and then heat-shocked for 90 sec at 42°C. Finally, the whole 
transformation reaction was seeded on 12 cm LB-Amp-CHL agar Petri plates and 
incubated overnight at 37°C. In addition, for an enhanced protein expression,  
VASP-AAA and VASP-DDE were also transformed in E.coli Rosetta or BL21-
CodonPlus-RP according to the manufacturer’s instructions. 
 
Transformation buffer, pH 6.3 
10 mM MES-KOH, 100 mM RbCl, 45 mM MnCl2, 10 mM CaCl2, 3 mM hexamminecobalt (III) chloride 
 
3.8.2 Protein expression in E.coli 
Insert-positive clones were picked and incubated in 3 mL/ 10 mL/ 100 mL LB-Amp-
CHL medium at 37°C and 220 rpm overnight. The next day, these 'pre-cultures' were 
added to a total volume of 50 mL/ 250 mL/ 500 mL LB-Amp-CHL medium for further 
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proliferation and cultivated at 37°C and 220 rpm until bacterial concentration reached 
an OD600 of 0.4-0.6 (log-phase). Then the reaction was briefly chilled on ice and 
protein expression was induced by addition of IPTG at a final concentration of 1 mM. 
Bacterial cultivation was subsequently continued at 220 rpm for 16-24 hours. In this 
context, different incubation conditions (16°C, 25°C, 30°C and 37°C at 130-220 rpm) 
as well as media (LB-Amp/ 2% (v/v) ethanol, Superbroth medium, Overnight Express 
Instant TB Medium) were tested regarding their potential of significantly improving 
protein expression. Finally, these 'expression cultures' were centrifuged at 7,000 x g 
(4°C) for 10 min and bacterial cell pellets (up to 20 g/ 500 mL expression culture) 
were stored at -80°C. Generally, protein expression was controlled by 1D-SDS-
PAGE and Western blotting. 
 
LB-Amp-CHL medium (1L) 
10 g Bacto tryptone, 5 g Bacto yeast extract, 5 g NaCl, 100 mg Amp, 34 mg CHL 
 
Superbroth medium (1L) 
35 g Bacto tryptone, 20 g Bacto yeast extract, 5 g NaCl 
 
3.8.3 Transfection of VASP deletion constructs in HEK293 cells 
HEK293 cells were cultivated in 6-well plates in HEK293 complete medium at 37°C 
and 5% CO2 up to a confluence of 60-70% (determined microscopically). 3 µg of 
plasmid DNA (i.e. VASP-AAA∆FAB, VASP-DDE∆FAB, VASP-AAA∆FAB∆TD and 
VASP-DDE∆FAB∆TD) were diluted in 200 µl 150 mM NaCl (sterile), mixed with  
9.87 µl ExGen 500 in vitro transfection reagent and incubated at room temperature 
for 10 min. For evaluation of transfection efficiency, pcDNA3.1/V5-HisA lacZ was 
used as a positive control. Upon exchanging the cell culture medium with 2 mL of 
fresh HEK293 complete medium per well, the individual transfection reactions were 
finally added to the cells and incubation was started at 37°C and 5% CO2. 
In case of transient expression, incubation was stopped after 48 hours; cells were 
harvested and stored at -80°C. For stable protein expression, the culture medium 
was exchanged with 2 mL G418-selection medium 24 hours after transfection and 
cell culture was continued for 4-6 weeks. During this procedure and depending on 
cell density, insert-positive cells were extended first in 25 cm² and then in 75 cm² 
tissue culture flasks. Recombinant protein expression was regularly controlled by 
Western blotting and in case of pcDNA3.1/V5-HisA lacZ expression additionally by  
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β-gal staining using the Invitrogen β-Gal Staining Kit according to the manufacturer’s 
instructions. Once established, stable recombinant HEK293 cell lines were 
confluently grown in 75 cm² tissue culture flasks and finally harvested and stored at  
-80°C until further usage. In addition, for long-time preservation harvested cell pellets 
of confluent 25 cm² tissue culture flasks were suspended in HEK293 cryomedium 
supplemented with 500 µg/ mL G418 (800 µL per pellet) and stored at -196°C. 
  
G418-selection medium 
DMEM, 1% (v/v) MEM, 10% (v/v) FCS, 1% (v/v) Pen/ Strep, 500 µg/ mL G418 
 
3.9 Cell lysis, protein purification and interactome screening 
3.9.1 Lysis of human platelets 
Platelet pellet aliquots (volume: 100 µL) were suspended in chilled native platelet 
lysis buffer (1 mL per aliquot) and the suspension was lysed by 10 intervals of 
sonication in a Sonorex RK 52 ultrasonic bath (5 sec at 70% maximum power rate). 
Each interval was followed by 3 sec of vortexing and chilling on ice. The resulting 
lysate was cleared from remaining cellular debris by 30 min ultracentrifugation at 
20,000 x g (4°C). The protein content of the supernatant was subsequently quantified 
by BCA assay. Following lysis, samples were either directly processed or 
immediately stored at -80°C. 
 
Native platelet lysis buffer (2x), pH 7.4 
100 mM Tris-HCl, 2 mM EDTA, 2% (v/v) Triton X-100 
Prior to use, 1x lysis buffer was completed with protease- and phosphatase inhibitors (Complete Mini Protease- 
and PhosSTOP Phosphatase Inhibitor, Roche, according to the manufacturer’s instructions). 
 
3.9.2 IMAC purification of His6-tagged bait proteins 
Harvested pellets of recombinant E.coli or HEK293 cells were completely 
resuspended in chilled lysis buffer at a final concentration of 0.2 g/ mL. Subsequent 
cell lysis was performed depending on the amount of starting material: Sample 
volumes up to 25 mL (i.e. 5 g) were lysed by 5 intervals of sonication using a 
Sonopuls UW 2070 ultrasonicator. Each interval (10 sec at 75% maximum power 
rate) was followed by chilling on ice. Larger sample amounts were disrupted twice in 
a French press at 1 kbar and 4°C. The lysate was ultracentrifuged at 28,000 x g 
(4°C) for 30 min and the resulting supernatant was incubated with Ni-NTA agarose 
(0.5 mL per 1 g starting material, pre-equilibrated with lysis buffer) in a gravity flow 
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column by head-over-tail rotation (4 hours at 4°C). Following incubation, the matrix 
was washed with 4 column volumes (CV) lysis buffer and 5 CV washing buffer. 
Bound proteins were finally eluted with 5 CV elution buffer and either processed 
further or stored at -80°C. 
 
Lysis buffer, pH 7.9 
20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole 
Prior to use, lysis buffer was completed with protease- and phosphatase inhibitors (Complete Mini Protease 
Inhibitor EDTA-free and PhosSTOP Phosphatase Inhibitor, Roche, according to the manufacturer’s instructions). 
 
Washing buffer, pH 7.9 
20 mM Tris-HCl, 500 mM NaCl, 25 mM imidazole 
 
Elution buffer, pH 7.9 
20 mM Tris-HCl, 500 mM NaCl, 400 mM imidazole 
 
Alternatively, in case of recombinant HEK293 cells, purification of His6-tagged 
proteins was also performed using Qiagen Ni-NTA spin columns. Accordingly, cell 
pellets of three biological replicates (i.e. 5 x 106 cells or three confluent 75 cm² tissue 
culture flasks) were pooled and processed based on the Ni-NTA Spin Kit protocol for 
protein purification either under native or denaturing conditions. In brief, cells were 
lysed by incubation in 700 µL of the respective Ni-NTA lysis buffer for 15-30 min on 
ice and endogenous DNA was digested by addition of Benzonase endonuclease  
(3 U/ mL culture volume). Cellular debris was removed by centrifugation at 12,000 x 
g for 30 min (4°C) and up to 600 µL of the lysate supernatant were consequently 
incubated on the Ni-NTA spin column (pre-equilibrated with Ni-NTA lysis buffer). The 
flow through was collected by 5-min centrifugation at 270 x g (4°C) and the column 
was washed twice with 600 µL Ni-NTA washing buffer. Bound proteins were finally 
eluted twice with 200-300 µL Ni-NTA elution buffer via centrifugation at 890 x g for  
2 min and stored at -80°C. In either case, the IMAC-based purification procedure was 
monitored by 1D-SDS-PAGE and Western blotting. 
 
Native Ni-NTA lysis buffer, pH 8.0 
50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 1% (v/v) NP-40 
Prior to use, lysis buffer was completed with protease- and phosphatase inhibitors (Complete Mini Protease 
Inhibitor EDTA-free and PhosSTOP Phosphatase Inhibitor, Roche, according to the manufacturer’s instructions). 
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Denaturing Ni-NTA lysis buffer, pH 8.0 
7 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl 
Prior to use, lysis buffer was completed with protease- and phosphatase inhibitors (Complete Mini Protease 
Inhibitor EDTA-free and PhosSTOP Phosphatase Inhibitor, Roche, according to the manufacturer’s instructions). 
 
Native Ni-NTA washing buffer, pH 8.0 
50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole 
 
Denaturing Ni-NTA washing buffer, pH 6.3 
8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl 
 
Native Ni-NTA elution buffer, pH 8.0 
50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole 
 
Denaturing Ni-NTA elution buffer, pH 4.5 
8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl 
 
3.9.3 Size exclusion chromatography of purified His6-tagged proteins 
IMAC elution fractions were pooled and loaded on a Superdex HiLoad 26/ 60 
separation column (pre-equilibrated with FPLC buffer at 4°C). SEC was subsequently 
performed in FPLC buffer on an ÄKTA FPLC system at 4°C and at a constant flow 
rate of 1.5 mL/ min for 4 hours. Fractions were collected every 2 min (i.e. 3 mL 
volume per fraction) and stored at 4°C. Finally, the separation column was washed 
and re-equilibrated with FPLC-buffer. The whole procedure was constantly monitored 
via the ÄKTA UV detector unit at 280 nm. 
 
FPLC buffer, pH 7.9 (degassed) 
20 mM Tris-HCl, 500 mM NaCl 
 
3.9.4 Immobilization of purified recombinant proteins 
Protein coupling to Affi-Gel 10 was performed under aqueous conditions according to 
the manufacturer’s instructions. For each sample, an Affi-Gel 10 slurry volume of  
1 mL was transferred to a fritted Econo Chromatography Column and washed with  
3 CV deionized water (4°C) at gravity flow. Upon addition of the protein solution (at 
least 0.5 mL per mL gel) binding was performed at 4°C for 4 hours. The column was 
subsequently washed with 1 CV PBS (pH 7.4) and remaining free active esters were 
blocked by incubating in 1 M ethanolamine-HCl solution (pH 8.0, at least 0.1 mL per 
mL gel) at 4°C for 1h. Finally, the resulting affinity matrix was washed with 3 CV of 
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ice-cold deionized water and stored in an aqueous solution of 0.2% (w/v) sodium 
azide (pH 7.4) at 4°C. 
 
3.9.5 Interactome screening of native platelet lysates 
The generated affinity columns were washed twice in ice-cold deionized water and 
then pre-equilibrated in 10 CV ice-cold PBS (pH 7.4) at 4°C. Native platelet lysates 
were added (at least 10 mg per mL affinity support), the remaining column volume 
was filled with native platelet lysis buffer and incubation was performed by head-
over-tail rotation overnight at 4°C. The next day, the supernatant was discarded by 
gravity flow, the bead material was washed with 10 CV PBS and bound proteins were 
eluted by applying a pH-gradient of 10 mM glycine/ HCl pH 6.0, pH 5.0, pH 4.0,  
pH 3.0 and pH 2.0. For each pH-step, an elution volume of 3 CV was used. 
Immediately after elution, pH-values were adjusted to pH 7.0 by addition of an 
appropriate volume of 1M Tris-buffer, and the total volume of the individual pH-
fractions was reduced to 1 mL in a SPD 111V Speed Vac (35°C). The resulting five 
elution samples were either processed further or stored at -80°C. 
 
3.10 Protein analysis 
3.10.1 Protein quantification by BCA assay 
Samples were diluted 1:10, 1:25 and 1:50 in water and quantified in triplets using the 
BCA Protein Assay Kit according to the manufacturer’s instructions. 
 
3.10.2 1D-SDS-PAGE 
For 1D-SDS-PAGE, NuPAGE precast Bis-Tris gels (gel size 80 mm x 80 mm), XCell 
SureLock Mini Cell electrophoresis chambers and NuPAGE MOPS SDS Running 
Buffer (1x, pH 7.7) were used. Appropriate sample amounts were resolved in  
1x NuPAGE LDS Sample Buffer, denatured at 85°C for 15 min (300 rpm) and applied 
to the sample wells. For subsequent molecular mass evaluation, 3 µL of Mark 12 MW 
Standard or See Blue Plus2 Pre-Stained Protein Standard (in case of subsequent 
Western blotting) were chosen. Electrophoresis was performed at 4°C first at 50 V for 
15 min, followed by 200 V for approximately 50 min using a PowerPac power supply. 
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3.10.3 Western blotting 
Electroblotting of PAGE-separated protein samples on nitrocellulose or PVDF 
membranes was performed using an XCell II Blot Modul according to the 
manufacturer’s instructions. Blotting membranes, pads and Whatman papers were 
pre-soaked with transfer buffer for 5 min. PVDF membranes were activated by 
incubation in ethanol for 2 min. Blotting was performed at a constant voltage of 30 V 
per membrane for 1 hour and subsequently controlled by briefly incubating the 
membranes in 5% (w/v) aqueous Ponceau S solution. For subsequent 
immunodetection, membranes were repeatedly washed with TBS-T buffer to remove 
remaining Ponceau S, and finally incubated in 50 mL blocking solution for at least  
1 hour at room temperature. 
 
Transfer buffer (1L) 
50 mL NuPAGE Transfer Buffer (20x), 100 mL methanol 
 
TBS-T buffer, pH 7.4 
10 mM Tris-HCl, 150 mM NaCl, 0.05% (v/v) Tween 20 
 
Blocking solution (see also Table 3.13) 
5% (w/v) BSA- or 5% (w/v) dried milk powder in TBS-T buffer 
 
3.10.4 Immunodetection 
Blocked blotting membranes were washed with TBS-T buffer (1 x 15 min, 2 x 5 min) 
and incubated with the primary antibody solution at room temperature for at least  
1.5 hours (see Table 3.13). After briefly rinsing with ultrapure water (twice), washing 
with TBS-T buffer was repeated as above, followed by incubation with the secondary 
antibody solution at room temperature for at least 1 hour. Unbound components were 
subsequently removed by washing as above and HRP-detection was performed 
using the SuperSignal West Pico Chemiluminescence Substrate. Accordingly, 
blotting membranes were rinsed with 2 mL detection solution (peroxide A : luminal B 
= 1:1) for 1 min and exposed to CL-X Posure films for 30 sec, 2 min and 10 min. 
Films were developed using an X-OMAT 1000 Processor. Alternatively, a Fusion FX7 
CCD Imaging System was applied for digital Western blot development and analysis. 
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Table 3.13: Primary antibodies 
IgG Source Dilution In 
mAB anti-CLP36 (PDLIM1) 
(Abcam, Cambridge, UK) 
Rabbit 1:1,000 TBS-T/ 5% BSA (w/v) 
mAB anti-GPIb (13G12) 
(Emfret, Eibelstadt, Germany) 
Rat 1:1,000 TBS-T/ 5% BSA (w/v) 
mAB anti-His4-tag 
(Qiagen GmbH, Hilden, Germany) 
Mouse 1:2,000 TBS-T/ 5% dried milk powder (w/v) 
mAB anti-His5-tag 
(Qiagen GmbH, Hilden, Germany) 
Mouse 1:2,000 TBS-T/ 5% dried milk powder (w/v) 
mAB anti-His6-tag 
(Roche Diagnostics, Mannheim, Germany) 
Mouse 1:6,000 TBS-T/ 5% BSA (w/v) 
mAB anti-His(C-term)-tag 
(Invitrogen GmbH, Karlsruhe, Germany) 
Mouse 1:5,000 TBS-T/ 5% BSA (w/v) 
mAB anti-STIM1 (5A2) 
(Abnova, Taipei, Taiwan) 
Mouse 1:1,000 TBS-T/ 5% BSA (w/v) 
mAB anti-V5-tag 
(Invitrogen GmbH, Karlsruhe, Germany) 
Mouse 1:5,000 TBS-T/ 5% dried milk powder (w/v) 
mAB anti-VASP IE273* Mouse 1:1,000 TBS-T/ 5% dried milk powder (w/v) 
 
* purified from hybridoma cells provided by Prof. Dr. Thomas Renné (Department of Molecular Medicine and  
   Surgery, Karolinska Institute, Stockholm, Sweden) 
 
Secondary antibodies (all from Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
pAB anti-mouse HRP-conjugated (1:8,000 in TBS-T) 
pAB anti-rabbit HRP-conjugated (1:8,000 in TBS-T) 
pAB anti-rat HRP-conjugated (1:8,000 in TBS-T) 
 
3.10.5 Colloidal Coomassie staining of 1D-SDS-PAGE gels 
Immediately after electrophoresis, NuPAGE precast Bis-Tris gels were incubated in 
100 mL Coomassie solution at room temperature at 60 rpm overnight. After extensive 
washing in ultrapure water, stained gels were scanned using a Power Look 2100 XL. 
Protein spots of interest were excised and stored in 0.5 mL Protein LoBind tubes at  
-80°C for subsequent analysis by protein mass spectrometry. 
 
Coomassie solution 
34% (v/v) methanol, 2% (v/v) ortho-phosphoric acid, 17% (w/v) ammonium sulfate, 0.066% (w/v) Coomassie  
G-250 
 
3.10.6 Silver staining of 1D-SDS-PAGE gels 
Immediately after electrophoresis, NuPAGE precast Bis-Tris gels were silver-stained 
according to a modified protocol (Table 3.14) based on Blum et al. [200]. 
 
Step Duration Components (in 100 mL ultrapure water) 
Fixation At least 1 h 40% (v/v) ethanol, 10% (v/v) acetic acid 
Sensitization 1 min 0.02% (w/v) sodium thiosulfate pentahydrate 
Staining 20 min (4°C) 0.1% (w/v) AgNO3 
Development Up to 10 min 3% (w/v) sodium carbonate, 0.05% (v/v) formaldehyde 
Stop 30 min 0.05 M EDTA 
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Stained gels were scanned and protein spots were excised and stored in 0.5 mL 
Protein LoBind tubes at -80°C for subsequent analysis by protein mass spectrometry. 
 
3.10.7 IP and Co-IP 
All IP samples were kindly provided by Dr. Attila Braun (Rudolf-Virchow-Center, 
Würzburg, Germany). In detail, purified resting platelets (approximately 0.5 x 109) of 
(a) human origin; or (b) of either wildtype (‘STIM1+/+’) or STIM1-/- mice (both C57Bl6-
Sv129 mixed background) were solubilized in 1 mL IP buffer and lysed at room 
temperature for 10 min. Cell debris was subsequently removed by centrifugation at 
14,000 rpm for 10 min. To reduce unspecific antibody binding, samples were initially 
incubated with 25 µL protein G sepharose (previously equilibrated in IP buffer) for 30 
min at 4°C under rotation. Upon centrifugation at 2,500 rpm for 5 min (4°C), the 
supernatants were separated from the protein G sepharose pellet and transferred 
into a fresh Eppendorf tube. Then the platelet samples were first probed with 10 µg of 
the required IP-antibody (see Table 3.15) for 1 hour at 4°C, followed by an overnight 
incubation with 25 µL equilibrated protein G sepharose at 4°C under rotation. 
 
Table 3.15: IP-antibodies 
IgG Source Dilution Manufacturer 
pAB anti-CLP36  Mouse 1:500 BD Biosciences, Heidelberg, Germany 
pAB anti-GPIb (15E2) Rat 1:1,000 Emfret, Eibelstadt, Germany 
pAB anti-STIM1 Rabbit 1:8,000 Cell Signaling, Frankfurt, Germany 
 
The next day, antibody-antigen complexes were washed three times with IP buffer 
(followed by centrifugation at 2,500 rpm at 4°C for 5 min), resolved in 60 µL 2x SDS 
sample buffer and denatured at 95°C for 5 min. Upon removal of remaining protein G 
sepharose by centrifugation at 12,000 rpm at room temperature for 5 min, the IP-
supernatants were finally analyzed by 1D-SDS-PAGE and subsequent silver staining 
and/ or immunoblotting against STIM1, CLP36 or GPIb proteins (3.10.3 and 3.10.4). 
 
IP buffer  
15 mM Tris-HCl (pH 8.0), 155 mM NaCl, 1 mM EDTA, 1% (v/v) Igepal, 0.005 % (w/v) sodium azide. Prior to use, 
IP buffer was completed with protease inhibitors (Complete Mini Protease Inhibitor, Roche, according to the 
manufacturer’s instructions). 
 
SDS sample buffer (2x)  
10% (v/v) 1.25 M Tris (pH 6.8), 10% (v/v) β-mercaptoethanol, 20 % (v/v) glycerol, 4% (w/v) SDS, 0.02% (w/v) 
bromophenol blue sodium salt 
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3.10.8 Calpain in-solution digestion 
Calpain in-solution digestion was performed based on a modified protocol of Lakey et 
al. [201]. Accordingly, 30 pmol of human CLP36 protein (PDLIM1, purchased from 
Abnova) were resolved in a total volume of 100 µL calpain activating solution. For 
proteolytic cleavage, 3 U calpain-1 and 4.5 U calpain-2 were added and samples 
were incubated at 25°C for up to 90 min. The reaction was stopped by heating at 
95°C for 10 min, thus inactivating calpain. In case of additional tryptic in-solution 
digestion, samples were subsequently diluted 1:1 with 20 mM Tris-HCl (pH 7.2) to 
reduce the content of β-mercaptoethanol and then incubated with Trypsin Gold 
solution (12.5 ng/ µL in freshly prepared 50 mM NH4HCO3) at a ratio of 50:1 (i.e. 
sample protein : trypsin) for 1 hour at 37°C. In parallel, for evaluation of distinct tryptic 
cleavage patterns, 5 pmol of human CLP36 protein were tryptically digested under 
equal conditions yet without prior calpain treatment. All proteolytic reactions were 
monitored by 1D-SDS-PAGE and finally, upon carbamidomethylation as described in 
3.10.9, analyzed for calpain and/ or trypsin cleavage sites by protein mass 
spectrometry. 
 
Calpain activating solution, pH 7.2 
0.1 M NaCl, 20 mM Tris-HCl, 2 mM MgCl2, 10 mM β-mercaptoethanol, 5 mM CaCl2 
 
3.10.9 In-gel digestion and peptide extraction 
Excised protein spots (see 3.10.5 and 3.10.6) were repeatedly washed in 50 mM 
NH4HCO3 (pH 7.8) and 25 mM NH4HCO3/ 50% (v/v) MeCN at 37°C for 10 min. Prior 
to protein digestion, carbamidomethylation of the sample was performed. 
Accordingly, disulfide bonds were reduced by incubating in 10 mM DTT (in 50 mM 
NH4HCO3) at 56°C for 30 min, followed by alkylation of the resulting free cysteines 
using 30 mM IAA (in 50 mM NH4HCO3) at 25°C for 30 min in the dark. The reaction 
was stopped by addition of 10 mM DTT (in 50 mM NH4HCO3). After this procedure, 
the sample was washed as above and completely dried in a SPD 111V Speed Vac at 
35°C. 10 µL Trypsin Gold solution (12.5 ng/ µL in freshly prepared 50 mM NH4HCO3) 
were added to the dried gel spots and excess liquid was removed after a 10-min 
period at 4°C. Tryptic digestion was then performed at 37°C overnight. Peptides were 
extracted twice with 10 µL 5% (v/v) FA (37°C, 15 min) and finally with 10 µL 5% (v/v) 
FA/ 50% (v/v) MeCN (37°C, 15 min). The three fractions were pooled, reduced to a 
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total volume of 15 µL using a SPD 111V Speed Vac at 35°C and stored at -80°C until 
being further analyzed by nano-LC-ESI-MS. Protein digestion was controlled by 
comparative 1D-SDS-PAGE of sample aliquots before and after digestion and 
subsequent silver staining. 
 
3.10.10 Nano-LC-ESI-MS/MS 
3.10.10.1 Instrumentation and nano-HPLC 
For protein identification, three different nano-LC-ESI-MS systems were applied: (a) 
a QStar Elite; (b) a Qtrap 4000; or (c) an LTQ XL mass analyzer. For analysis of 
calpain-digested samples, an LTQ-FT Ultra was used. Both QStar and Qtrap 
instruments were online coupled to a Famos™, Switchos™, Ultimate™ nano-HPLC 
system; the LTQ XL and the LTQ-FT Ultra were coupled to an Ultimate 3000 system. 
Since there were hardly any differences in nano-LC separation parameters of the 
four MS systems, the procedure can generally be described as follows: Tryptic 
sample peptides were reconstituted in 15 µL 0.1% (v/v) TFA and loaded onto a self-
packed C18 trapping column (Synergi Hydro RP, inner diameter 100 µm, length  
2 cm, particle size 4 µm, pore size 80 Å) for further desalting and preconcentration in 
the nano-HPLC system (flow rate 7 µL/ min 0.1% (v/v) TFA, prolonged loading time 
of 25 min). Peptide separation was then performed at 60°C on a self-packed 
reversed-phase main column (Synergi Hydro RP, inner diameter 75 µm, length  
30 cm, particle size 2 µm, pore size 80 Å) by applying a 40-min binary gradient 
(alternatively 80-min) of solvent A and B ranging from 5 to 50% solvent B at a flow 
rate of 270 nL/ min. Separated peptides were directly eluted into the online ESI ion 
source for subsequent MS (and MS/MS) acquisition, columns were washed at 95% 
solvent B for 5 min and finally re-equilibrated at 5% solvent B for 15 min. 
 
Solvent A 
0.1% (v/v) FA 
for QStar 0.2% (v/v) FA  
 
Solvent B 
0.1% (v/v) FA/ 84% (v/v) MeCN 
for QStar 0.2% (v/v) FA/ 84% (v/v) MeCN 
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3.10.10.2 MS and MS/MS acquisition 
MS data acquisition was comparable for all four mass spectrometers; a summary of 
parameters is provided in Table 3.16. Generally, full MS survey scans from 350 to 
2,000 m/z were acquired and the three most intense peaks were subjected to CID 
MS/MS. To increase the dynamic range of the analysis, a dynamic exclusion of  
20 sec was taken into account thus avoiding repeated fragmentation of previously 
analyzed precursor ions. Automatic MS/MS accumulation was set to highest quality 
and a maximum accumulation time of 2 sec. Mass spectra were recorded using 
adequate MS operating software (Table 3.16). 
 
Table 3.16: MS acquisition parameters used in this study 
Acquisition Mass spectrometer  
Parameter QStar Elite LTQ XL Qtrap 4000 LTQ-FT Ultra 
Ionisation voltage 2.2 kV 1.7 kV 2.3 kV 1.4 kV (Nano Mate, Advion) 
MS survey scan, 
max. accumulation time 
380-1,500 m/z, 
0.5 sec 
400-2,000 m/z 
1.2 sec 
380-1,500 m/z, 
1.0 (or 0.5*) sec 
350-2,000 m/z 
1.0 sec 
CID MS/MS scans, 
max. accumulation time 
110-1,500 m/z, 
2 sec 
Default 
0.5 sec 
115-1,500 m/z, 
0.5 sec   
Default 
0.5 sec 
Operating software Analyst QS 2.0 Xcalibur 2.1.0 Analyst 1.4 Xcalibur 2.1.0 
 
* in enhanced resolution mode 
 
3.10.10.3 MS data evaluation 
Generally, upon conversion of LC-MS raw data into Mascot generic format (mgf), 
database searching was performed using the Mascot™ search algorithm for MS/MS 
spectra (Mascot Daemon 2.2.02 software platform and Mascot server version 
2.2.04). The procedure was comparable for all four mass spectrometers; individual 
specifications are summarized in Table 3.17. In the following, evaluation of QStar 
Elite MS data files, which were the first to be generated in the course of this study, is 
exemplarily described in more detail: 
Accordingly, QStar Elite MS data files were transformed into mgf-format using the 
Analyst QS software version 2.0 with the mascot.dll plug-in 1.6b7. Spectra with less 
than 10 signals were omitted, precursor mass tolerance for grouping was set to  
0.05 Da, and the maximum number of cycles between groups was set to 3. Signals 
below 0.1% base peak intensities were removed. Mascot searches were 
subsequently performed as outlined in Table 3.17. All peptide MS/MS spectra with a 
minimum Mascot score of 34 (p-value of 0.05) were taken into consideration for 
further interpretation and were additionally validated manually. This procedure 
included evaluation of (a) the signal-to-noise ratio; (b) the adequate annotation of 
prominent signals; and (c) the sequence coverage, in particular of b- and y-ions. To 
Materials and Methods 
   
 
 
72 
consider an identified protein a ‘true hit’, at least two peptides had to be validated 
positively. 
 
Table 3.17: Mascot search parameters used in this study 
Mascot search Mass spectrometer  
Parameter QStar Elite LTQ XL Qtrap 4000 LTQ-FT Ultra 
mgf-conversion plug-in Analyst QS 2.0, 
mascot.dll 1.6b7 
Xcalibur 2.0, 
extract_msn 
Analyst 1.4, 
Mascot.dll 1.6b5 
Xcalibur 2.0, 
extract_msn 
Taxonomy Homo sapiens/ 
Mus musculus 
Homo sapiens 
 
Homo sapiens 
 
Homo sapiens 
Database UniProtKB/ 
Swiss-Prot* 
UniProtKB/ 
Swiss-Prot* 
UniProtKB/ 
Swiss-Prot* 
UniProtKB/ 
Swiss-Prot* 
Enzyme Trypsin Trypsin Trypsin Trypsin/ 
semiTrypsin/ 
None 
Missed cleavage sites 2 2 2 0 
Fixed modification Carbamidom. (C) Carbamidom. (C) Carbamidom. (C) Carbamidom. (C) 
Variable modification Oxidation (M) 
Phosph. (STY) 
Oxidation (M) 
Phosph. (STY) 
Oxidation (M) 
Phosph. (STY) 
Oxidation (M) 
Phosph. (STY) 
Peptide tolerance ± 0.2 Da ± 1.5 Da ± 0.4 Da ± 4 ppm 
Peptide charge 2+ and 3+ 2+ and 3+ 2+ and 3+ 2+ and 3+ 
MS/MS tolerance ± 0.5 Da ± 1.5 Da ± 0.4 Da ± 0.4 Da 
Instrument ESI-QUAD-TOF ESI-Trap ESI-4-SECTOR ESI-FTICR 
 
* www.uniprot.org, 11/2009:   512,994 sequences 
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4 Results 
 
4.1 Recombinant protein expression in E.coli 
The intended pull down-based approach was started by recombinant expression of 
modified VASP and STIM1 bait proteins. Upon purification and immobilization on an 
Affi-Gel 10 affinity support, these should consequently be utilized to selectively 
screen for specific interaction partners in resting human platelets. Further differential 
analysis and protein identification of all interactome samples should finally be 
performed by 1D-SDS-PAGE and subsequent nano-LC-ESI-MS/MS. 
Therefore, recombinant vector constructs STIM1Ctail (in pGEX 6p1), VASP-AAA and 
VASP-DDE (both in pQE-30) were transformed into Ca2+-competent E.coli BL21 (see 
3.8.1) and plated on LB-Amp-CHL agar plates for overnight selection. For an 
enhanced protein expression in case of VASP-constructs, E.coli Rosetta or BL21-
CodonPlus-RP were also applied. Insert positive clones were subsequently used for 
large scale protein expression in 500 mL of bacterial growth medium. In this context, 
several cell culture protocols have been compared regarding expression efficiency 
and reproducibility (see 3.8.2), with 21 hours expression in LB-Amp medium/ 2% 
(v/v) ethanol at 16°C proving to be the most reliable one. As a control, 100 µL 
bacterial suspension were taken prior to IPTG induction and at multiple time points 
during the 21-hours culture and analyzed for accumulation of recombinant proteins 
by 1D-SDS-PAGE and - in case of phospho-mimetic VASP constructs - by VASP-
specific Western blotting. 
Accordingly, upon 1D-SDS-PAGE and subsequent Coomassie staining, successful 
expression of STIM1Ctail fusion protein was indicated by presence of a dominant 
band at 50 kDa (MW STIM1Ctail: 49 kDa) (Figure 4.1 A left). In contrast, such clear 
evidence was not observable for cells transformed with the VASP-AAA and -DDE 
constructs (expected MW: 40-50 kDa), even though simultaneous expression of an 
MBP-fusion tag vector as positive control proved adequacy of the applied 
transformation and incubation conditions (Figure 4.1 A right, protein band at 40 kDa). 
Instead, multiple additional protein bands were detected in an MW range of 40 to  
50 kDa in both VASP-derived samples. Whether these bands marked truncated 
forms of the intended fusion proteins, e.g. due to incorrect biosynthesis, will be 
discussed in more detail in 5.2.1. 
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Figure 4.1: Recombinant protein expression of STIM1Ctail, VASP-AAA and VASP-DDE constructs in 
E.coli BL21 (STIM1Ctail) and Rosetta (VASP-constructs). Bacterial culture was performed in LB-Amp 
medium supplemented with 2% (v/v) ethanol at 16°C. An MBP-fusion tag vector was transformed and 
expressed as a positive control. (A) 1D-SDS-PAGE and subsequent Coomassie staining of 5 µL 
bacterial suspension (left: 10% Bis-Tris gel; right: 4-12% Bis-Tris gel). (B) Monitoring of VASP-AAA 
and -DDE protein expression by VASP-specific Western blotting. T0: before IPTG induction; T1-21: 1-21 
hours after induction. 
 
Following 1D-SDS-PAGE, VASP-specific Western blotting was also performed on 
VASP-AAA- and VASP-DDE-transformed bacterial samples before (T0) and after 
IPTG induction (after 1, 2, 3 and 4 hours of incubation; i.e. T1-4). Here, protein signals 
detected at approximately 50 kDa finally indicated adequate bacterial expression of 
these two fusion proteins as well. Moreover, a constant enhancement of signal 
intensities over time reflected the increasing amounts of newly generated 
recombinant VASP proteins as a consequence of both bacterial proliferation and de 
novo protein expression (Figure 4.1 B). However, the absence of any prominent 
VASP-AAA and -DDE protein band in Coomassie-stained SDS-gels - in particular 
upon comparison to those of STIM1Ctail and the MBP-positive control - led to the 
conclusion that the overall expression levels of these two protein constructs were 
considerably low. Thus further protein enrichment was required. 
 
4.2 Purification of STIM1Ctail, VASP-AAA and VASP-DDE protein from E.coli 
For enrichment of His6-tagged proteins, IMAC purification was performed. First, 
bacterial cell pellets (up to 20 g resulting from 500 mL expression culture) were lysed 
using a French press. Upon ultracentrifugation, recombinant His6-tagged STIM1Ctail, 
VASP-AAA and VASP-DDE proteins were isolated from the resulting supernatants 
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using Ni-NTA agarose IMAC (for details see 3.9.2). For monitoring, the pure lysate 
supernatant (‘input’) and the column flow through, as well as the first and the last 
wash- and selected elution fractions were analyzed by 1D-SDS-PAGE. 
 
 
Figure 4.2: IMAC purification of recombinant STIM1Ctail (A), VASP-AAA and VASP-DDE (B) via Ni-
NTA agarose; control by 1D-SDS-PAGE (10% Bis-Tris gels, Coomassie staining). S: lysate 
supernatant (5 µL); FT: column flow through (5 µL); 1-4: individual wash- and elution fractions (20 µL). 
Washing was repeatedly performed with lysis buffer (1, 2) and washing buffer (3, 4). 
 
As depicted in Figure 4.2 A, IMAC purification of STIM1Ctail samples particularly 
enriched a 50 kDa protein subset (elution fractions) and reduced unspecific protein 
background (compare wash fraction 1 with fraction 2 and 4, respectively). The 
majority of lysate proteins, however, passed the column without significant 
retardation (see input compared to flow through samples). For further purification and 
removal of contaminating particulate material (e.g. remnants of Ni-NTA agarose), the 
STIM1Ctail elution fractions were pooled and SEC was performed (see 3.9.3). During 
the 4-hours separation procedure, a total of 120 2-min elution fractions were 
collected and stored at 4°C. The resultant UV280 chromatogram (Figure 4.3 A) 
displayed two distinct peaks: a comparatively small, early-eluting one at fraction 31-
33 and a dominant one at fractions 38-40 which was accompanied by prolonged 
tailing (fractions 44 and 45). These eight fractions plus fractions 48 and 49, which 
also included a minor peak of the chromatogram, were consequently analyzed by 
1D-SDS-PAGE. In accordance with the UV280 chromatogram, the majority of proteins 
eluted in SEC fractions 38-40, including a dominant protein subset of an estimated 
molecular mass of 50 kDa (Figure 4.3 B). 
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Figure 4.3: SEC of STIM1Ctail IMAC samples using a Superdex HiLoad 26/ 60 separation column and 
an ÄKTA FPLC system. The 4-hours procedure was constantly monitored via the ÄKTA UV detector 
unit and a total of 120 2-min elution fractions were collected. (A) UV280 chromatogram. Elution 
windows containing distinct peaks and/ or tailing are marked in blue and (B) were analyzed by 1D-
SDS-PAGE (4-12% Bis-Tris gel, sample volume: 20 µL, Coomassie staining). 
 
Following in-gel trypsinisation and subsequent MS measurement on a QStar Elite 
mass analyzer, these prominent 50 kDa protein bands were related to the STIM1Ctail 
protein construct, i.e. STIM1 aa 484-685 (Figure 4.4, display of an identified 
STIM1Ctail fragment ion: STIM1 aa 503-514). 
In contrast to STIM1Ctail, a parallel approach focussing on purification of 
recombinant VASP-AAA and -DDE constructs did not yield significant protein 
enrichment. Accordingly, following 1D-SDS-PAGE of VASP-derived IMAC samples, 
Coomassie-stained protein bands were comparatively weak (Figure 4.2 B, at 40- 
50 kDa) and did not contain any detectable VASP-related sequences when analyzed 
by nano-LC-ESI-MS/MS. Moreover, the presence of further equidistant protein bands 
in both VASP-AAA and -DDE samples (see Figure 4.2 B, at approximately 60 and 
100 kDa) led to the hypothesis that the signals detected here were more likely to 
originate from unspecific binding of protein multimers to the bead matrix than from 
specifically enriched VASP constructs. Hence, it had to be deduced that, at least in 
our hands, protein expression in E.coli was insufficient for both generation (see 4.1) 
and consequent isolation of these two specific fusion proteins. As this might have 
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been due to limitations inherent to the prokaryotic E.coli expression system (for 
details see 5.2.1), an alternative strategy using HEK293 cells for eukaryotic 
biosynthesis of recombinant VASP-AAA and -DDE was consequently developed. 
 
 
 
Figure 4.4: Identification of purified STIM1Ctail by MS/MS analysis on a QStar Elite mass analyzer 
following in-gel trypsinisation of Coomassie-stained control gels. 
 
4.3 Generation of mutant VASP-DNA constructs for eukaryotic transfection 
For synthesis of recombinant VASP fusion proteins in HEK293 cells, the original 
VASP-AAA and -DDE DNA-constructs had to be further modified (for details see 
5.2.2) and cloned into the eukaryotic expression vector pcDNA3.1/V5-HisA. Hence, 
for both VASP-AAA and VASP-DDE, two different constructs were developed: one 
solely lacking the VASP tetramerization domain (∆TD; nt 1,027-1,143) and a second 
one additionally lacking the VASP FAB-region (∆FAB∆TD; nt 775-1,143). 
Accordingly, using the original VASP pQE-30 vector constructs VASP-AAA and 
VASP-DDE as DNA-templates, Pfu-PCRs were performed to generate the four 
truncated VASP-inserts ‘VASP-AAA∆TD’ and ‘VASP-DDE∆TD’ (nt 1-1,026), as well 
as ‘VASP-AAA∆FAB∆TD’ and ‘VASP-DDE∆FAB∆TD’ (nt 1-774) (for details see 
3.7.1.2). In this context, to enable subsequent insertion into the pcDNA3.1/V5-HisA 
MCS, all VASP deletion primers were specifically designed to convey an additional 
BamHI restriction site to the 5’- and an EcoRI restriction site to the 3’-end of each 
VASP insert. The resulting PCR products were verified based on molecular mass 
evaluation by agarose gel electrophoresis (illustrated in Figure 4.5). Upon 
purification, PCR products were amplified in StrataClone SoloPack competent E.coli 
cells, typically yielding an average DNA concentration of 2-3 µg/ µL (see 3.7.1.4 and 
MS/MS Fragmentation of LTEPQLGLGSQR 
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Monoisotopic mass of neutral peptide: 1297.6990 
Fixed modification: carbamidomethylation 
Ions score: 76 (expect: 1.6e-006) 
Matches: 17/118 fragment ions (25 most intense peaks) 
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3.7.1.5). In parallel, the pcDNA3.1/V5-HisA target vector was also amplified and 
purified in a maxiprep approach (DNA concentration: 3-5 µg/ µL). 
 
 
Figure 4.5: Electrophoretic control of VASP-deletion PCR products (1% agarose gel, GelRed staining). 
In each case a sample volume of 2 µL was applied. Bp-values were estimated via the 123 bp DNA 
Ladder (for VASP∆TD ~1,000-1,100 bp, for VASP∆FAB∆TD ~700-800 bp) and are in good correlation 
with the calculated ones (for VASP∆TD 1,027 bp, for VASP∆FAB∆TD 775 bp). 
 
For generation of compatible 5’- and 3’-sticky ends, which is obligatory for targeted 
insert-vector recombination, overnight BamHI/ EcoRI restriction digests were 
performed on the four VASP-pSC-A-amp/kan vector constructs (‘VASP insert 
release’), as well as on the pcDNA3.1/V5-HisA target vector (appropriate opening of 
the MCS). Digest efficiencies were monitored by gel electrophoresis (Figure 4.6), 
samples were purified and quantified by OD260 measurement (DNA concentration:  
2-3 µg/ µL). 
Finally, VASP-inserts were integrated into the linearized pcDNA3.1/V5-HisA target 
vector (insert-to-vector ratio 4:1) and ligation reactions were performed as described 
in 3.7.1.7. Resulting recombinant VASP vector constructs were amplified in E.coli 
DH5α and isolated in a maxiprep approach, thereby yielding the following 
concentrations (see also Figure 4.7 A): VASP-AAA∆TD (6,527 bp) 4.9 µg/ µL, VASP-
AAA∆FAB∆TD (6,275 bp) 5.4 µg/ µL, VASP-DDE∆TD (6,527 bp) 3.9 µg/ µL and 
VASP-DDE∆FAB∆TD (6,275 bp) 3.4 µg/ µL. 
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Figure 4.6: Electrophoretic control of BamHI/ EcoRI restriction digests of (a) VASP-pSC-A-amp/kan 
vector constructs; and (b) of pcDNA3.1/V5-HisA target vector. In each case a sample volume of 2 µL 
was applied on a 1% agarose gel (GelRed staining). Bp-values were estimated via the GeneRuler 1kb 
DNA Ladder. Large DNA fragments correspond to linearized pcDNA3.1/V5-HisA (5.5 kb) or pSC-A-
amp/kan  vector (4.3 kb), shorter ones to released VASP inserts VASP∆TD (~1,000-1,100 bp) and 
VASP∆FAB∆TD (~700-800 bp), respectively. 
 
4.4 Validation of VASP-vector assembly 
Correct VASP-vector recombination was validated by several strategies: First, control 
PCRs using VASP deletion primers VASP-Fwd/ -RevI (for VASP∆TD) or VASP-Fwd/ 
-RevII (for VASP∆FAB∆TD) were performed on all four VASP constructs. As 
depicted in Figure 4.7 B, estimated molecular masses of resulting PCR products 
corresponded to those calculated for the intended VASP inserts: 1,000-1,100 bp for 
VASP∆TD (calculated 1027 bp) and 700-800 bp for VASP∆FAB∆TD (775 bp). This 
finding was moreover confirmed by BamHI/ EcoRI control digests, where - besides 
linearized pcDNA3.1/V5-HisA target vector at 5.5 kb - DNA fragments of similar sizes 
could be identified (see Figure 4.7 C). 
Finally, DNA sequencing reactions were performed on each vector construct. First, 
precise in-frame integration of VASP inserts in the MCS of pcDNA3.1/V5-HisA was 
evaluated by analyzing the close sequence proximity of the individual 5’- and 3’-
insertion sites. This has been executed in-house by sequencing PCRs using the 
GenomeLab DTCS Quick Start Kit and either PCR primer T7-Fwd (binds 5’ of BamHI 
restriction site) or BGH-Rev (3’ of EcoRI). Generally, both the BamHI- and the EcoRI 
ligation junctions proved to be correct in all four VASP-constructs - thus confirming 
accurate reading frames - and were moreover followed by the intended DNA 
sequences. In detail, downstream of the BamHI restriction site, the first 324-340 bp of 
linearized pSC-A-amp/kan  
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VASP (including the start codon) could be identified in case of T7-Fwd sequences. 
BGH-Rev sequencing data covered only the last 44 (for VASP-∆FAB∆TD) to 273 (for 
VASP-∆TD) bp of VASP; however, since these sequences included the VASP stop 
codon upstream of the EcoRI restriction site, they were still sufficient to verify 
adequate VASP-vector assembly. Ultimate full-length DNA sequencing was finally 
provided by GATC Biotech (Konstanz, Germany) and confirmed the previous 
sequencing results. In addition, the V5- and His6-coding sequences could be 
detected in-frame, and premature termination sites as well as any other point 
mutation or nt-sequence aberration could be excluded for all four VASP-vector 
constructs. For a detailed view on the respective sequencing data, please refer to 
7.4. 
 
 
 
Figure 4.7: Electrophoretic control of VASP-pcDNA3.1/V5-HisA vector constructs. (A) Purified plasmid 
maxipreps, (B) control PCR (primer combinations: VASP-Fwd/ -RevI for VASP∆TD and VASP-Fwd/  
-RevII for VASP∆FAB∆TD), (C) BamHI/ EcoRI restriction digest. In each case a sample volume of  
2 µL was applied on a 1% agarose gel (GelRed staining). Bp-values were estimated via the 
GeneRuler 1kb DNA Ladder. Large DNA fragments correspond to either (A) intact VASP-vector 
constructs (~6.5 kb) or (C) linearized pcDNA3.1/V5-HisA vector (5.5 kb). Shorter sequences (B, C) 
indicate released VASP inserts VASP∆TD (~1,000-1,100 bp) and VASP∆FAB∆TD (~700-800 bp), 
respectively. 
 
4.5 Transfection of VASP deletion constructs in HEK293 cells 
For stable, long-term expression of recombinant proteins, the VASP-vector 
constructs were transfected in eukaryotic HEK293 cells following the ExGen 500 
transfection manual. Since the pcDNA3.1-based vector also confers resistance to 
neomycin, stably-transfected cells having integrated the vector plasmid in the 
genome were selected and extended in neomycin (G418) selection medium. As 
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confirmed microscopically in comparison to non-transfected HEK293 (wildtype, HEK-
wt), transfection neither affected cell morphology, nor cell division rate (Figure 4.8). 
In parallel, a fifth HEK293 cell line stably expressing the vector construct 
pcDNA3.1/V5-HisA lacZ was generated to serve both as (a) an indicator for 
transfection efficiency by β-gal staining; and (b) as a positive control during 
evaluation of subsequent protein purification procedures (including 1D-SDS-PAGE 
and Western blotting against the V5- and His6-tagged protein products). Thereby, 
transfection efficiencies were estimated by determining the ratio between transfected 
(i.e. β-gal stained) HEK-lacZ cells and the total cellular amount. As exemplarily 
shown in Figure 4.9 A, ExGen 500 transfection efficiency could generally be 
considered as high and typically amounted up to 80-90%. 
 
 
Figure 4.8: Stably-transfected HEK293 vs HEK293 wildtype. Cells were monitored for 1-6 days (d1-d6) 
after transfection. For evaluation of cell morphology, cell adhesion as well as protrusion formation was 
taken into consideration. As displayed in the d1-series, morphological differences between the cell 
lines were negligible. Regarding the cell division rate, half-confluence was generally achieved after 
three days (d3) and total confluence after 6 days (d6) of incubation. 
 
To verify adequate protein expression, V5-specific Western blotting was 
subsequently performed on all five stable HEK293 cell lines. Accordingly, the 
intended recombinant fusion proteins were clearly detectable, with individual MW-
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values (estimated via the See Blue Plus2 Pre-Stained Protein Standard) being in 
good correlation with the calculated ones (for VASP∆TD 38 kDa, for VASP∆FAB∆TD 
29 kDa and for lacZ fusion protein 121 kDa, see Figure 4.9 B). Thus, for purification 
of appropriate protein amounts sufficient for subsequent generation of Affi-Gel-based 
affinity supports, extended cell cultures were performed and harvested cells were 
stored until further usage. 
 
 
 
Figure 4.9: Protein expression of stable HEK cell lines. (A) β-gal staining of HEK293 cells stably 
expressing the V5-His6-tagged lacZ fusion protein (HEK-lacZ) confirmed high transfection efficiency of 
the applied ExGen 500 transfection protocol. Left: overview; right: zoomed-in image. (B) V5-specific 
Western blotting of native lysates of HEK-VASP-AAA∆TD, -VASP-AAA∆FAB∆TD, -VASP-DDE∆TD,  
-VASP-DDE∆FAB∆TD and -lacZ in comparison to non-transfected HEK-wt (4-12% Bis-Tris gel, 
sample amounts 50 µg). 
 
4.6 Purification of recombinant proteins from HEK293 cells 
For initial evaluation of IMAC-based protein purification from the stable HEK293 cell 
lines, HEK-lacZ positive controls were processed first and compared to equally-
treated HEK-wt. In detail, cells from five confluent 75 cm² tissue culture flasks of 
either HEK-lacZ or HEK-wt (i.e. approximately 8 x 106 cells) were pooled, lysed by 
sonication and submitted to Ni-NTA agarose IMAC as described in 3.9.2 (section 1). 
Analogous to 4.2, purification efficiency was finally monitored by analyzing the crude 
cell lysate, the lysate supernatant upon ultracentrifugation (‘input’), as well as the 
column flow through and selected wash- and elution fractions by 1D-SDS-PAGE. 
As depicted in Figure 4.10, comparison of protein purification patterns did not reveal 
distinct differences between HEK-lacZ and HEK-wt samples, neither in the input nor 
in any of the eluted fractions. Moreover, though the individual input protein profiles 
markedly differed from the corresponding elution fractions (‘output’) - thus indicating 
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adequate purification - significant enrichment of the 121 kDa lacZ fusion protein could 
not be observed. Since this finding was in contrast to the Western blot data displayed 
in Figure 4.9 B, the Ni-NTA purification procedure was further modified by altering (a) 
the binding; (b) the washing; and (c) the elution conditions. First, to improve ligand 
binding, incubation time was varied from one hour up to an overnight incubation at 
4°C. In addition, since exceeding imidazole concentrations may interfere with weak 
His6-Ni-NTA interactions, the respective content was altered from 5 to 1 mM in the 
lysis buffer and from 25 to 10 mM in the washing buffer. Alternatively, imidazole-free 
purification protocols have also been examined, which included recombinant protein 
elution either by shifting the buffer pH below a value of 4.0 (where His6-tags are 
protonated and consequently dissociate from Ni2+ bead material) or by adding Ni2+-
chelating agents to the elution buffer system (e.g. 200 mM EDTA). 
 
 
Figure 4.10: IMAC purification of recombinant lacZ protein from HEK-lacZ via Ni-NTA agarose in 
comparison to equally treated non-transfected HEK-wt. Control by 1D-SDS-PAGE (4-12% Bis-Tris 
gels) and subsequent Coomassie staining. S: lysate supernatant (5 µL); L: crude cell lysate (5 µL);  
FT: column flow through (5 µL); 1-4: individual wash- and elution fractions (20 µL). Washing was 
repeatedly performed with lysis buffer (1, 2) and washing buffer (3, 4). 
 
However, neither of these strategies subsequently resulted in an improved 
enrichment of the anticipated 121 kDa lacZ fusion protein in the elution fractions. The 
respective 1D-SDS control gels closely resembled those exemplarily given in Figure 
4.10. Hence, the Ni-NTA agarose-based approach was regarded as insufficient for 
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protein purification from the generated stable HEK293 cell lines and alternative 
strategies were consequently taken into consideration. 
The most promising one was provided by the Qiagen Ni-NTA Spin Kit, which has 
been reported to enable reliable purification of His6-tagged fusion proteins from a 
variety of biological sources (including HEK293 cells) even under low expression 
conditions. Following the manufacturer’s instructions, three confluently grown 75 cm² 
tissue culture flasks of each of the recombinant HEK293 cell lines (i.e. approximately 
5 x 106 cells) were pooled and processed under native conditions (described in 3.9.2, 
section 2). The resulting elution fractions were subsequently controlled for qualitative 
and quantitative fusion protein enrichment via V5-specific Western blotting and 
differential 1D-SDS-PAGE. According to the anti-V5 Western blot data, all five 
recombinant proteins were present in the eluted fractions (Figure 4.11 A), with 
individual signal intensities being comparable to those displayed in Figure 4.9 B. This 
finding, however, could not be confirmed when analyzing analogous Coomassie-
stained control gels: Here, in comparison to equally treated HEK-wt, neither 
differential protein purification patterns nor specific enrichment of proteins of the 
expected molecular masses could be observed for IMAC purified VASP (VASP∆TD 
38 kDa, VASP∆FAB∆TD 29 kDa) and lacZ samples (121 kDa) (see Figure 4.11 B). 
 
 
Figure 4.11: IMAC purification of recombinant VASP-AAA∆TD, VASP-AAA∆FAB∆TD, VASP-
DDE∆TD, VASP-DDE∆FAB∆TD and lacZ proteins from stable HEK293 cell lines using the Qiagen Ni-
NTA Spin Kit (native approach). Analysis of combined eluted fractions; equally-treated HEK-wt 
samples were taken as a negative control. Control by (A) V5-specific Western blotting and (B) 1D-
SDS-PAGE and subsequent Coomassie staining. In each case 4-12% Bis-Tris gels and sample 
amounts of 50 µg were applied. 
 
  
MW 
[kDa]   
B 
 
 
   
 
 
 
39 
28 
191 
 
 
64 
51 
 
39 
28 
 
97 97 
MW 
[kDa] 
 
 
Western blot: mAB anti-V5-tag 
 
 
 
 
 
A 
1: VASP-AAA∆TD 
2: VASP-AAA∆FAB∆TD 
3: VASP-DDE∆TD 
4: VASP-DDE∆FAB∆TD 
5: lacZ 
6: wildtype 
 1   2  3   4   5   6 
1    2    3     4    5    6 
Results 
   
85 
To consequently enhance recombinant protein binding to the Ni-NTA spin column, 
stringency of the method was successively reduced by lowering the imidazole 
concentrations of the lysis buffer (10 to 1 mM) as well as of the washing buffer (20 to 
10 mM). This has been performed in accordance with the manufacturer’s 
instructions. However, as indicated by 1D-SDS-PAGE analysis subsequent to IMAC 
purification of adequate HEK293 samples, none of these modifications positively 
affected enrichment of VASP or lacZ fusion proteins.  
Having so far intensively yet unsuccessfully worked on an optimization of the IMAC 
conditions, it finally had to be excluded that the observed difficulties in recombinant 
protein enrichment were inherent to the fusion protein constructs themselves. As 
reported in 4.4, full length DNA sequencing proved correctness of all four VASP 
vector constructs, including the C-terminal V5- and His6-encoding sequences (the 
pcDNA3.1/V5-HisA lacZ vector provided by Invitrogen has not additionally been 
controlled by DNA sequencing). Moreover, V5-specific Western blotting in stably 
transfected HEK293 cell lines verified expression of C-terminally V5-tagged fusion 
proteins, with individual molecular masses reflecting those of the intended 
recombinant proteins (Figure 4.9 B, Figure 4.11 A). Thus, deriving from all these 
previous findings, primary sequence aberrations were unlikely to be present in the 
expressed products. In this context, however, VASP-specific Western blotting could 
not be performed since the available primary antibodies also recognized endogenous 
VASP of HEK293, hence resulting in superposition of signals (tested with mAB anti-
VASP IE273, data not shown).  
To furthermore evaluate the structural accessibility of the C-terminal His6-tag, IMAC 
purification via the Qiagen Ni-NTA Spin Kit was also executed under denaturing 
conditions, which would consequently expose so-far partially hidden protein 
sequences (see 3.9.2, section 2). The resulting sample fractions (i.e. crude cell 
lysates, lysate supernatants upon ultracentrifugation, column flow through, as well as 
wash- and elution fractions) were differentially analyzed by 1D-SDS-PAGE and 
compared to those deriving from native protocols (see 3.9.2). As an example, 
Coomassie-stained control gels of purified lacZ samples are presented in Figure 4.12 
in comparison to equally treated HEK-wt negative controls. Gel data of purified VASP 
fusion proteins resembled those of lacZ and are thus not explicitly shown. Protein 
purification patterns noticeably varied in samples isolated under denaturing 
conditions vs natively purified ones. However, a detailed differential analysis of lacZ 
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vs corresponding wildtype fractions did not reveal any significant differences both 
upon native and denaturing purification. Moreover, in either case distinct enrichment 
of the 121 kDa lacZ fusion protein could not be confirmed in the eluted fractions. The 
majority of protein bands visualized on the gels may thus above all originate from 
unspecific interaction of endogenous HEK293 proteins with the affinity support, which 
would consequently mask signals deriving from comparably lower abundant His6-
tagged target proteins and associated complex components. 
 
 
Figure 4.12: IMAC enrichment of recombinant lacZ protein from HEK-lacZ via Qiagen Ni-NTA Spin Kit 
vs equally treated HEK-wt. Comparison of native and denaturing protein purification conditions. 
Control by 1D-SDS-PAGE (4-12% Bis-Tris gels) and subsequent Coomassie staining. L: crude cell 
lysate (5 µL); S: lysate supernatant (‘input’, 5 µL); FT: column flow through (5 µL); 1-3: individual 
wash- and elution fractions (20 µL). 
 
The fact, that application of this IMAC strategy did not lead to considerable 
enrichment of both lacZ (i.e. the per se standard control for correct fusion protein 
expression) and recombinant VASP protein constructs even under denaturing 
 
 
191 
 
97 
 
64 
 
51 
 
39 
 
28 
 
 
 
 
 
  
native 
conditions 
denaturing 
conditions 
wash 
fraction 
wash 
fraction 
wash 
fraction 
elution 
fraction 
wash 
fraction 
elution 
fraction 
elution 
fraction 
HEK-lacZ HEK-wt 
 
elution 
fraction 
MW 
[kDa]     L  S  FT  1   2   3   1   2 
MW 
[kDa]   L   S  FT  1   2   3   1   2 
MW 
[kDa]    L  S  FT   1   2   3   1   2 
191 
 
97 
 
64 
 
51 
 
39 
 
28 
191 
 
97 
 
64 
 
51 
 
39 
 
28 
191 
 
97 
 
64 
 
51 
 
39 
 
28 
MW 
[kDa]    L  S  FT  1   2   3   1   2 
Results 
   
87 
conditions, raised the question as to whether the C-terminal His6-tag conferred by the 
pcDNA3.1/V5-HisA vector was generally accessible to the Ni-NTA support. This 
theory was furthermore strengthened by polyHis-specific Western blotting of crude 
HEK293 cell lysates: Even though four different monoclonal anti-His-tag antibodies 
were tested during the course of several experiments (i.e. anti-His4-tag, anti-His5-tag, 
anti-His6-tag and anti-His[C-term]-tag; see 3.10.4), no clear evidence could be 
provided for the presence of adequately tagged proteins neither in the four stable 
VASP-HEK293 cell lines nor in the lacZ positive control line (exemplarily shown in 
Figure 4.13). This finding was in contrast to the previously gained anti-V5 Western 
blotting data that were generated in a similar approach and proved accurate full-
length expression of the intended fusion proteins (e.g. Figure 4.9 B). Therefore, the 
C-terminal His6-tag itself had to be regarded as structurally inaccessible, which would 
consequently prevent both polyHis-specific Western blotting and Ni-NTA-based 
IMAC purification. Under these conditions and also considering the low expression 
levels of the designated constructs, which would demand high temporal and material 
efforts to achieve sufficient biosynthesis and enrichment of HEK293-derived fusion 
proteins, the intended VASP-specific interaction study was finally abandoned. The 
focus of this work was consequently shifted towards analyzing the interactome of 
STIM1Ctail. 
 
 
Figure 4.13: PolyHis-specific Western blotting of crude lysates of all four stable VASP-HEK293 cell 
lines in comparison to HEK-lacZ (positive control) and HEK-wt (negative control). Samples were 
separated by 1D-SDS-PAGE (4-12% Bis-Tris gels) and subsequently immunoblotted against the  
C-terminal His6-tag using (A) the mAB anti-His6-tag (Roche Diagnostics, 1:6,000) and (B) the mAB 
anti-His(C-term)-tag (Invitrogen GmbH, 1:5,000). In each case a sample amount of 50 µg was applied. 
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4.7 Generation of STIM1Ctail affinity column and platelet interactome screening 
N-terminal coupling of purified recombinant STIM1Ctail protein (i.e. the total volume 
of all pooled STIM1Ctail SEC fractions, see 4.2) to the Affi-Gel 10 affinity matrix was 
performed as described in 3.9.4. Coupling efficiency was subsequently confirmed by 
1D-SDS-PAGE of (a) the bead material prior and after incubation with STIM1Ctail; 
and (b) the column flow through in comparison to an aliquot of uncoupled pooled 
SEC fractions (data not shown). 
Resting human platelets were isolated from healthy donors and lysed under native 
conditions (for details see 3.6.3 and 3.9.1), typically yielding protein concentrations of 
5-7 mg/ mL. For each interaction experiment, platelet lysates of two different donors 
were then pooled and incubated with the STIM1Ctail affinity column (SC) overnight at 
4°C. In parallel, to also evaluate the impact of unspecific protein binding to the affinity 
support, an equal volume of pooled platelet lysates was incubated with uncoupled 
Affi-Gel 10 matrix (i.e. control column, Ctrl). As outlined in 3.9.5, bound platelet 
proteins were finally eluted by applying a stepwise pH gradient from pH 6.0 to 2.0. 
The eluted fractions of both affinity columns were differentially analyzed by 1D-SDS-
PAGE and subsequent silver staining (Figure 4.14). In addition, the column flow 
through as well as the first and the last wash fraction were also monitored. 
Accordingly, the bulk of platelet proteins passed the columns in the flow through 
fractions. Unspecific protein binding was efficiently reduced by washing with 10 CV 
PBS and by application of 3 CV glycine/ HCl pH 6.0 (i.e. the first elution step). The 
majority of specifically bound proteins were finally released from the affinity supports 
by addition of 3 CV glycine/ HCl pH 2.0, whereas eluting effects of glycine/ HCl  
pH 5.0 - pH 3.0 were relatively low. Comparing the pH 2.0 fractions of three 
independent biological replicates, a total of 18 differential protein bands were 
reproducibly detected in the SC vs the Ctrl samples (marked by numbered arrows in 
Figure 4.14). For identification of these putative STIM1Ctail interaction partners in 
resting human platelets, the respective protein bands were excised, tryptically 
digested and nano-LC-ESI-MS/MS analysis was performed on an LTQ XL and a 
Qtrap 4000 mass analyzer as described in 3.10.9 and 3.10.10. 
Results 
   
89 
 
 
Figure 4.14: Interaction of native lysates of resting human platelets with the STIM1Ctail affinity column 
(SC) vs control column (Ctrl). Control by differential 1D-SDS-PAGE (10% Bis-Tris gels, silver staining). 
FT: column flow through (5 µL); w1, w10: first and last wash fractions (20 µL); pH 6.0 -  
pH 2.0: pooled glycine/ HCl elution fractions (20 µL). Arrows indicate differential protein bands which 
were subsequently excised and analyzed by protein mass spectrometry. 
 
4.8 Identification of differential proteins by nano-LC-ESI-MS/MS analysis 
Data deriving from nano-LC-ESI-MS/MS analyses of all differential protein bands of 
SC vs Ctrl human platelet samples (i.e. three biological replicates) were searched 
against the UniProtKB/ Swiss-Prot human subset and validated as described in 
3.10.10.3. Thereby, only protein identifications which had been verified by at least 
two independent corresponding peptides were accepted. As a result, of the 18 
differential protein bands exemplarily depicted in Figure 4.14 a total of 14 were 
annotated adequately. Accordingly, a data summary of three independent MS/MS 
analyses delivered 93 individual proteins, with molecular masses stretching from 
approximately 270 to 11 kDa. A comprehensive overview of all protein identifications 
is provided in Table 4.1. 
Based on detailed analyses via the UniProtKB/ Swiss-Prot knowledgebase, the 
majority of the 93 identified proteins - i.e. 55.9% - originated from the cytosol; another 
15.1% were classified as being localized within or associated to cellular membranes 
(in particular the plasma membrane). Moreover, 7.5% of all identified proteins were 
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related to granules, vesicles or endosomes, and a total amount of 17.2% originated 
from diverse cellular organelles - such as the Golgi apparatus, the sarcoplasmatic 
reticulum and, above all, mitochondria (12 individual proteins, i.e. 12.9%). The 
described subcellular distribution together with corresponding actual protein amounts 
are illustrated in Figure 4.15 A. 
 
Table 4.1: Individual proteins identified in 14 of the 18 differential protein bands of SC vs Ctrl human 
platelet samples; summary of LTQ XL and Qtrap 4000 nano-LC-ESI-MS/MS data of three independent 
biological replicates. Hits are listed according to corresponding protein bands and with decreasing 
Mascot scores. MW: molecular weight [Da]; Acc.Nr.: UniProtKB/ Swiss-Prot accession number; MA: 
mass analyzer; PB: protein band in Figure 4.14. 
# Protein identifications MW Acc.Nr. Score MA PB 
1 Myosin heavy chain 9 226,532 P35579 12,169 LTQ 1 
2 Talin 1 269,767 Q9Y490 1,078 LTQ  
3 Integrin alpha 2b 113,377 P08514 1,719 LTQ 2 
4 Vinculin 123,799 P18206 984 LTQ  
5 Gelsolin 85,698 P06396 969 LTQ 3 
6 Unc-112-related protein 2 (Kindlin 3) 75,953 Q86UX7 921 LTQ 5 
7 Caldesmon, isoform 4 62,683  Q05682-4 648 Qtrap  
8 78 kDa glucose-regulated protein 72,333 P11021 632 Qtrap  
9 Very-long-chain specific acyl-CoA dehydrogenase 70,390 P49748 570 LTQ  
10 Syntaxin-binding protein 2 66,453 Q15833 235 LTQ  
11 Bridging integrator 2, isoform 1 61,874 Q9UBW5-1 179 Qtrap  
12 Platelet glycoprotein V, precursor 60,959 P40197 123 Qtrap  
13 ATP synthase subunit beta, precursor 56,560 P06576 1,482 LTQ 7 
14 ATP synthase subunit gamma 32,996 P36542 1,095 Qtrap  
15 ATP synthase subunit b 28,909 P24539 920 Qtrap  
16 ATP5G1 protein 14,277 Q6FIH7 465 Qtrap  
17 ATP synthase subunit alpha, precursor 59,751 P25705 360 LTQ  
18 Integrin-linked protein kinase 51,419 Q13418 308 LTQ  
19 ATP5A1 protein 54,494 A8K092 264 Qtrap  
20 Pyruvate kinase isozymes M1/M2 57,937 P14618 150 LTQ  
21 Beta-actin 41,737 P60709 4,038 LTQ 8 
22 Alpha-actin 1, skeletal muscle 42,051 P68133 2,077 LTQ  
23 Tropomodulin 3 39,595 Q9NYL9 229 Qtrap  
24 ACTA2 protein, fragment 36,807 Q13707 223 Qtrap  
25 DnaJ homolog subfamily B member 11, precursor 40,514 Q9UBS4 94 Qtrap  
26 DKFZp686D0972, hypothetical protein LOC345651 42,003 Q562R1 90 Qtrap  
27 Alpha-actin, cardiac muscle 42,019 P68032 2,077 LTQ 9 
28 Gamma-actin 41,793 P63261 5,165 LTQ 10 
29 Glyceraldehyde-3-phosphate dehydrogenase 36,053 P04406 503 LTQ  
30 Tropomyosin beta chain, isoform 2 32,990 P07951-2 292 Qtrap  
31 F-actin capping protein subunit alpha 1 32,923 P52907 266 LTQ  
32 Tropomyosin alpha 4 chain, isoform 2 32,723 P67936-2 197 Qtrap  
33 PDZ and LIM domain protein 1 36,072 O00151 122 Qtrap  
34 Ras suppressor protein 1 31,540 Q15404 691 LTQ 11 
35 Tropomyosin alpha 1 chain, isoform 7 32,678 P09493-7 504 Qtrap  
36 Guanine nucleotide-binding protein subunit beta 1 37,377 P62873 375 LTQ  
37 Tropomyosin alpha 4 chain, isoform 1 28,522 P67936-1 248 Qtrap  
38 Guanine nucleotide-binding protein subunit beta 2 37,331 P62879 241 LTQ  
39 Prohibitin 29,804 P35232 217 Qtrap  
40 Tropomyosin alpha 3 chain, isoform 2 29,033 P06753-2 165 Qtrap  
41 F-actin capping protein subunit alpha 2 32,949 P47755 165 LTQ  
42 Tropomyosin alpha 3 chain, isoform 1 32,819 P06753 147 Qtrap  
43 PINCH 1 37,251 P48059 143 LTQ  
44 Clathrin light chain A, non-brain isoform 27,077 P09496-2 141 Qtrap  
45 1Q subcomponent-binding protein, precursor 31,362 Q07021 126 Qtrap  
46 Tubulin beta 1 chain 50,327 Q9H4B7 97 LTQ  
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47 Tropomyosin alpha-1 chain 32,709 P09493 63 LTQ  
48 14-3-3 protein epsilon 29,174 P62258 770 LTQ 12 
49 Keratin, type II cytoskeletal 1 66,039 P04264 745 Qtrap  
50 Ras-related protein Ral-B, precursor 23,409 P11234 683 LTQ  
51 14-3-3 protein zeta/delta 27,745 P63104 508 LTQ  
52 Keratin, type I cytoskeletal 9 62,064 P35527 489 Qtrap  
53 Ras-related protein Ral-A, precursor 23,567 P11233 450 LTQ  
54 Keratin, type I cytoskeletal 10 58,827 P13645 410 Qtrap  
55 14-3-3 protein eta 28,219 Q04917 311 LTQ  
56 Keratin, type I cytoskeletal 14 51,561 P02533 267 Qtrap  
57 GTP:AMP phosphotransferase 25,565 Q9UIJ7 128 Qtrap  
58 14-3-3 protein beta/alpha 28,082 P31946 80 LTQ  
59 14-3-3 protein sigma 27,774 P31947 70 LTQ  
60 Ras-related protein Rap-1B, precursor 20,825 P61224 1,320 LTQ 15 
61 Ras-related protein Rap-1A, precursor 20,987 P62834 939 LTQ  
62 ATP synthase O subunit 23,277 P48047 260 LTQ  
63 Heat shock protein beta 1 22,783 P04792 252 Qtrap  
64 Ras-related protein Rab-8B  23,584 Q92930 216 LTQ  
65 Tumor protein D54, isoform 1 22,238 O43399-1 145 Qtrap  
66 Tumor protein D54, isoform 2 19,901 O43399-2 135 Qtrap  
67 NADH dehydrogenase iron-sulfur protein 3, precursor 30,242 O75489 120 Qtrap  
68 Ras-related protein Rab-8A 23,668 P61006 116 LTQ  
69 Myosin regulatory light chain 2, nonsarcomeric 19,794 P19105 1,829 LTQ 16 
70 Myosin regulatory light chain 2, smooth muscle isoform 19,827 P24844 1,528 LTQ  
71 Myosin light chain 4 21,565 P12829 719 Qtrap  
72 Myosin regulatory light chain 12B 19,779 O14950 448 Qtrap  
73 ADP-ribosylation factor-like protein 8B 21,539 Q9NVJ2 284 LTQ  
74 ADP-ribosylation factor-like protein 8A 21,416 Q96BM9 240 LTQ  
75 Actin-related protein 2/3 complex subunit 4 19,667 P59998 202 LTQ  
76 Metalloproteinase inhibitor 3 24,145 P35625 200 LTQ  
77 Myosin regulatory light chain 3 19,794 Q53X45 142 Qtrap  
78 Ras-related protein Rab-1B 22,171 Q9H0U4 113 LTQ  
79 Transforming protein RhoA, precursor 21,768 P61586 490 LTQ 17 
80 ADP-ribosylation factor 1 20,697 P84077 438 LTQ  
81 Calpain small subunit 1 28,316 P04632 415 LTQ  
82 Rho-related GTP-binding protein RhoB 22,123 P62745 313 LTQ  
83 Cofilin 1, non-muscle isoform 18,502 P23528 253 LTQ  
84 Ras-related C3 botulinum toxin substrate 1 21,450 P63000 248 LTQ  
85 ADP-ribosylation factor 5 20,530 P84085 211 LTQ  
86 ADP-ribosylation factor 4 20,511 P18085 188 LTQ  
87 Ras-related C3 botulinum toxin substrate 3 21,379 P60763 100 LTQ  
88 Myosin light polypeptide 6 16,930 P60660 1,169 LTQ 18 
89 Myosin light polypeptide 6B 22,764 P14649 397 LTQ  
90 Peptidyl-prolyl cis-trans isomerase A 18,012 P62937 200 LTQ  
91 Platelet factor 4 10,845 P02776 173 LTQ  
92 Myosin light polypeptide 6, non-muscle isofom 18,037 G3V1V0 135 Qtrap  
93 Calmodulin 16,838 P62158 105 LTQ  
 
With regard to STIM1 acting in the context of platelet activation, adhesion, Ca2+-
signaling and cytoskeleton reorganization, the identified proteins were further 
analyzed for functional features indicating participation in any of these issues (Figure 
4.15 B). Accordingly, five proteins (i.e. 5.4%) were annotated as being involved in cell 
adhesion, another five in secretion processes. A total of 13 proteins (i.e. 
approximately 14.0 %) were implicated in intracellular signaling pathways. Strikingly, 
34.4% of all identified proteins were related to cell shape dynamics, which included 
seven cytoskeleton and cytoskeleton adaptor proteins, and 25 proteins (i.e. 26.9%) 
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known to mediate cell shape remodelling. A more detailed analysis regarding the 
relevance of these data with respect to STIM1 function will be provided in 5.3.1. 
To further validate these preliminary findings by alternative strategies, STIM1-specific 
IP and Co-IP experiments were subsequently performed on native lysates of resting 
platelets of both human and murine origin and samples were consequently analyzed 
for global and specific protein interactions. 
 
 
 
Figure 4.15: (A) Subcellular distribution of 93 proteins identified in 14 of the 18 differential protein 
bands of SC vs Ctrl human platelet samples. (B) Share of proteins being related to distinct features of 
platelet activation and/ or STIM1 function. Data interpretation was based on the UniProtKB/ Swiss-Prot 
database (11/2009, human functional and subcellular localization entries). Total protein numbers are 
indicated in parentheses. 
 
4.9 Interactome screening by STIM1-specific Co-IP in native platelet lysates 
For an additional global interactome screening, STIM1-specific Co-IPs were 
performed on native resting platelet lysates of either human or murine wildtype 
(‘STIM1+/+‘) blood samples (as outlined in 3.10.7). As a negative control analogue 
STIM1-specific Co-IPs were performed on equally-treated platelet lysates of STIM1-/- 
mice. Both mouse lines derived from C57Bl6-Sv129 (mixed background). The 
purified antibody-antigen complexes were subsequently separated by 1D-SDS-
PAGE, silver-stained and differential proteins bands (i.e. in comparison to STIM1-/- 
Co-IP samples, see Figure 4.16) were finally identified by protein mass spectrometry 
using a QStar Elite mass analyzer. Depending on the sample origin, the generated 
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spectra were searched either against the UniProtKB/ Swiss-Prot human or mouse 
subsets and validated as outlined in 3.10.10.3. 
As a result for STIM1-specific Co-IP of human platelet lysates, all 16 differential 
protein bands depicted in Figure 4.16 could be annotated. Summarized data show a 
total of 40 individual proteins (Table 4.2), with molecular masses stretching from 
approximately 332 to 15 kDa. 
 
 
Table 4.2: Individual proteins identified in 16 differential protein bands of STIM1-specific Co-IP 
samples of native lysates of resting human platelets (summary of QStar Elite nano-LC-ESI-MS/MS 
data). Hits are listed according to corresponding protein bands and with decreasing Mascot scores. 
MW: molecular weight [Da]; Acc.Nr.: UniProtKB/ Swiss-Prot accession number; PB: protein band in 
Figure 4.16, lane 3. 
# Protein identifications MW Acc.Nr. Score PB 
1 Desmoplakin  331,774 P15924 218 1 
2 Junction plakoglobin 81,745 P14923 113   
3 Talin 1 269,767 Q9Y490 1,171 2 
4 Talin 2  271,613 Q9Y4G6 104   
5 Myosin heavy chain 9 226,532 P35579 2,054 3 
6 Emilin 1 106,667 Q9Y6C2 653   
7 Multimerin 1 138,110 Q13201 553   
8 Spectrin alpha chain 280,014 P02549 433   
9 Platelet glycoprotein Ib alpha chain 68,955 P07359 130   
10 Alpha-actinin 1 103,058 P12814 3,428 4 
11 Alpha-actinin 4  104,854 O43707 1,768   
12 Alpha-actinin 2 103,854 P35609 897   
Figure 4.16: 1D-SDS-PAGE and subsequent 
silver staining of STIM1-specific Co-IP samples 
of native resting platelet lysates of both human 
and murine origin (STIM1+/+ and STIM1-/-). 
In each case a loading volume of 20 µL was 
applied and separated on 10% Bis-Tris gels. 
Arrows indicate differential protein bands which 
were subsequently excised and analyzed by 
protein mass spectrometry. Samples were 
kindly provided by Dr. Attila Braun (Rudolf-
Virchow-Center, Würzburg, Germany). 
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13 Integrin alpha 2b 113,377 P08514 1,211 5 
14 Integrin beta 3 87,058 P05106 261   
15 Vinculin 123,799 P18206 184   
16 Integrin beta 1  88,415 P05556 137   
17 Gelsolin 85,698 P06396 442 6 
18 Filamin A  280,739 P21333 402   
19 Platelet glycoprotein IV  53,053 P16671 320   
20 Myosin XVIIIa 233,115 Q92614 102   
21 Platelet glycoprotein V 60,959 P40197 445 7 
22 78 kDa glucose-regulated protein 72,333 P11021 340   
23 Thrombospondin 1 129,383 P07996 186 8 
24 Fibrinogen gamma chain 51,512 P02679 364 9 
25 Fibrinogen alpha chain 94,973 P02671 167   
26 Beta-parvin 41,714 Q9HBI1 65 10 
27 PDZ and LIM domain protein 1  36,072 O00151 64   
28 Clusterin  52,495 P10909 222 11 
29 Tropomyosin alpha 1 chain 32,709 P09493 651 12 
30 Tubulin beta 1 chain 50,327 Q9H4B7 222 13 
31 Tropomyosin alpha 4 chain 28,522 P67936 989 14 
32 Tropomyosin beta chain 32,851 P07951 737   
33 Tropomyosin alpha 3 chain 32,819 P06753 452   
34 Ras suppressor protein 1 31,540 Q15404 88   
35 Putative tropomyosin alpha 3 chain-like protein 26,269 A6NL28 281 15 
36 Myosin regulatory light polypeptide 9  19,827 P24844 1,278 16 
37 Myosin regulatory light chain 2 19,794 P19105 1,276   
38 Myosin light polypeptide 6 16,930 P60660 244   
39 Leucine-rich repeat flightless-interacting protein 2 82,171 Q9Y608 103   
40 Fatty acid-binding protein 9 15,093 Q0Z7S8 95   
 
As illustrated in Figure 4.17 A, the majority of the 40 identified proteins were either 
localized in the cytoplasm (57.5%) or within (or associated to) cellular membranes 
(30.0%). The amount of proteins originating from other cellular compartments or 
organelles, however, was comparably low and thus negligible. 
 
 
 
Figure 4.17: (A) Subcellular distribution of 40 proteins identified in STIM1-specific Co-IP samples of 
native lysates of resting human platelets. (B) Share of proteins being related to distinct features of 
platelet activation and/ or STIM1 function. Data interpretation was based on the UniProtKB/ Swiss-Prot 
database (11/2009, human functional and subcellular localization entries). Total protein numbers are 
indicated in parentheses. 
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Functionally, the majority of identified proteins were classified as being related to cell 
adhesion (37.5%) or cellular shape maintenance and/ or remodelling (30.0%, see 
Figure 4.17 B). Upon additional inclusion of eight cytoskeleton proteins, the latter 
group of proteins being involved in cell shape-regulation even amounted to 50.0%. In 
contrast to the findings in 4.8, here only two of the identified proteins (i.e. 5.0%) were 
implicated in intracellular signaling pathways. 
Parallel MS analyses of STIM1-specific Co-IP samples of native resting platelet 
lysates of STIM1+/+ mice also resulted in annotation of all ten differential protein 
bands displayed in Figure 4.16. Here, a total of 28 individual proteins were identified 
and are summarized in Table 4.3. 
 
Table 4.3: Individual proteins identified in ten differential protein bands of STIM1-specific Co-IP 
samples of native resting platelet lysates of STIM1+/+ mice; summary of QStar Elite nano-LC-ESI-
MS/MS data. Hits are listed according to corresponding protein bands and with decreasing Mascot 
scores. MW: molecular weight [Da]; Acc.Nr.: UniProtKB/ Swiss-Prot accession number; PB: protein 
band in Figure 4.16, lane 2. 
# Protein identifications MW Acc.Nr. Score PB 
1 Spectrin alpha chain 279,865 P08032 1,001 1 
2 Myosin light polypeptide 6 16,930 Q60605 896    
3 Spectrin beta chain 245,250 P15508 473   
4 Myosin light chain 4 21,159 P09541 369    
5 Myosin regulatory light chain 2-B 19,779 Q3THE2 314   
6 Myosin regulatory light polypeptide 9 19,854 Q9CQ19 228   
7 Myosin light chain 6B 22,749 Q8CI43 201   
8 Myosin light chain 3 22,422 P09542 129   
9 Uncharacterized protein KIAA1211 132,286 Q5PR69 106 2 
10 Alpha-actinin 1 103,068 Q7TPR4 1,749 3 
11 Alpha-actinin 4 104,977 P57780 1,425   
12 Alpha-actinin 2 103,653 Q9JI91 469   
13 Alpha-actinin 3 103,043 O88990 306   
14 Stromal interaction molecule 1 77,567 P70302 627 4 
15 Ig mu chain C region secreted form 49,972 P01872 141 5 
16 Stress-70 protein, mitochondrial 73,528 P38647 821 6 
17 Heat shock cognate 71 kDa protein 70,871 P63017 614   
18 Heat shock-related 70 kDa protein 2 69,642 P17156 351   
19 78 kDa glucose-regulated protein 72,422 P20029 327   
20 Zyxin  60,546 Q62523 113   
21 Beta-actin 41,737 P60710 1,068 7 
22 Tropomodulin 3  39,503 Q9JHJ0 349   
23 PDZ and LIM domain protein 1 35,774 O70400 1,000 8 
24 Calponin 2  33,156 Q08093 67 9 
25 Tropomyosin alpha 4 chain 28,468 Q6IRU2 434 10 
26 Tropomyosin alpha 3 chain  32,863 P21107 204   
27 Tropomyosin alpha 1 chain 32,681 P58771 141   
28 Tropomyosin beta chain 32,837 P58774 113   
 
Molecular masses stretched from approximately 280 to 17 kDa. As in human STIM1-
specific Co-IP samples, the majority of the identified proteins were localized in the 
cytoplasm (82.2%); however, this time there was no evidence for membrane- or 
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membrane-associated localization (Figure 4.18 A). The share of proteins derived 
from other cellular organelles or compartments was also negligible. Regarding 
protein function, only one protein was annotated as being involved in cell adhesion, 
another one in cell signaling (Figure 4.18 B). The majority of all identified murine 
proteins, namely 71.5%, were once again implicated in cell shape dynamics. This 
included 15 typical cytoskeleton and cytoskeleton adaptor proteins (i.e. 53.6%), and 
five proteins (i.e. 17.9%) known to mediate cell shape remodelling. For a more 
detailed analysis regarding the relevance of these data with respect to STIM1 
function, please also refer to 5.3.1. Thus, as an intermediate result of all three global 
interactome screening approaches on native resting platelet lysates (4.8 and 4.9), 
STIM1 was reproducibly found in apparent interaction with diverse cytoskeleton 
components and cytoskeleton adaptor proteins, as well as with protein factors known 
to regulate cytoskeleton dynamics - and thus cell shape remodelling. 
 
 
 
Figure 4.18: (A) Subcellular distribution of 28 proteins identified in STIM1-specific Co-IP samples of 
native lysates of resting STIM1+/+ mouse platelets. (B) Share of proteins being related to distinct 
features of platelet activation and/ or STIM1 function. Data interpretation was based on the UniProtKB/ 
Swiss-Prot database (11/2009, mouse functional and subcellular localization entries). Total protein 
numbers are indicated in parentheses. 
 
4.10 Validation of specific STIM1-CLP36 interaction in resting murine platelets 
As initially mentioned in 1.3.2, the question whether both the translocation of STIM1 
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further adaptor and/ or scaffolding factors still needs to be solved. For this purpose, 
the cytoskeleton- and shape-dynamics related protein datasets generated during this 
study were additionally searched for eligible candidates. Amongst the proteins 
identified during all three global interactome screening approaches on native resting 
platelet lysates (4.8 and 4.9), in particular one candidate - i.e. the cytoskeleton 
adaptor protein ‘PDZ and LIM domain protein 1’ (approximately 36 kDa, alternative 
names: CLP36, PDLIM1, CLIM1, Elfin) - proved to be promising as it was 
reproducibly detected in all three datasets (Table 4.1 #33, Table 4.2 #27, Table 4.3 
#23; see also Figure 4.19). 
 
 
 
Figure 4.19: Identification of PDZ and LIM domain protein 1 by MS/MS analysis on a QStar Elite mass 
analyzer. Data derived from STIM1-specific Co-IP samples of native lysates of resting STIM1+/+ mouse 
platelets (see Figure 4.16, lane 2, PB 8; in-gel trypsinisation). 
 
This theory was moreover backed by intensive literature research as well as by 
existence of adequate PDZ-binding motifs within the STIM1 aa-sequence (for further 
details please refer to 5.3.2). Hence, to validate the assumed interaction between 
STIM1 and CLP36, STIM1-specific Co-IP was performed on native lysates of resting 
platelets of STIM1+/+ mice as outlined in 3.10.7. The purified antibody-antigen 
complexes were subsequently separated by 1D-SDS-PAGE and immunoblotting was 
executed to validate simultaneous co-precipitation of CLP36 (Figure 4.20 B). As a 
specificity control of the used anti-STIM1 antibodies, a parallel STIM1-specific IP was 
also performed on resting platelets of STIM1+/+ and STIM1-/- mice (both C57Bl6-
Sv129, mixed background), followed by immunoblotting against the STIM1 protein 
(approximately 77.5 kDa; see Figure 4.20 A). 
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Figure 4.20: Analysis of STIM1-CLP36 interaction by Co-IP experiments. (A) STIM1-specific IP and  
-immunoblotting in resting platelets of STIM1+/+ and STIM1-/- mice. (B) STIM1- and CLP36-specific IP 
and subsequent CLP36-specific immunoblotting in resting platelets of STIM1+/+ mice. Data were 
generated in cooperation with Dr. Attila Braun (Rudolf-Virchow-Center, Würzburg, Germany). 
 
In addition, CLP36-specific IP and subsequent immunoblotting against CLP36 in 
purified platelet samples of STIM1+/+ mice served as a binding control for the 
monoclonal anti-CLP36 antibody (Figure 4.20 B). According to Figure 4.20, IP 
against STIM1 protein proved to be specific in resting platelet lysates of STIM1+/+ 
mice (presence of an 80 kDa STIM1 protein band in Figure 4.20 A) as evaluated in 
comparison to equally-treated STIM1-/- samples, and moreover revealed concurrent 
co-precipitation of CLP36 when maintaining native conditions throughout the whole 
procedure (36 kDa protein band in Figure 4.20 B). Together with our previous 
observations (4.8 and 4.9), this finding thus provided further evidence for an in vivo 
interaction between STIM1 and CLP36 proteins in resting platelets. 
 
4.11 GPIb-CLP36 interaction in resting platelets 
As described in 5.3.1, the proteins identified in the course of this study can be 
organized in four functional complexes: (a) the signaling-related complex; (b) the 
actin-myosin complex; (c) the adhesion complex; and (d) the GPIb-IX-V subcomplex. 
Since the latter complex mediates the initial steps of platelet activation, namely 
platelet recruitment and rolling on the vessel surface, it was intriguing to examine 
whether there was any functional connection between GPIb-IX-V and STIM1 or 
CLP36, respectively (see also Table 4.1 #12 and Table 4.2 #9 and #21). For this 
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purpose, GPIb-specific Co-IPs, targeted either against the GPIb alpha or beta chain 
(i.e. GPIbα and GPIbβ), were executed on native lysates of resting platelets of 
STIM1+/+ mice (wildtype C57Bl6-Sv129, mixed background). The resulting antibody-
antigen complexes were subsequently separated by 1D-SDS-PAGE and 
immunoblotted for presence of co-precipitated CLP36. For additional verification, 
analogous counter-IPs were also performed against CLP36, and the generated 
samples were then immunoblotted against GPIb. The corresponding data are 
presented in Figure 4.21 A. 
 
 
 
Figure 4.21: Analysis of GPIb-CLP36-STIM1 interaction in resting platelets of STIM1+/+ mice. (A) 
CLP36-, GPIbα- and GPIbβ-specific Co-IPs and subsequent GPIb- and CLP36-specific 
immunoblotting. (B) GPIb-, CLP36- and STIM1-specific Co-IPs and subsequent CLP36-specific 
immunoblotting. Data were generated in cooperation with Dr. Attila Braun (Rudolf-Virchow-Center, 
Würzburg, Germany). 
 
Accordingly, as verified by occurrence of an adequate 36 kDa protein band, CLP36 
was detected in GPIb-specific Co-IPs and vice versa (i.e. 135 kDa GPIbα protein 
band in CLP36-specific Co-IP samples). Thus, an interaction between GPIb and 
CLP36 - either directly or indirectly via further adaptor proteins – appears as 
possible. In addition, repeated Co-IP experiments on native lysates of resting 
STIM1+/+ mouse platelets against (a) GPIb; (b) STIM1; and (c) CLP36 (as a 
specificity control for the monoclonal anti-CLP36 antibody), followed by CLP36-
specific immunoblotting, furthermore outlined a potential CLP36-mediated structural 
linkage between GPIb and STIM1 (Figure 4.21 B). 
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4.12 Calpain effect on CLP36 stability 
Since supporting studies by Dr. Attila Braun (Rudolf-Virchow-Center, Würzburg, 
Germany) indicated Ca2+-dependent degradation of CPL36 by calpain endoproteases 
in activated STIM1+/+ mouse platelets (wildtype C57Bl6-Sv129; for further details 
please refer to 5.3.4), this finding was validated by performing both in silico and in 
vitro calpain digestion assays of full-length human CLP36 protein. 
In silico digestion was executed via the bioinformatics tools for calpain cleavage 
prediction provided on www.calpain.org (based on [202]). Here, the output data of all 
four prediction models (i.e. SVM-RBF kernel, SVM-linear kernel, PSSM and MKL) for 
processing of the human CLP36 aa-sequence were compared, with corresponding 
results being summarized in Table 4.4. Accordingly, of the total amount of 24 
predicted calpain cleavage sites located in human CLP36, the most probable ones 
were at aa-positions H181, Q220 and V315 (independently determined by all four 
prediction algorithms). Two of these sites (i.e. H181 and Q220) were situated in 
between the CLP36 PDZ- and LIM-domain. 
For in vitro calpain in-solution digestion based on Lakey et al. [201], 30 pmol of 
purified human CLP36 protein (purchased from Abnova) were incubated with  
3 U calpain-1 and with 4.5 U calpain-2 as described in 3.10.8. Proteolytic peptides 
were subsequently analyzed on an LTQ-FT Ultra mass analyzer and the generated 
spectra were searched against the UniProtKB/ Swiss-Prot human subset with 
enzyme specificity being set to ‘none’ (see 3.10.10.3). All MS data were furthermore 
validated manually for fitting with the theoretically predicted calpain cleavage sites. 
To distinguish specific proteolytic peptides from unspecific ones as well as from 
peptide ions generated by spontaneous fragmentation of labile CLP36 sites, MS/MS 
spectra of 0.5 pmol human CLP36 protein without prior calpain treatment were 
recorded in an equal approach. The resulting data are summarized in Table 4.4 (in 
comparison to the in silico ones). For a detailed view please also refer to 7.5. 
Of the 24 in silico predicted putative calpain cleavage sites in human CLP36, 16 were 
also unambiguously detected by this in vitro digestion approach. As in particular 
H181 was reproducibly identified by all in silico prediction models, as well as by the in 
vitro study, this site might be regarded as the most probable calpain target. 
Accordingly, calpain induction by increase of free intracellular Ca2+ (e.g. upon platelet 
activation) may mediate CLP36 shedding at H181 and thus separate the CLP36-
PDZ- from the -LIM domain. 
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Table 4.4: In silico vs in vitro determined calpain cleavage sites in human CLP36 protein. (A) In silico 
sites were obtained via prediction models SVM-RBF kernel, SVM-linear kernel, PSSM and MKL. For 
each model the 10 best scores are displayed, with higher scores corresponding to higher cleavage 
probabilities. Amino acid cleavage positions identified by all four algorithms are shaded in blue. (B) In 
vitro data were generated by in-solution digestion of recombinant human CLP36 via calpain-1 and 
calpain-2 (based on Lakey et al. [201]) and subsequent analysis on an LTQ-FT Ultra mass analyzer. 
In silico predicted yet non-detected calpain cleavage sites, as well as unspecific fragmentation sites 
are shaded in grey, the most probable site is marked in red. The aa-sequence of full-length human 
CLP36 is provided below (based on the UniProtKB/ Swiss-Prot database, Acc.Nr. O00151). The 
CLP36 PDZ-domain is marked in green, the LIM-domain in yellow. 
# Cleavage In silico prediction models In vitro detected 
 position SVM-RBF kernel SVM-linear kernel PSSM MKL cleavage position 
1 Q9 0.14    Yes 
2 F24 0.21 0.23   Yes 
3 R32 0.12 0.12   No 
4 V93  0.12   No 
5 H115  0.12   Yes 
6 S123 0.12    Yes 
7 T128    0.36 Yes 
8 T136 0.14 0.14  0.33 Yes 
9 V139   0.80  No 
10 T141   1.04 0.32 Yes 
11 Q143   0.91  Yes 
12 Y144 0.15 0.16   Yes 
13 Y151    0.30 Yes, yet also unspecific 
14 K166 0.12  1.75  Yes, yet also unspecific 
15 H181 0.22 0.21 3.74 0.42 Yes 
16 L217   1.84  Yes 
17 Q220 0.13 0.12 3.98 0.32 Yes, yet also unspecific 
18 R238   0.88  Yes 
19 K241  0.13   Yes 
20 K246    0.31 Yes 
21 A248    0.32 No 
22 R314   1.86  Yes 
23 V315 0.14 0.13 2.02 0.38 No 
24 T325    0.32 Yes 
 
 
O00151|PDLI1_Human PDZ and LIM domain protein 1 (CLP36); 329 aa 
001 MTTQQIDLQG PGPWGFRLVG GKDFEQPLAI SRVTPGSKAA LANLCIGDVI 
051 TAIDGENTSN MTHLEAQNRI KGCTDNLTLT VARSEHKVWS PLVTEEGKRH 
101 PYKMNLASEP QEVLHIGSAH NRSAMPFTAS PASSTTARVI TNQYNNPAGL 
151 YSSENISNFN NALESKTAAS GVEANSRPLD HAQPPSSLVI DKESEVYKML 
201 QEKQELNEPP KQSTSFLVLQ EILESEEKGD PNKPSGFRSV KAPVTKVAAS 
251 IGNAQKLPMC DKCGTGIVGV FVKLRDRHRH PECYVCTDCG TNLKQKGHFF 
301 VEDQIYCEKH ARERVTPPEG YEVVTVFPK 
 
 
As a consequence of these findings, a transgenic mouse line lacking the CLP36-LIM 
domain (i.e. ‘CLP36∆LIM’) was generated and analyzed regarding its morphological 
and functional platelet phenotype (including Ca2+-response). Here, all corresponding 
experiments were performed in cooperation with Dr. Attila Braun (Rudolf-Virchow-
Center, Würzburg, Germany) and will be presented in section 5.3.5 of this work. 
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5 Discussion 
 
5.1 Overview: Screening the VASP and STIM1 interactome in resting platelets 
To specifically address the VASP and STIM1 interactome in resting platelets, a 
differential proteomics strategy was developed based on affinity-chromatography and 
subsequent protein identification by MS measurement (Figure 5.1). 
 
 
 
Figure 5.1: Workflow for platelet interactome screening via affinity chromatography based on 
recombinant (A) VASP proteins (1) in pQE-30 vector: VASP-AAA, VASP-DDE; (2) in pcDNA3.1/V5-
HisA vector: VASP-AAA∆TD, VASP-DDE∆TD, VASP-AAA∆FAB∆TD and VASP-DDE∆FAB∆TD (B) 
STIM1 protein: STIM1Ctail, in pGEX 6p1 vector. 
 
Inspired by studies of Benz et al. [199], affinity-tagged fusion proteins of phospho-
mimetic mutants of human VASP (VASP-AAA and -DDE) and of the cytoplasmic 
portion of human STIM1 (STIM1Ctail) were overexpressed in E.coli Rosetta, 
consequently purified and finally immobilized on an affinity support to thus generate 
the required affinity matrices. In this context, recombinant protein expression was 
controlled by 1D-SDS-PAGE of bacterial lysates and subsequent Coomassie 
staining, as well as by Western blotting or by MS analysis. 
However, as indicated by these controls, the expression levels of VASP fusion 
proteins were not sufficient for the intended purpose. Therefore, the VASP DNA-
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constructs were further modified (i.e. VASP-AAA/ -DDE∆TD and VASP-AAA/  
-DDE∆FAB∆TD) and cloned into the eukaryotic expression vector pcDNA3.1/V5-
HisA for subsequent stable transfection into HEK293 cells (for details see 5.2.2). 
Following this strategy, heterologous expression of all four VASP constructs was 
finally achieved. Nevertheless, whereas subsequent IMAC purification via the 
introduced C-terminal His6-tags verifiably isolated recombinant STIM1Ctail protein, 
this technique did not succeed in case of the generated VASP fusion proteins. This 
was probably due to both low protein expression levels and structural inaccessibility 
of the constructs’ His6-affinity tag. As a consequence, the intended VASP-specific 
interaction study was finally abandoned and the focus of this work was shifted 
towards an analysis of the STIM1 interactome in resting platelets. 
During platelet purification, particular care was taken to preserve resting platelet 
conditions and thus prevent unintended activation (see 3.6.3 and 3.9.1). Moreover, to 
maintain protein folding structures even during cell lysis, platelet material was treated 
under mild conditions, e.g. by applying non-ionic detergents in the lysis buffer. The 
resulting native platelet lysates were then incubated with the generated STIM1-
specific affinity support. Upon elution, samples were separated by 1D-SDS-PAGE 
and differential protein bands were finally analyzed by nano-LC-ESI-MS/MS. By this 
approach, a total of 93 individual proteins were identified. In parallel, STIM1-specific 
Co-IP experiments both in human and in murine native platelet lysates, followed by 
MS analysis, resulted in identification of another 68 proteins. This also included an 
additional amount of 36 proteins which had not been detected by the initial affinity-
column based approach. One promising candidate, the ‘PDZ and LIM domain protein 
1’ (or ‘CLP36’), was finally chosen for a more detailed verification. 
 
5.2 Analysis of the VASP interactome in platelets 
5.2.1 Expression of human VASP fusion proteins in E.coli 
In 2008, Benz et al. presented a differential proteomics approach to identify the 
phospho-interactome of VASP in human endothelial cells [199]. Accordingly, using  
N-terminally His6-tagged human VASP-DNA in pQE-30 as a template (based on 
[203]), the VASP phosphorylation sites S157, S239 and T278 were exchanged (a) 
with alanines (S157A, S239A, T278A) to mimic a constitutively non-phosphorylated 
state; or (b) with acidic amino acids (S157D, S239D, T278E) to mimic constitutive 
VASP phosphorylation. Prokaryotic plasmid expression in E.coli B strain BL21 
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resulted in fusion proteins of 45 kDa (His6-VASP-S157A, S239A, T278A; i.e.  
‘VASP-AAA’) or 50 kDa (His6-VASP-S157D, S239D, T278E; i.e. ‘VASP-DDE’). These 
were subsequently purified as described by Bachmann et al. [59] and covalently 
coupled to an Affi-Gel 10 support. In parallel, the cytosolic protein fraction of 
endothelial EA.hy926 cells was prepared as described in [204] and then applied to 
the generated VASP-affinity columns. Bound proteins were finally eluted and 
analyzed by 2D-PAGE and protein mass spectrometry via MALDI-TOF-PMF. Of the 
eleven detected proteins which revealed specific interaction with VASP-AAA and not 
with VASP-DDE, αII-spectrin was further verified by Co-IP, GST pull-down assays 
and confocal immunofluorescence microscopy. Deriving from these studies, the 
authors identified αII-spectrin as a novel VASP interaction partner and consequently 
proposed a new mechanism for actin cytoskeleton formation and perijunctional 
filament assembly during cell-cell adhesion. In this context, the spectrin-VASP 
interaction was moreover reported as being down-regulated upon PKA-mediated 
phosphorylation of the VASP S157 residue [199, 205]. 
Based on this previous study, we here intended application of a similar approach to 
enable efficient screening of the phospho-specific VASP interactome in human 
platelets. For this purpose, adequate affinity-tagged phospho-mimetic VASP-AAA 
and -DDE constructs were kindly provided by Prof. Dr. Thomas Renné (Department 
of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden). 
However, even though prokaryotic plasmid expression was performed as outlined by 
Benz et al. [199], biosynthesis of sufficient protein amounts turned out to be 
challenging in our hands. This could have been due to codon bias problems during 
heterologous expression of human VASP-DNA sequences in E.coli BL21. Generally, 
the ‘codon bias’ describes the phenomenon that the frequency of occurrence of 
different synonymous codons in coding DNA varies in between species. This 
species-dependent ‘preference’ of certain codons is reflected by the respective 
intracellular pool of tRNAs - and thus directly impacts mRNA translation. At presence 
of atypical codons, as given during heterologous expression of eukaryotic gene 
material in prokaryotic systems, recombinant protein synthesis may consequently be 
decelerated, interrupted (leading to truncated protein fragments), or totally inhibited. 
For E.coli B strains, such rare codons are represented by AGG, AGA, AUA, CUA, 
CCC and GGA, which thus negatively affects synthesis of R-, I-, L-, P- and G-rich  
aa-sequences (see Table 5.1). 
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Table 5.1: Frequency of occurrence of selected codons (per 1,000 bp of coding DNA) in E.coli B vs 
Homo sapiens. Values were based on the codon usage database on http://www.kazusa.or.jp/codon. In 
addition, the amount of these codons within the human VASP nt-sequence is also provided. 
 Encoded Frequency of occurrence per 1,000 bp # in human 
Codon amino acid E.coli B Homo sapiens VASP nt-seq. 
AGG R 2.1 12.0 6 
AGA R 2.4 12.2 3 
AUA I 5.0 7.5 1 
CUA L 3.4 7.2 2 
CCC P 2.4 19.8 26 
GGA G 8.2 16.5 10 
 
Since the human VASP nt-sequence contains several of these codons - particularly 
26 CCC and 10 GGA that encode for the central proline- and glycine-rich regions 
(see Table 5.1) - prokaryotic synthesis of human VASP-AAA and -DDE fusion 
proteins may be affected here. This would explain the observed low expression 
levels in E.coli BL21 as well as the presence of multiple additional protein bands in 
an MW-range of 40 to 50 kDa upon 1D-SDS-PAGE of bacterial culture samples (see 
4.1). Accordingly, the latter ones probably indicate truncated versions of the intended 
fusion proteins caused by an interrupted biosynthesis. Due to these limitations, VASP 
protein expression was consequently also examined in E.coli Rosetta and E.coli 
BL21-CodonPlus-RP, since these strains provide additional tRNAs for the indicated 
codons [206]. However, neither this approach nor further modification of the 
expression conditions (e.g. by varying incubation temperatures or by using high-level 
expression media such as Superbroth medium and Overnight Express Instant TB 
Medium) contributed to a subsequently improved fusion protein synthesis. 
 
5.2.2 Expression of human VASP fusion proteins in HEK293 
Benz et al. finally circumvented the described codon bias problem by supplementing 
their bacterial growth medium with additional amounts of the limiting tRNAs and by 
lowering the incubation temperature to 12°C ([199], unpublished data). However, due 
to further limitations inherent to the strategy applied by Benz et al., which per se 
demanded additional modification of the applied VASP constructs (see below), we 
decided to completely change to a human-derived model system. For this purpose, 
the HEK293 cell line was chosen for eukaryotic expression of the intended VASP 
fusion proteins. Being easy to transfect and maintain under cell culture conditions, 
HEK293 (i.e. immortalized human embryonic kidney cells) are commonly widely 
applied both as a eukaryotic model organism to study protein effects in vitro, and as 
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an efficient cellular producer strain for synthesis of transgenic proteins, as well as of 
adenoviral and retroviral vectors. 
As a prerequisite for generation of recombinant VASP proteins in HEK293 cells, the 
original VASP-AAA- and -DDE DNA-constructs were (a) specifically modified via 
deletion of the C-terminal TD-domain to prevent hetero-oligomerization with 
endogenous, HEK-derived VASP proteins (i.e. ‘VASP-AAA/ -DDE∆TD’); and (b) 
cloned from the prokaryotic pQE-30 plasmid into the eukaryotic expression vector 
pcDNA3.1/V5-HisA. This vector confers both a V5- and a His6-tag to the C-terminal 
end of the resulting fusion protein. Moreover, as mentioned in the beginning, an issue 
which had not been considered by Benz et al. when performing their VASP-specific 
interactome screening approach [199] was the risk of co-purifying unspecific 
cytoskeleton-associated proteins due to the high affinity of VASP bait material to 
actin filaments [59-61, 207]. During differential MS analyses these unspecific 
components can consequently not be distinguished from ‘true’ VASP interaction 
partners, hence increasing the rate of false positive identifications. In addition, since 
cytoskeleton and cytoskeleton-associated proteins are commonly highly abundant in 
biological samples, respective contamination would probably mask the presence of 
lower abundant yet VASP-specific interacting candidates, which furthermore limits 
subsequent MS analyses and thus the potential of this approach. Hence, to address 
these issues, two additional VASP-constructs were developed, displaying deletion of 
the VASP TD- and -FAB-domains (i.e. ‘VASP-AAA/ -DDE ∆FAB∆TD’, see Figure 
5.2). For evaluation and verification of both transfection efficiency and recombinant 
protein expression, a fifth HEK293 cell line stably expressing the pcDNA3.1/V5-HisA 
lacZ vector construct was finally also established as a positive control. 
However, even though all generated stable HEK293 cell lines reproducibly expressed 
the intended fusion proteins (as monitored by β-gal staining and tag-specific Western 
blotting), subsequent IMAC purification targeted against the C-terminal His6-tag still 
failed. This could have been due to insufficient protein expression levels as 
evidenced by the absence of specifically enriched protein bands in Coomassie-
stained 1D-SDS control gels of crude recombinant HEK293 cell lysates. Improving 
expression conditions and increasing the cellular amounts applied during purification 
did also not contribute to enhanced protein yields. 
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Figure 5.2: Strategy for eukaryotic expression of truncated, affinity-tagged VASP proteins VASP-
AAA∆TD, VASP-AAA∆FAB∆TD, VASP-DDE∆TD and VASP-DDE∆FAB∆TD in HEK293 cells. 
 
Apart from low expression levels, negative impact of primary and higher-order protein 
structures of the expressed VASP constructs on the indicated workflow might also be 
discussed, particularly with regard to efficiency of the IMAC-based protein 
enrichment. As an example, the C-terminal His6-tag of the VASP fusion proteins 
might be structurally inaccessible, an issue which had also been addressed within 
the manufacturer’s instructions of the Qiagen Ni-NTA Spin Kit. Consistent with this 
theory, though performing multiple Western blotting experiments with various His-tag-
specific primary antibodies, the C-terminal His6-tag could not be detected in any of 
the stable HEK293 cell lines. This was particularly unexpected as adequate 
expression of all fusion proteins could reproducibly be monitored by similar Western 
blotting targeted against the constructs’ C-terminal V5-tag, which is located just 
upstream of the His6-tag (see 4.5 and 4.6). Since unintended His-tag deletion could 
moreover be excluded by full-length DNA-sequencing, the most probable explanation 
of this observation might thus be given by the initially mentioned structural 
inaccessibility of the VASP fusion proteins’ C-terminal His6-tag. However, in contrast 
to this theory, the C-terminal His6-tag could also not be detected within HEK-lacZ 
positive controls where limiting structural effects of adjacent aa-sequences could per 
se be excluded. As indicated by both β-gal staining and V5-specific Western blotting 
(see 4.5), this finding was also not due to inadequate protein expression levels or 
inappropriate Western blotting conditions. Therefore insufficient affinity and/ or 
specificity of the applied His-tag-specific primary antibodies also have to be 
considered in this context. As an example, this issue has previously been reported by 
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Debeljak et al. [208] who observed striking variability when testing four different 
antibodies targeted against C-terminal His6-tags. 
Taken together, the difficulties in purifying human VASP-derived proteins from stably-
transfected HEK293 cells under native conditions might have been caused by 
multiple reasons: This may include low protein expression levels as well as 
presumably limiting effects of primary and higher-order protein structures on the 
applied IMAC-based enrichment techniques. 
 
5.2.3 Concluding remarks on the VASP-specific interactome study 
Heterologous expression of affinity-tagged phospho-mimetic VASP fusion proteins 
failed both in the used prokaryotic and eukaryotic model systems. Protein synthesis 
in E.coli was most probably inhibited as a consequence of the codon bias problem 
inherent to prokaryotic vs eukaryotic expression. In this context, particularly the 
VASP central proline- and glycine-rich domains might have contributed to severe 
deceleration of translation, finally resulting in reduced yields of target protein which, 
upon purification, were not sufficient for subsequent generation of VASP-specific 
affinity columns. Regarding stably-transfected eukaryotic HEK293 cells the problem 
was comparable: Though adequate protein expression was validated by V5-specific 
Western blotting, only low recombinant protein levels could be detected, 
consequently resulting in insufficient protein enrichment. In addition, IMAC-based 
protein purification might have been further limited by partial or total structural 
inaccessibility of the constructs’ C-terminal His6-tag, which was consistent with our 
finding of generated fusion proteins being undetectable by His6-specific Western 
blotting. In future attempts, this challenge might be faced by moving the His6-tag to 
the opposite end of the protein. However, since our interactome screening approach 
was targeted against free and unaltered N-terminal VASP domains, such a strategy 
was not advisable here. Therefore, under the given conditions, the intended VASP-
specific interactome study was stopped and the focus of this work was shifted 
towards an analysis of the STIM1 interactome. 
Nevertheless, the generated stable cell lines might still be useful to address the 
phospho-specific VASP interactome of the eukaryotic HEK293 model system in 
alternate approaches. Since the respective VASP fusion proteins contain both His6- 
and V5-tags, V5-specific Co-IP experiments could be performed on native HEK293 
cell lysates and co-precipitated putative VASP interaction partners could 
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subsequently be analyzed by differential SDS-PAGE and protein MS. The data 
deriving from such an approach might also be relevant with regard to the VASP 
interactome of platelets and consequently enable targeted studies here as well. 
Another strategy to address the phospho-specific VASP interactome of platelets is 
provided by classical Co-IPs against endogenous platelet VASP. In this context, 
VASP phosphorylation can for instance be induced by addition of specific PKA 
agonists (such as the AC activator forskolin), which, depending on the applied 
concentration, would mediate phosphorylation first of VASP S157, followed by S239 
and finally T278. However, when performing such an approach, it is challenging to 
control and discriminate single and multiple VASP phosphorylation events, and to 
adequately deduce the accompanying effects on the related phospho-site specific 
interactomes. Moreover, due to the high affinity of VASP to cytoskeleton actin 
filaments, it has to be considered that the detected putative VASP-interaction 
partners could still originate from co-purified actin-bound yet VASP-unrelated 
proteins. 
Finally, to enable a more stringent control of VASP phosphorylation patterns when 
performing VASP-specific interactome studies, an alternative strategy could be 
applied: Native platelet lysates could be analyzed in an affinity chromatography 
approach based on resin-bound synthetic peptides which specifically contain only 
one of the three characteristic VASP phosphorylation sites in either phosphorylated 
or non-phosphorylated form. Since these sites are located in close proximity of well-
defined VASP domains (i.e. the recruiting poly-Pro-site, as well as the GAB- and the 
FAB-region; [61]), one disadvantage of this approach might be that withdrawal of 
S157, S239 and T278 from their functional surroundings may also result in a loss of 
biological relevance of the delivered data. 
 
5.3 Analysis of the STIM1 interactome in platelets 
5.3.1 Remarks on the identified STIM1 interactome 
The resulting total amount of 161 proteins detected throughout the STIM1-related 
study (see 4.8 and 4.9) still contained several redundant isoforms, as well as proteins 
not distinctively related to platelets, including typical organelle-specific and metabolic 
ones. Upon removal of these components, the number of identifications was finally 
reduced to 87. In this context, candidates which had been annotated as ‘precursors’ 
(based on the UniProtKB/ Swiss-Prot entries) were treated similar to ‘mature’ ones. 
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Of these remaining 87 individual proteins, 23 were repeatedly discovered by at least 
two independent approaches - i.e. (a) the STIM1Ctail affinity column strategy, or 
STIM1-specific Co-IP either in (b) human; or (c) mouse platelet lysates - including a 
total of seven which were even detected by all three performed analyses (see Figure 
5.3 and Table 5.2). 
STIM1Ctail affinity 
column (60)
STIM1 Co-IP, mouse 
(23)
STIM1 Co-IP, human 
(34)
 
Figure 5.3: Relative display and intersectional regions of platelet-related proteins identified by all 
STIM1-specific interactome studies performed in this work. The total number of proteins detected in 
each approach is provided in parenthesis. 
 
Apart from Ras suppressor protein-1, which reportedly plays a role in Ras signal 
transduction pathways, these multiply detected proteins were closely related to 
diverse cytoskeletal functions. Myosin, tubulin and β-actin (i.e. cytoplasmic actin) are 
typical cytoskeleton proteins; tropomyosin is implicated in actin filament stabilization 
[209, 210]. Gelsolin and tropomodulin are both involved in actin-cytoskeleton 
modelling: Ca2+-regulated gelsolin binds to the barbed ends of actin filaments, where 
it promotes actin-monomer-to-filament assembly (i.e. ‘nucleation’) and prevents 
monomer exchange (i.e. ‘capping function’) [211]. Tropomodulin, on the other hand, 
inhibits both elongation and depolymerization at the pointed ends of actin-filaments, 
thus stabilizing short proto-filaments which particularly define membrane skeleton 
geometry [212]. 
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Table 5.2: List of proteins repeatedly identified during all STIM1-specific interactome studies. SC: 
STIM1Ctail affinity column approach; hIP: STIM1-specific Co-IP in human platelets; mIP: STIM1-
specific Co-IP in platelets of STIM1+/+ mice. Positive identifications are marked by an ‘X’. 
# Protein identifications SC hIP mIP 
1 Alpha-actinin 1  X X 
2 Alpha-actinin 2   X X 
3 Alpha-actinin 4   X X 
4 Beta-actin X  X 
5 Gelsolin X X  
6 Integrin alpha 2b X X  
7 Myosin heavy chain 9 X X  
8 Myosin light chain 4 X  X 
9 Myosin light polypeptide 6 X X X 
10 Myosin regulatory light chain 2 X X X 
11 Myosin regulatory light polypeptide 9   X X 
12 PDZ and LIM domain protein 1 X X X 
13 Platelet glycoprotein V X X  
14 Ras suppressor protein 1 X X  
15 Spectrin alpha chain  X X 
16 Talin 1 X X  
17 Tropomodulin 3 X  X 
18 Tropomyosin alpha 1 chain X X X 
19 Tropomyosin alpha 3 chain X X X 
20 Tropomyosin alpha 4 chain X X X 
21 Tropomyosin beta chain X X X 
22 Tubulin beta 1 chain X X  
23 Vinculin X X  
 
Other identified proteins are related to cytoskeleton attachment: α-actinins crosslink 
F-actin filaments and mediate actin anchoring to various intracellular and membrane 
structures [213]. PDZ and LIM domain protein 1 (alternative names: CLP36, PDLIM1, 
CLIM1, Elfin) acts as a protein-to-cytoskeleton adaptor [213, 214], spectrin maintains 
plasma membrane integrity and regulates Ca2+-dependent cytoskeleton movement at 
membrane regions (e.g. during secretion) [215], and at cell-substratum contacts  
talin-1 connects the actin cytoskeleton to the plasma membrane [216, 217]. In this 
context, a notable number of proteins were also directly related to cell adhesion and 
movement. One such example is provided by vinculin, an F-actin-binding protein 
implicated in maintenance of cell morphology, as well as cell-to-matrix adhesion and 
locomotion [51, 69-71, 218]. Moreover, it regulates the expression of E-cadherin, i.e. 
a Ca2+-dependent cell adhesion protein at the cell surface. Finally, with glycoprotein 
V (GPV) and integrin αllb, typical platelet-derived adhesive membrane proteins were 
discovered: In detail, the GPIb-IX-V complex component GPV functions in the 
context of vWF-dependent platelet adhesion to the blood vessel wall [219, 220]. 
Upon subsequent platelet activation, integrin αllb, as part of the integrin αIIbβ3 
fibrinogen receptor, mediates platelet-platelet interaction - and thus thrombus 
formation [221, 222]. 
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Deriving from these preliminary findings, almost all non-redundant, platelet-related 
proteins identified in the course of this study were organized in four functional 
complexes: (a) the actin-myosin complex; (b) the adhesion complex, which also 
included the (c) GPIb-IX-V subcomplex; and (d) the signaling-related complex 
(compare Table 5.3). 
 
Table 5.3: Functional grouping of non-redundant, platelet-related proteins identified during all 
performed STIM1-specific interactome screenings. Evaluations were based on functional annotations 
provided by the UniProtKB/ Swiss-Prot database. 
Actin-myosin complex  Adhesion complex  Signaling-related complex 
ACTA2 protein  Alpha-actinin 1  Calmodulin 
Actin-related protein 2/3 complex SU 4  Alpha-actinin 2  Guanine nucleotide-bind. prot. SU beta 1 
Alpha-actin  Alpha-actinin 3  Guanine nucleotide-bind. prot. SU beta 2 
Alpha-actinin 1  Alpha-actinin 4   Leucine-rich rep. flightless-interact. prot. 2 
Alpha-actinin 2  Beta-parvin  14-3-3 protein alpha/ beta 
Alpha-actinin 3  Filamin A  14-3-3 protein delta/ zeta 
Alpha-actinin 4   Integrin alpha 2b  14-3-3 protein epsilon 
Beta-actin  Integrin beta 1  14-3-3 protein eta 
Caldesmon  Integrin beta 3  14-3-3 protein sigma 
Calponin 2  Integrin-linked protein kinase  Ras-related C3 botulinum toxin subst. 1 
Cofilin 1  Kindlin 3  Ras-related C3 botulinum toxin subst. 3 
F-actin capping protein SU alpha 1  Multimerin 1  Ras-related protein Rab-1B 
F-actin capping protein SU alpha 2  PDZ and LIM domain protein 1  Ras-related protein Rab-8A 
Filamin A   PINCH1  Ras-related protein Rab-8B  
Gamma-actin  Platelet glycoprotein IV  Ras-related protein Ral-A 
Gelsolin  Spectrin alpha chain  Ras-related protein Ral-B 
Myosin XVIIIa  Spectrin beta chain  Ras-related protein Rap-1A 
Myosin heavy chain 9  Talin 1  Ras-related protein Rap-1B 
Myosin light chain 3  Talin 2   Ras suppressor protein 1 
Myosin light chain 4  Thrombospondin 1  Rho-related GTP-binding protein RhoB 
Myosin light chain 6B  Vinculin  Transforming protein RhoA 
Myosin light polypeptide 6  Zyxin   
Myosin regulatory light chain 2     
Myosin regulatory light chain 3  GPIb-IX-V subcomplex   
Myosin regulatory light chain 12B  Filamin A   
Myosin regulatory light polypeptide 9  PDZ and LIM domain protein 1   
PDZ and LIM domain protein 1  Platelet glycoprotein Ib alpha chain   
Tropomodulin 3  Platelet glycoprotein V   
Tropomyosin alpha chain  Spectrin alpha chain   
Tropomyosin alpha 1 chain  Spectrin beta chain   
Tropomyosin alpha 3 chain      
Tropomyosin alpha 4 chain     
Tropomyosin beta chain     
 
The ‘signaling-related complex’ mainly contained typical components of the Ras-, 
Rho- and 14-3-3 signaling pathway. As these protein factors are altogether involved 
in a huge variety of intracellular regulatory processes and are thus probably not 
specifically related to the STIM1 function, they were only of minor interest in the 
context of this work. 
The ‘actin-myosin complex’, on the other hand, predominantly consisted of 
cytoskeleton proteins of the actin family, as well as of myosin and tropomyosin. In 
addition, it comprised filament crosslinking components, such as α-actinin or 
caldesmon, and proteins mediating cytoskeleton polymerization (e.g. the Arp-2/3 
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complex), branching (filamin A), capping, or shape remodelling (cofilin-1, calponin-2) 
[67, 210, 213, 219] . Since some of the members initially organized in the actin-
myosin complex - i.e. α-actinins, filamin A and cytoskeleton adaptor protein CLP36 - 
are also related to stabilization of adherens-type junctions by anchoring cytoskeleton 
filaments and associated proteins to the plasma membrane, these candidates were 
moreover also included in the so-called ‘adhesion complex’. 
Generally, this third functional complex summarized a total of 22 proteins involved in 
cell-cell or cell-substratum interaction, particularly in the context of platelet adhesion. 
As an example, upon activation of kindlin-3, which is present in the F-actin 
surrounding ring structure of podosomes in hematopoietic cells, the integrin receptor 
subunits β1 and β3 regulate platelet-to-endothelial cell adhesion [85, 222, 223]. This 
is mediated via binding to a wide array of ligands, such as collagen, laminin, 
cytotactin, vitronectin, thrombospondin, vWF or VCAM1. In addition, integrin β3, as 
part of the already-mentioned integrin αIIbβ3 fibrinogen receptor, interacts with 
fibronectin and soluble fibrinogen during platelet-platelet interaction [221, 222]. In 
activated platelets, the integrin β3 subunits of integrin αIIbβ3 or αVβ3 receptors are also 
implicated in downregulation of thrombin generation by binding to multimerin-1, i.e. 
an extracellular matrix protein which stabilizes platelet factor V. Another component 
closely connected to regulation of integrin inside-out signaling is the integrin-linked 
protein kinase (ILK) which, together with integrin signaling effector PINCH-1 and 
cytoskeleton-associated β-parvin, forms the so-called IPP focal adhesion complex 
[224, 225]. Finally, intracellular linkage of integrin to the actin cytoskeleton is 
mediated by talins, in particular by adhesion plaque protein talin-2 [216, 217]. Apart 
from integrins, further detected cell adhesion-related molecules were platelet 
membrane glycoprotein IV (GPIV; interacts with collagen, thrombospondin and 
oxidized LDL, [226]), and zyxin which binds to α-actinin and targets Ena/ VASP 
family members to regions of focal adhesion [51, 69-71]. 
In addition, with platelet glycoprotein Ib alpha chain (GPIbα) and platelet glycoprotein 
V (GPV) two subunits of the vWF-binding GPIb-IX-V receptor complex were 
identified. Since this platelet membrane complex, known to support the initial step of 
platelet rolling on the exposed subendothelial surface of injured blood vessels, 
generally co-localizes with filamin A (via direct GPIbα interaction) and spectrin, and 
since CLP36 has been reported to be closely associated to these two proteins [213], 
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all these components were consequently summarized in a fourth functional complex - 
i.e. the adhesional ‘GPIb-IX-V subcomplex’. 
Interestingly, apart from the signaling-related complex, filamin A and CLP36 proved 
to be associated to all described functional complexes. Moreover, as the latter one 
was also amongst those proteins which were reproducibly detected in all performed 
STIM1-specific interactome screening approaches this putative STIM1 interaction 
candidate was finally selected and further examined in more detail. This included 
evaluation of the specificity of interaction (e.g. via targeted Co-IP experiments), as 
well as functional analysis with regard to its implication in STIM1-mediated platelet 
effects. 
 
5.3.2 STIM1 interaction with PDZ and LIM domain protein family member CLP36 
Classification of the ‘PDZ and LIM domain protein family’ (PDLIM) is based on 
structural similarities: Accordingly, each family member contains at least one PDZ 
domain (i.e. ‘postsynaptic density 95, discs large and zonula occludens-1’) and at 
least one LIM domain (i.e. ‘Lin-11, Isl-1 and Mec-3’) [227]. These two frequent 
protein-protein interaction motifs are related to multiple biological processes, such as 
regulation of actin structure and dynamics, or integrin-dependent adhesion and 
signaling [228-232]. In this context, they also function in organization of postsynaptic 
density and neuronal pathfinding, as well as in regulation of membrane protein 
activity and trafficking.  
In detail, the PDZ domain consists of 80-100 aa residues, including a highly 
conserved GLGF sequence [233], and has been reported to bind to short C-terminal 
as well as internal PDZ binding motifs found in a variety of interaction partners [234]. 
The LIM domain (approximately 60 aa), on the other hand, is a conserved zinc- 
binding, cysteine-rich motif consisting of two tandemly repeated zinc-fingers and 
containing the consensus sequence CX2CX16-23HX2CX2CX2CX16-21CX2(C/ H/ D) 
[235]. Though LIM domains have been detected in various proteins and are involved 
in multiple cellular functions, no distinct LIM domain binding motif has yet been 
identified. However, in some proteins LIM domains have been observed to form 
dimers with other LIM domains and are moreover frequently involved in linking 
proteins to specific protein kinases (e.g. Src, Clik, or PKC; [236-238]) and 
phosphatases [213, 239]. Since discovery of the first PDZ-LIM domain protein, 
enigma, in 1994 [240], ten PDLIM proteins have been identified in mammals so far, 
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and are organized in four subfamilies (Figure 5.4 A): (a) actinin-associated LIM 
proteins (ALP); (b) enigma and enigma-homologue proteins (ENH); (c) LIM domain 
kinases (LIMK1, LIMK2); and (d) LIM domain only protein-7 (LMO7) [241, 242]. 
 
 
 
Figure 5.4: The PDLIM protein family. (A) Structural organization of ALP-, enigma-, LIMK- and LMO7- 
PDLIM subfamilies. (B) PDLIM protein specific mRNA expression profiles of murine blood cells 
(platelets, macrophages) and lymphatic tissue (lymph nodes, thymus). This RT-PCR study was 
exclusively targeted against members of the PDLIM ALP- and enigma-subfamilies (i.e. mystique, ALP, 
RIL, CLP36 and enigma, ZASP, ENH) and was performed by Dr. Attila Braun (Rudolf-Virchow-Center, 
Würzburg, Germany). 
 
Together with mystique (PDLIM2, SLIM), ALP (PDLIM3), and RIL (PDLIM4), the  
36 kDa protein CLP36 belongs to the PDLIM ALP-subfamily. It thus contains one  
N-terminal PDZ domain and, following a short linker region, one C-terminal LIM 
domain [227]. Previous studies of Kotaka et al. indicated CLP36 co-localization with 
α-actinin- 2 at myocardial Z-lines [243]. Later, in 2000, Bauer et al. also reported 
CLP36 association with α-actinin-1 in resting platelets and moreover observed 
translocation of this protein complex to regions of newly generated actin filaments 
upon platelet activation [213]. These data are consistent with our own observations: 
As revealed by RT-PCR studies on the expression profile of several PDLIM family 
members in murine blood cells and lymphatic tissue, CLP36 appears to be the sole 
member of the PDLIM ALP- and enigma-subfamilies which is expressed in platelets 
(Figure 5.4 B). Thus, the platelet effects reported by Bauer et al. are distinctively 
related to CLP36 and not biased by overlapping activities of other PDLIM proteins. 
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According to Vallenius et al., the described interaction of CLP36 with non-muscle  
α-actinin isoforms (i.e. α-actinin-1, but also α-actinin-4) is executed via the CLP36 
PDZ domain and involved in actin stress fiber-mediated processes, such as 
regulation of cell shape, polarity, migration and cytokinesis in non-muscle cells [214]. 
However, in contrast to this finding, deriving from yeast 2-hybrid experiments Bauer 
et al. concluded that the observed association between CLP36 and α-actinin-1 is 
rather due to binding of the short CLP36 intervening region to the spectrin-like 
repeats 2 and 3 of α-actinin-1 - and hence not dependent on the CLP36 PDZ and 
LIM domains [213]. Thus, the true impact of CLP36 related protein interactions and 
subsequent effects are still far from being fully understood. 
To validate the association of STIM1 and CLP36 indicated by our studies, the full-
length aa-sequence of human STIM1 was analyzed for putative PDZ binding sites by 
applying the Expasy-Prosite database search tool for protein domains, families and 
functional sites (http://prosite.expasy.org). As displayed in Figure 5.5 A, nine such 
PDZ binding sites were identified, with the first two - i.e. STIM1 aa 344-347 (PEAL) 
and aa 402-405 (LDDV) - being moreover located in close proximity to the annotated 
STIM1-ORAI1 binding site (STIM1 aa 384-389, KKKRNT). This in silico evidence for 
an apparent interaction between STIM1 and the CLP36 PDZ domain was also 
verified in vivo, since STIM1-specific Co-IP experiments on native lysates of resting 
platelets resulted in concomitant co-precipitation of CLP36 in STIM1+/+ mice, whereas 
this effect was totally absent in equally-treated samples of STIM1-/- animals (see 
4.10). Thus, at least in resting platelets, an interaction of STIM1 and CLP36 appears 
to be most likely. Interestingly, when subsequently performing multiple sequence 
alignments of human, mouse, rat, Xenopus laevis, Fugu and Drosophila 
melanogaster STIM1 proteins (via the Blastp sequence alignment tool provided on 
http://blast.ncbi.nlm.nih.gov), the first two in silico predicted PDZ binding sites 
moreover proved to be highly conserved amongst species, in particular mammalian 
ones (Figure 5.5 B). This strongly indicates their implication in distinct biological 
processes. In this context, CLP36 binding to one of these two PDZ binding motifs 
might mask the ORAI1 binding site of STIM1. As premature STIM1-ORAI1 complex 
formation would consequently be prevented, the proposed CLP36-STIM1 interaction 
might consequently have a stabilizing effect on platelet resting conditions. However, 
this theory requires further validation by supplementary studies, which would also 
include specific identification of the involved STIM1 PDZ binding site. 
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Figure 5.5: PDZ binding sites in human STIM1 protein as annotated by the Expasy-Prosite database 
search tool. (A) Nine putative PDZ binding sites (marked in red) were identified in the human STIM1 
full length aa-sequence. The first two sites, STIM1 aa 344-347 (PEAL) and aa 402-405 (LDDV), are 
situated adjacent to the STIM1-ORAI1 binding site (marked in green). (B) Sequence alignments of the 
first two PDZ binding sites (marked in red) of human, mouse, rat, Xenopus laevis, Fugu and 
Drosophila melanogaster STIM1 proteins. 
 
5.3.3 GPIb-CLP36 interaction 
As outlined in 5.3.1, based on database and literature research functional association 
of CLP36 to the adhesional GPIb-IX-V subcomplex appeared to be plausible. Indeed, 
GPIb-specific Co-IPs targeted against both receptor subunits GPIbα and GPIbβ in 
native resting platelets lysates of STIM1+/+ mice (i.e. C57Bl6-Sv129 mixed 
background, wildtype) reproducibly resulted in co-precipitation of CLP36 - and vice 
versa (see 4.11). Thus, an association between GPIb and CLP36 was also indicated 
in vivo; however, whether this interaction occurs directly or by interaction with further 
adaptor proteins still needs to be determined. 
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Generally, the GPIb-IX-V receptor complex consists of four transmembrane subunits: 
GPIbα, covalently linked to GPIbβ via disulfide-bridges, and non-covalently attached 
GPIX and GPV [219, 220]. Moreover, the GPIbα cytoplasmic domains (i.e. aa 557-
575) interact with the C-terminal region of actin-binding filamin A, which was also 
identified in our own STIM1-specific interactome screening approaches [244, 245]. 
This association was reported as crucial for platelet adhesion to vWF, for stabilizing 
platelet shape and integrity under resting conditions, as well as for regulating signal 
transduction during platelet activation [246, 247]. In 2006, Nakamura et al. unravelled 
the crystal structure of the GPIbα-filamin A complex and localized the GPIbα binding 
site at filamin A domain 17 [219]. Based on these findings and on previously 
published data concerning the GPIb-IX-V receptor composition [248], the entire 
protein complex composed of GPIb-IX-V, filamin A and F-actin was finally assembled 
as depicted in Figure 5.6. In addition, as published by Bauer et al. [213], α-actinin-
mediated crosslinking of F-actin filaments, as well as CLP36 interaction with both  
F-actin and α-actinin were also included in this schematic drawing. 
In detail, filamin A - which forms homodimers via its C-terminal domains - anchors the 
cell surface receptor complex GPIb-IX-V to the F-actin cytoskeleton. This association 
is mediated by (a) interaction between the cytoplasmic part of GPIbα and filamin A 
domain 17; and (b) conserved actin-binding domains located at the filamin A  
N-termini and typically contain two CH-domains. F-actin filament crosslinking is 
mediated by symmetric antiparallel α-actinin dimers. These are rod-shaped 100 kDa 
proteins with (a) an N-terminal globular head harbouring the 2-CH-actin-binding 
domain; and (b) a C-terminal tail containing two Ca2+-binding EF-hand motifs [249-
252]. The latter domains have been related to α-actinin targeting to integrin  
β-subunits and focal adhesion sites. As reported by Bauer et al., at least for  
α-actinin-1 this function appears to be modulated by CLP36, which commonly co-
localizes with this particular α-actinin isoform. Accordingly, upon interaction of the 
CLP36 short linker sequence with α-actinin spectrin-like repeats 2 and 3, binding of 
α-actinin-1 to integrin subunits and adhesional plaques is inhibited. This also explains 
the absence of CLP36 at focal adhesions in activated platelets [213]. Instead, the 
CLP36-α-actinin-1 complex is retained on actin filaments and stress fibers, where it 
executes its actin bundling activity [250]. As a consequence, the observed co-
precipitation of CLP36 in GPIb-specific Co-IP experiments is probably due to its firm 
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association with the α-actinin-F-actin complex (or with F-actin alone). Hence the 
GPIb-CLP36 interaction presumably has to be regarded as an indirect one. 
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Figure 5.6: Scheme of the GPIb-IX-V receptor complex in association with dimerized filamin A and  
F-actin filaments (based on [219]). Included are CLP36 interactions with F-actin and F-actin-coupled 
α-actinin as reported by Bauer et al. for resting platelets [213]. Moreover, binding of the CLP36 PDZ 
domain to ER-localized STIM1 monomers, as derived from our own studies, is depicted below. 
 
Moreover, under the described conditions the PDZ and LIM domains of α-actinin-
bound CLP36 are free to link further proteins - for instance related to cell signaling, 
as well as to regulation of cell shape and integrity - to the F-actin filaments. In this 
context, as illustrated in Figure 5.6, CLP36 may also function as an adaptor that 
anchors the cytoplasmic tail of ER-localized STIM1 to the cytoskeleton. This binding 
may have a stabilizing effect on the platelets’ resting state, thus preventing 
uncontrolled intravascular activation since homotypic oligomerization of STIM1 
monomers and subsequent formation of ER-PM junctions are consequently avoided - 
until platelet activity is finally induced by the interaction of GPIb-IX-V with 
subendothelial vWF. 
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However, it has to be mentioned that although CLP36 was specifically found in 
association with GPIb and - in a separate approach - with STIM1 (both indicated by 
our Co-IP studies), this does not necessarily prove CLP36-mediated interrelation 
between these two components. On the contrary, CLP36 is implicated in so many 
cellular processes that these two findings might also be completely independent. 
Thus, for further confirmation of this theory, more enhanced functional assays will 
have to be performed. 
 
5.3.4 Ca2+-dependent degradation of CLP36 by calpain 
Based on the finding of an association between CLP36 and Ca2+-sensing STIM1, the 
question was posed how CLP36 may be affected by STIM1-related fluctuation of 
intracellular calcium levels. For this purpose, Braun et al. investigated the impact of 
artificially induced SOCE on CLP36 stability in purified platelets of STIM1+/+ mice (i.e. 
C57Bl6-Sv129 mixed background, wildtype). In detail, by adding the Ca2+-ionophore 
ionomycin in presence of 1 mM extracellular calcium, Ca2+-influx increased via direct 
stimulation of store-operated cation entry across the biological membranes (SOCE) 
[253]. Interestingly, as depicted in Figure 5.7 A (left), subsequent Western blotting 
revealed distinct degradation of CLP36 over time, whereas protein levels of GPIb and 
tubulin (loading control) remained relatively unaltered. Moreover, since this effect on 
CLP36 levels was not observable when platelets were equally treated in absence of 
extracellular calcium (under these conditions, ionomycin-induced  Ca2+-fluxes were 
solely due to calcium store depletion), it was clearly a consequence of SOCE-
mediated [Ca2+]i increase (Figure 5.7 B, left). 
Thus having an obvious evidence for Ca2+-dependent protein degradation, the next 
step was to investigate a potential implication of calpain activity. Generally, calpains 
are Ca2+-dependent cysteine proteases [254-256] and functionally closely related to 
cytoskeleton reorganization, cell motility - and also hemostasis [257, 258]. There are 
two classes of ubiquitously expressed calpains: calpain-1 (µ-calpain), which only 
requires micromolar Ca2+-concentrations for full activity, and calpain-2 (m-calpain), 
which demands presence of higher (i.e. millimolar) calcium levels [254]. In activated 
mouse platelets, calpain has been shown to mediate proteolytic processing of 
various targets, such as talin, filamin and other proteins related to cytoskeleton 
integrity, contractility or integrin signaling (e.g. integrin αIIbβ3) [257, 259]. Thereby, 
according to Azam et al., calpain-1 accounts for 80% of the total platelet calpain 
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activity and is particularly relevant during Ca2+-dependent late platelet response 
[254]. 
 
 
 
Figure 5.7: SOCE-dependent degradation of CLP36 by calpain. Platelets of STIM1+/+ mice (n=2) were 
treated with calcium ionophore ionomycin and/ or specific calpain inhibitor calpeptin (A) in presence or 
(B) in absence of extracellular calcium. Time-dependent protein levels of GPIb, CLP36 and tubulin 
(loading control) were subsequently determined via specific Western blotting. Data were kindly 
provided by Dr. Attila Braun (Rudolf-Virchow-Center, Würzburg, Germany). 
 
Based on this knowledge, Braun et al. repeated their experiments in presence of the 
specific calpain inhibitor calpeptin. As a result, upon ionomycin addition,  
pre-treatment with calpeptin efficiently prevented the previously observed SOCE-
induced degradation of CLP36 in platelets of STIM1+/+ mice (Figure 5.7 A, middle). 
Hence, it may be concluded that SOCE-induced [Ca2+]i increase upon platelet 
activation also induces platelet calpain (i.e. presumably calpain-1) which 
consequently mediates Ca2+-dependent limited proteolysis of various target proteins - 
including CLP36. This theory was further backed both by in silico prediction of 
calpain cleavage sites in the CLP36 aa-sequence, as well as by in vitro calpain 
digestion assays of recombinant human CLP36 protein (see 4.12): Accordingly, of 
the 24 calpain cutting sites predicted in silico for CLP36, 19 were also identified by 
the MS-based in vitro digestion assay. However, since three of these sites were also 
detected in undigested samples and may thus as well result from unspecific 
spontaneous fragmentation, the total amount of putative calpain cleavage sites of 
CLP36 was reduced to 16. One of these candidates, i.e. CLP36 H181, was 
reproducibly identified by all four in silico prediction models, as well as by the in vitro 
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calpain digestion assay, and hence represents the most promising calpain cleavage 
site located in human CLP36. 
Deriving from these findings, calpain, as induced by SOCE-mediated increase of 
intracellular Ca2+-levels (e.g. upon platelet activation), may mediate proteolytic 
cleavage of CLP36 at aa-position H181 (or other sites) and consequently disconnect 
the CLP36 PDZ from the LIM domain. This parting of the CLP36 short linker 
sequence may also negatively affect its previously described interaction with the 
spectrin-like repeats 2 and 3 of α-actinin-1. As a consequence, CLP36 would 
dissociate from α-actinin-1, hence leaving its F-actin bound state. Assuming an 
association of CLP36 and STIM1 via the CLP36 PDZ domain in resting platelets (as 
depicted in Figure 5.6), Ca2+-unloaded STIM1 monomers would subsequently be 
released from their cytoskeleton-anchored resting state and finally be able to 
dimerize and translocate to the ORAI1 complex at regions of ER-PM junctions. 
 
5.3.5 Negative regulation of GPVI signaling by CLP36 
Since CLP36 turned out to be the sole expressed PDLIM family member in murine 
platelets (see Figure 5.4 B), its loss of function cannot be compensated by other 
PDLIM proteins. Thus, disruption of the Clp36 gene provides a promising tool to 
further characterize the proteins physiological role in vivo, particularly with regard to 
platelet activation and subsequent Ca2+-signaling. In this context, there is plenty of 
data available indicating implication of the CLP36 PDZ domain in multiple protein-
protein interactions (see 5.3.2). Moreover, the related PDZ binding sites are well 
defined. In contrast, the functional impact of the CLP36 LIM domain still needs to be 
further specified. For this purpose, Braun et al. generated a transgenic mouse line 
(C57Bl6-Sv129 mixed background) where the CLP36 LIM domain has been deleted 
by inserting a Geo-gene-trap cassette (containing a downstream transcriptional 
termination sequence) in the intronic region between exon 5 and 6 of the Clp36 locus 
- and hence upstream of the LIM domain encoding region. As a consequence, 
CLP36 transcription is terminated prematurely at the inserted site, hence resulting in 
expression of the chimeric CLP36∆LIM-β-GEO fusion protein instead of full-length 
CLP36. In the following, mice homozygously expressing this truncated version of 
CLP36 are referred to as ‘Clp36∆LIM‘ mice. 
Platelets of Clp36∆LIM mice were subsequently analyzed morphologically and 
functionally. Accordingly, upon comparison to wildtype samples (i.e. C57Bl6-Sv129 
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mixed background), Clp36∆LIM platelets did not reveal any specific morphological 
differences: Platelet spreading as well as F-actin and stress fiber formation were 
normal, and so was the subcellular distribution of the truncated protein. Also blood 
platelet counts, mean platelet volume and platelet life span were unaffected. Thus, 
the CLP36 LIM domain was apparently not involved in platelet production, structural 
integrity and actin cytoskeleton remodelling. However, when Clp36∆LIM platelet 
activation was functionally tested in presence of different agonists, an enhanced 
response to GPVI agonists (e.g. collagen or C-reactive protein CRP) has been 
observed in vitro, which resulted in increased degranulation, integrin αIIbβ3 activation 
and aggregation. In this context, it is important to note that this unexpected effect 
was not due to a per se pre-activated state of Clp36∆LIM platelets since there was no 
evidence for spontaneous aggregation. Moreover, GPVI-independent platelet 
activation, e.g. via induction of GPCR signaling by thrombin, TxA2 or ADP (see 1.1.3) 
proved to be unaltered in comparison to wildtype samples. Thus, the detected 
prothrombotic Clp36∆LIM phenotype can specifically be related to an amplified GPVI 
signaling cascade. 
GPVI is an Ig-like platelet collagen receptor and crucial for platelet activation upon 
contact with the subendothelial matrix [260]. It is non-covalently attached to the 
signal-transducing Fc receptor gamma chain (FcRγ), which harbours a so-called 
‘immunoreceptor tyrosine-based activation motif’ (ITAM) [261]. Collagen binding to 
GPVI induces FcRγ tyrosine phosphorylation by the Src family kinases Fyn and Lyn 
[262, 263]; ITAM phosphorylation, on the other hand, links the Syk kinase to the 
GPVI-FcRγ receptor complex. This results in a series of tyrosine phosphorylation 
events, followed by recruitment of adaptor proteins and subsequent induction of 
effector proteins such as PI3K and PLCγ2 [264]. As a consequence, PLCγ2-
mediated hydrolysis of PIP2 into IP3 and DAG (see also 1.1.3) culminates in (a) IP3-
induced Ca2+-store release, consequently leading to SOCE; and (b) further increase 
of Ca2+-influx due to DAG-mediated activation of platelet ‘transient receptor potential 
cation channels’ (e.g. TRPC6) [265, 266]. This sudden enhancement of [Ca2+]i 
subsequently promotes Ca2+-dependent downstream signaling pathways, finally 
leading to thrombus formation. 
In accordance with this model, upon GPVI activation by CRP application, Braun et al. 
noticed increased Ca2+-store depletion (in absence of extracellular Ca2+), as well as 
an elevated SOCE (in presence of extracellular Ca2+) in Clp36∆LIM platelets (Figure 
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5.8). Thereby, the induced Ca2+-fluxes exceeded those of equally treated wildtype 
samples, which provides further evidence that the observed prothrombotic Clp36∆LIM 
phenotype is related to an enhanced GPVI-ITAM signaling. 
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Figure 5.8: CRP-induced Ca2+-signaling in Clp36∆LIM vs wildtype (wt) platelets. Time-dependent 
fluorimetrical Ca2+-measurements were performed upon addition of 10 µg/ mL CRP in (A) absence of 
extracellular Ca2+ (n=4); or (B) presence of 1 mM extracellular Ca2+ (n=6). Store release was 
significantly increased in Clp36∆LIM vs wt samples (A), which consequently also resulted in an elevated 
SOCE in response to CRP (B). Data were kindly provided by Dr. Attila Braun (Rudolf-Virchow-Center, 
Würzburg, Germany). 
 
However, when DTS Ca2+-stores were artificially depleted by addition of the non-
competitive SERCA inhibitor thapsigargin, the consequent Ca2+-flux of Clp36∆LIM 
platelets was similar to the one measured in wildtype samples. This indicates that 
CLP36 may not directly function in the process of Ca2+-store release or SOCE 
complex assembly. Instead, it is more likely to act as an endogenous negative 
regulator of GPVI-ITAM signaling, presumably by CLP36 LIM domain-dependent 
cytoskeleton retention of some of the involved protein kinases (see also 5.3.2). This 
theory was further backed by the finding that both tyrosine phosphorylation of 
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multiple proteins related to the GPVI signaling cascade and PLCγ2 activity, as 
determined by IP3-measurements, were markedly elevated in CRP-activated 
Clp36∆LIM vs wildtype platelets. All described data related to the analysis of GPVI-
ITAM signaling in Clp36∆LIM mice are currently under submission [267]. 
 
5.3.6 Concluding remarks on the STIM1-specific interactome study 
Having intensively analyzed the interactome of the cytosolic part of STIM1 in resting 
human and mouse platelets, a total of 87 non-redundant, platelet-related proteins 
were identified which displayed association with this Ca2+-sensing molecule. These 
components could be organized in four functional complexes: (a) the actin-myosin 
complex; (b) the adhesion complex, including the (c) GPIb-IX-V subcomplex; and (d) 
the signaling-related complex. One of the most promising candidates in this context, 
the ‘PDZ and LIM domain protein 1’ (CLP36), was finally chosen for a more detailed 
verification. 
Deriving from cooperative studies with Dr. Attila Braun (Rudolf-Virchow-Center, 
Würzburg, Germany), CLP36 was consequently identified as a putative negative 
regulator of platelet activity, with possible implication in both STIM1- as well as GPVI-
mediated effects. Accordingly, under resting platelet conditions, α-actinin-bound 
CLP36, via its PDZ domain, presumably anchors the STIM1 cytosolic region to the  
F-actin cytoskeleton. Assuming that both homotypic oligomerization of STIM1 and its 
subsequent translocation to sites of ER-PM junctions is consequently prevented, the 
proposed CLP36-STIM1 interaction may contribute to avoid uncontrolled 
intravascular platelet activation. Our data also indicate implication of the GPIb-IX-V 
receptor complex in this context; however, this finding might also be due to CLP36/ 
STIM1-independent linking of GPIb subunits to F-actin filaments (as e.g. mediated by 
GPIb-bound filamin A). Thus it needs to be further examined. Moreover, as revealed 
by in silico site predictions, two of the putative PDZ binding sites of STIM1 (i.e. 
STIM1 aa 344-347 and aa 402-405) are located in close proximity to the annotated 
STIM1-ORAI1 binding site (STIM1 aa 384-389). Thus, binding of CLP36 to either of 
these motifs might also have a masking effect on this latter site and hence inhibit 
premature STIM1-ORAI1 interaction. However, for further verification of these 
preliminary findings, the functional impact of the described interactions needs to be 
specified in more detail. As an example, deletion of the CLP36 PDZ domain and/ or 
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of the assumed PDZ binding sites of STIM1 may provide feasible tools to 
characterize the true nature of interaction in future in vitro and in vivo studies. 
Apart from the discussed functional association between CLP36 and STIM1, 
analyses of Clp36∆LIM mice furthermore revealed that loss of the CLP36 LIM domain 
directly affected GPVI-ITAM signaling: Accordingly, in comparison to wildtype 
samples, an elevated PLCγ2-activity has been observed in platelets of Clp36∆LIM 
mice in response to CRP, with consequently enhanced Ca2+-store depletion and 
Ca2+-influx (data currently under submission, [267]). As indicated by Braun et al., this 
effect was presumably due to an increased recruitment of protein kinases related to 
the GPVI-ITAM signaling pathway in Clp36∆LIM samples, whereas in wildtype 
samples, upon interaction with the LIM domain of α-actinin-bound full-length CLP36, 
the same components would be maintained in a cytoskeleton-associated, fixed state. 
However, to fully understand the mechanism of how CLP36 regulates GPVI-ITAM 
signaling, the identity of these kinases still needs to be resolved. 
In addition, calpain-dependent degradation of CLP36 was also observed as a 
consequence of SOCE in wildtype platelets. Hence it is striking to assume that this 
Ca2+-dependent protease, which mediates limited proteolysis of multiple key factors 
related to platelet activation (see 5.3.4), might also be implicated in this process as 
well. This is particularly true as multiple putative calpain cleavage sites were 
identified within the CLP36 aa-sequence, with the most probable one, H181, being 
located within the CLP36 short linker region. Accordingly, following platelet 
stimulation with e.g. GPVI agonists, the subsequent moderate [Ca2+]i increase, which 
results from store depletion, TRPC6 activation and early SOCE, may activate platelet 
calpain and hence promote proteolytic degradation of F-actin-localized CLP36. As a 
consequence, cytoskeleton-retained protein kinases (via the CLP36 LIM domain), as 
well as F-actin-anchored STIM1 monomers (via the CLP36 PDZ domain) would 
finally be released from their immobilized state, hence contributing to a further 
enhancement of both GPVI-ITAM signaling and SOCE-mediated Ca2+-influx. 
Taken together, this recent study, which originally focused on identifying novel STIM1 
interaction partners in resting platelets, indicates a multifaceted role of the 
cytoskeleton adaptor protein CLP36 during prevention of intravascular occlusive 
thrombus formation. In this context, CLP36 appears to function as an important 
negative regulator of both STIM1- and GPVI-mediated effects particularly taking 
place during late platelet response (i.e. platelet degranulation and aggregation). 
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Thus, the tendency of intravascular platelet activation and hence the risk of 
manifestation of acute ischemic diseases (e.g. stroke or myocardial infarction) might, 
in addition to further factors, be directly related to the endogenous CLP36 activity. 
Therefore, further research on this promising protein candidate may help in the 
ongoing task of unravelling the physiological mechanisms regulating prevention of 
uncontrolled intravascular platelet activation, and might thus improve our 
understanding of cardiovascular pathologies. 
Literature 
   
128 
6 Literature 
 
[1] Despopoulos, A., Silbernagl, S. (2008) Color Atlas of Physiology. 6th edn. Thieme, Stuttgart, 
88ff. 
[2] Hartwig, J, Italiano, J., Jr. (2003) The birth of the platelet. J Thromb Haemost 1, 1580-1586. 
[3] Deutsch, V. R., Torner, A. (2006) Megakaryocyte development and platelet production. Brit J 
Haem 134, 453-466. 
[4] Ruggeri, M. Z. (2002) Platelets in atherothrombosis. Nat. Med. 8, 1227-1234. 
[5] Zellner, M., Winkler, W., Hayden, H., Diestinger, M., et al. (2005) Quantitative validation of 
different protein precipitation methods in proteome analysis of blood platelets. Electrophoresis 
26, 2481-2489. 
[6] Despopoulos, A., Silbernagl, S. (2008) Color Atlas of Physiology. 6th edn. Thieme, Stuttgart, 
102ff. 
[7] Diacovo, T. G., Catalina, M. D., Siegelman, M. H., von Andrian, U. H. (1998) Circulating 
activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. J 
Exp Med 187, 197-204.  
[8] Nannizzi-Alaimo, L., Alves, V. L., Phillips, D. R. (2003) Inhibitory effects of glycoprotein IIb/IIIa 
antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. 
Circulation 107, 1123-1128.  
[9] Welt, F. G., Rogers, S. D., Zhang, X., Ehlers, R., et al. (2004) GP IIb/IIIa inhibition with 
eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary 
intervention. Catheter Cardiovasc Interv 61, 185-189. 
[10] Celotti, F., Colciago, A., Negri-Cesi, P., Pravettoni, A., et al. (2006) Effect of platelet-rich plasma 
on migration and proliferation of SaOS-2 osteoblasts: role of platelet-derived growth factor and 
transforming growth factor-β. Wound Repair Regen 14, 195-202. 
[11] O’Connell, S.M., Impeduglia, T., Hessler, K., Wang, X.J., et al. (2008) Autologous platelet-rich 
fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair 
Regen 16, 749-756. 
[12] Siess, W., Grünberg, B., Luber, K., Vauti, F., et al. (1992) Platelet signal transduction 
mechanisms induced by eicosanoids. Eicosanoids 5, 13-15. 
[13] Jain, R. K., Duda, D. G., Clark, J. W., Loeffler, J. S. (2006) Lessons from phase III clinical trials 
on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3, 24-40. 
[14] Vroling, L., Yuana, Y., Schuurhuis, G.J., van Hinsbergh, V. W., et al. (2007) VEGFR2 
expressing circulating (progenitor) cell populations in volunteers and cancer patients. Thromb 
Haemost 98, 440-450. 
[15] Maynard, D. M., Heijnen, H. F., Horne, M. K., White, J. G., et al. (2007) Proteomic analysis of 
platelet alpha-granules using mass spectrometry. J Thromb Haemost 5, 1945-1955. 
[16] McNicol, A., Israels, S. J. (1999) Platelet dense granules: structure, function and implications for 
haemostasis. Thromb. Res. 95, 1-18. 
Literature 
   
129 
[17] Kenney, D. M., Linck, R. W. (1985) The cystoskeleton of unstimulated blood platelets: structure 
and composition of the isolated marginal microtubular band. J Cell Sci 78, 1-22. 
[18] Fox, J. E., Boyles, J. K., Berndt, M. C., Steffen, P. K., et al. (1988) Identification of a membrane 
skeleton in platelets. J Cell Biol 106, 1525-1538.  
[19] Boyles, J., Fox, J. E., Phillips, D. R., Stenberg, P. E. (1985) Organization of the cytoskeleton in 
resting, discoid platelets: preservation of actin filaments by a modified fixation that prevents 
osmium damage. J Cell Biol 101, 1463-1472.  
[20] Schwarz, U. R., Walter, U., Eigenthaler, M. (2001) Taming platelets with cyclic nucleotides. 
Biochem Pharmacol 62, 1153-1161. 
[21] Offermanns, S. (2000) The role of heterotrimeric G proteins in platelet activation. Biol Chem 
381, 389-396. 
[22] Philipose, S., Konya, V., Sreckovic, I., Marsche, G., et al. (2010) The prostaglandin E2 receptor 
EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus 
formation. Arterioscler Thromb Vasc Biol 30,2416-2423. 
[23] Geiger, J., Nolte, C., Butt, E., Sage, S. O., et al. (1992) Role of cGMP and cGMP-dependent 
protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human 
platelets.  Proc Natl Acad Sci USA 89, 1031-1035. 
[24] Soderling, S. H., Beavo, J. A. (2000) Regulation of cAMP and cGMP signaling: new 
phosphodiesterases and new functions. Curr Opin Cell Biol 12, 174-179. 
[25] Gambaryan, S., Geiger, J., Schwarz, U. R., Butt, E., et al. (2004) Potent inhibition of human 
platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 103, 2593-
2600. 
[26] Fox, J. E., Berndt, M. C. (1989) Cyclic AMP-dependent phosphorylation of glycoprotein Ib 
inhibits collagen-induced polymerization of actin in platelets. J Biol Chem 264, 9520-9526. 
[27] Hettasch, J. M., Sellers, J. R. (1991) Caldesmon phosphorylation in intact human platelets by 
cAMP-dependent protein kinase and protein kinase C. J Biol Chem 266, 11876-11881. 
[28] Butt, E., Walter, U. (1996) Cyclic nucleotides: measurement and function. In: Platelets: A 
practical approach. Edited by Watson, S. University Press, Oxford, 259-278. 
[29] Surks, H. K. (2007) cGMP-dependent protein kinase I and smooth muscle relaxation: a tale of 
two isoforms. Circulation research 101, 1078-1080. 
[30] Fredrickson, B. J., Dong, J.  F., McIntire, L. V., Lopez, J. A. (1998) Shear-dependent rolling on 
von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. 
Blood 92, 3684-3693. 
[31] Nieswandt, B., Brakebusch, C., Bergmeier, W., Schulte, V., et al. (2001) Glycoprotein VI but not 
alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20, 2120-2130. 
[32] Saelman, E. U., Nieuwenhuis, H. K., Hese, K. M., de Groot, P. G., et al. (1994) Platelet 
adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by 
GPIa/IIa (alpha 2 beta 1-integrin). Blood 83, 1244-1250. 
Literature 
   
130 
[33] Tsuji, M., Ezumi, Y., Arai, M., Takayama, H. (1997) A novel association of Fc receptor gamma-
chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J 
Biol Chem 272, 23528-23531. 
[34] Watson, S. P., Gibbins, J. (1998) Collagen receptor signalling in platelets: extending the role of 
the ITAM. Immunol Today 19, 260-264. 
[35] Roberts, W., Michno, A., Aburima, A., Naseem, K. M. (2009) Nitric oxide inhibits von Willebrand 
factor-mediated platelet adhesion and spreading through regulation of integrin alpha(IIb)beta(3) 
and myosin light chain. J Thromb Haemost 7, 2106-2115. 
[36] Shattil, S. J., Brass, L. F. (1987) Induction of the fibrinogen receptor on human platelets by 
intracellular mediators. J Biol Chem 262, 992-1000. 
[37] Lian, L., Wang, Y., Draznin, J., Eslin, D., et al. (2005) The relative role of PLCbeta and 
PI3Kgamma in platelet activation. Blood 106, 110-117. 
[38] Gohla, A., Offermanns, S., Wilkie, T. M., Schultz, G. (1999) Differential involvement of Galpha12 
and Galpha13 in receptor-mediated stress fiber formation. J Biol Chem 274, 17901-17907. 
[39] Klages, B., Brandt, U., Simon, M. I., Schultz, G., et al. (1999) Activation of G12/G13 results in 
shape change and Rho/Rho-kinase- mediated myosin light chain phosphorylation in mouse 
platelets. J Cell Biol 144, 745-754. 
[40] Shattil, S. J. (1999) Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, 
and sideways. Thromb Haemost 82, 318-325. 
[41] Prevost, N., Woulfe, D., Tanaka, T., Brass, L. F. (2002) Interactions between Eph kinases and 
ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has 
occurred. Proc Natl Acad Sci USA 99, 9219-9224. 
[42] Angelillo-Scherrer, A., de Frutos, P., Aparicio, C., Melis, E., et al. (2001) Deficiency or inhibition 
of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7, 215-221. 
[43] Nachmias, V. T., Yoshida, K. I. (1988) The cytoskeleton of the blood platelet: a dynamic 
structure. Adv Cell Biol 2, 181-211. 
[44] Stossel, T. P. (1993) On the crawling of animal cells. Science 260, 1086-1094. 
[45] Kang, F., Purich, D. L., Southwick, F. S. (1999) Profilin promotes barbed-end actin filament 
assembly without lowering the critical concentration. J Biol Chem 274, 36963-36972. 
[46] Pollard, T. D., Borisy, G. G. (2003) Cellular motility driven by assembly and disassembly of actin 
filaments. Cell 112, 453-465. 
[47] dos Remedios, C. G., Chhabra, D., Kekic, M., Dedova, I. V., et al. (2003) Actin binding proteins: 
regulation of cytoskeletal microfilaments. Physiol Rev 83, 433-473. 
[48] Witke, W. (2004) The role of profilin complexes in cell motility and other cellular processes. 
Trends Cell Biol 14, 461-469. 
[49] Yarmola, E. G., Bubb, M. R. (2006) Profilin: emerging concepts and lingering misconceptions. 
Trends Biochem Sci 31, 197-205. 
[50] Krause, M., Bear, J. E., Loureiro, J. J., Gertler, F. B. (2002) The Ena/VASP enigma. J Cell Sci 
115, 4721-4726. 
Literature 
   
131 
[51] Reinhard, M., Jarchau, T., Reinhard, K., Walter U. (1999) VASP. In: Guidebook to the 
cytoskeletal and motor proteins. Edited by Kreis, T., Vale, R. University Press, Oxford, 168-171. 
[52] Gertler, F. B., Niebuhr, K., Reinhard, M., Wehland, J., et al. (1996) Mena, a relative of VASP 
and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell 87, 227-
239. 
[53] Reinhard, M., Jouvenal, K., Tripier, D., Walter, U. (1995) Identification, purification, and 
characterization of a zyxin-related protein that binds the focal adhesion and microfilament 
protein VASP (vasodilator-stimulated phosphoprotein). Proc Natl Acad Sci USA 92, 7956-7960. 
[54] Butt, E., Abel, K., Krieger, M., Palm, D., et al. (1994) cAMP- and cGMP-dependent protein 
kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein 
(VASP) in vitro and in intact human platelets. J Biol Chem 269, 14509-14517. 
[55] Aszodi, A., Pfeifer, A., Ahmad, M., Glauner, M., et al. (1999) The vasodilator-stimulated 
phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced 
platelet aggregation, but is dispensable for smooth muscle function. EMBO J 18, 37-48. 
[56] Hauser, W., Knobeloch, K. P., Eigenthaler, M., Gambaryan, S., et al. (1999) Megakaryocyte 
hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated 
phosphoprotein knockout mice. Proc Natl Acad Sci USA 96, 8120-8125. 
[57] Kwiatkowski, A. V., Gertler, F. B., Loureiro, J. J. (2003) Function and regulation of Ena/VASP 
proteins. Trends Cell Biol 13, 386-392. 
[58] Ball, L. J., Kühne, R., Hoffmann, B., Häfner, A., et al. (2000) Dual epitope recognition by the 
VASP EVH1 domain modulates polyproline ligand specificity and binding affinity. EMBO J 19, 
4903-4914. 
[59] Bachmann, C., Fischer, L., Walter, U., Reinhard, M. (1999) The EVH2 domain of the vasodilator 
stimulated phosphoprotein mediates tetramerization, F-actin binding, and actin bundle 
formation. J Biol Chem 274, 23549-23557. 
[60] Ahern-Djamali, S. M., Comer, A. R., Bachmann, C., Kastenmeier, A. S., et al. (1998) Mutations 
in Drosophila enabled and rescue by human vasodilator-stimulated phosphoprotein (VASP) 
indicate important functional roles for Ena/VASP homology domain 1 (EVH1) and EVH2 
domains. Mol Biol Cell 9, 2157-2171. 
[61] Ferron, F., Rebowski, G., Lee, S. H., Dominguez, R. (2007) Structural basis for the recruitment 
of profilin-actin complexes during filament elongation by Ena/VASP. EMBO J 26, 4597-4606. 
[62] Ermekova, K. S., Zambrano, N., Linn, H., Minopoli, G., et al. (1997) The WW domain of neural 
protein FE65 interacts with proline-rich motifs in Mena, the mammalian homolog of Drosophila 
enabled. J Biol Chem 272, 32869-32877. 
[63] Bear, J. E., Krause, M., Gertler, F. B. (2001) Regulating cellular actin assembly. Curr Opin Cell 
Biol, 13, 158-166. 
[64] Mahoney, N. M., Rozwarski, D. A., Fedorov, E., Fedorov, A. A., et al. (1999) Profilin binds 
proline-rich ligands in two distinct amide backbone orientations. Nat Struct Biol 6, 666-671. 
[65] Chereau, D., Dominguez, R. (2006) Understanding the role of the G-actin-binding domain of 
Ena/VASP in actin assembly. J Struct Biol 155, 195-201. 
Literature 
   
132 
[66] Bear, J. E., Svitkina, T. M., Krause, M., Schafer, D. A., et al. (2002) Antagonism between 
Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 109, 509-521. 
[67] Skoble, J., Auerbuch, V., Goley, E. D., Welch, M. D., et al. (2001) Pivotal role of VASP in Arp2/3 
complex-mediated actin nucleation, actin branch-formation, and Listeria monocytogenes motility. 
J Cell Biol 155, 89-100. 
[68] Barzik, M., Kotova, T. I., Higgs, H. N., Hazelwood, L., et al. (2005) Ena/VASP proteins enhance 
actin polymerization in the presence of barbed end capping proteins. J Biol Chem 280, 28653-
28662. 
[69] Reinhard, M., Jouvenal, K., Tripier, D., Walter, U. (1995) Identification, purification, and 
characterization of a zyxin-related protein that binds the focal adhesion and microfilament 
protein VASP (vasodilator-stimulated phosphoprotein). Proc Natl Acad Sci USA 92, 7956-7960. 
[70] Brindle, N. P., Holt, M. R., Davies, J. E., Price, C. J., et al. (1996) The focal-adhesion 
vasodilator-stimulated phosphoprotein (VASP) binds to the proline-rich domain in vinculin. 
Biochem J 318,753–757. 
[71] Krause, M., Dent, E. W., Bear, J. E., Loureiro, J. J., et al. (2003) Ena/VASP proteins: regulators 
of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 19, 541-564. 
[72] Harbeck, B., Hüttelmaier, S., Schluter, K., Jockusch, B. M., et al. (2000) Phosphorylation of the 
vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 275, 
30817-30825. 
[73] Blume, C., Benz, P. M., Walter, U., Ha, J., et al. (2007) AMP-activated protein kinase impairs 
endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated 
phosphoprotein. J Biol Chem 282, 4601-4612. 
[74] Howe, A. K., Hogan, B. P., Juliano, R. L. (2002) Regulation of vasodilator-stimulated 
phosphoprotein phosphorylation and interaction with Abl by protein kinase A and cell adhesion. 
J Biol Chem 277, 38121-38126. 
[75] Halbrügge, M., Friedrich, C., Eigenthaler, M., Schanzenbacher, P., et al. (1990) Stoichiometric 
and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- 
and cAMP-elevating vasodilators. J Biol Chem 265, 3088-3093. 
[76] Zahedi, R. P., Lewandrowski, U., Wiesner, J., Wortelkamp, S., et al. (2008) Phosphoproteome 
of resting human platelets. J Proteome Res 7, 526-534. 
[77] Rink, T. J., Sage, S. O. (1990) Calcium signaling in human platelets. Annu Rev Physiol 52, 431-
449. 
[78] Hathaway, D. R., Adelstein, R. S. (1979) Human platelet myosin light chain kinase requires the 
calcium-binding protein calmodulin for activity. Proc Natl Acad Sci USA 76, 1653-1657. 
[79] Shattil, S. J., Brass, L. F. (1987) Induction of the fibrinogen receptor on human platelets by 
intracellular mediators. J Biol Chem 262, 992-1000. 
[80] Brune, B., Ullrich, V. (1991) Different calcium pools in human platelets and their role in 
thromboxane A2 formation. J Biol Chem, 266, 19232-19237. 
Literature 
   
133 
[81] Cavallini, L., Coassin, M., Alexandre, A. (1995) Two classes of agonist-sensitive calcium stores 
in platelets, as identified by their differential sensitivity to 2,5-di-(tert-butyl)-1,4-
benzohydroquinone and thapsigargin. Biochem J 2, 449-52. 
[82] Papp, B., Enyedi, A., Kovacs, T., Sarkadi, B., et al. (1991) Demonstration of two forms of 
calcium pumps by thapsigargin inhibition and radio-immuno blotting in platelet membrane 
vesicles. J Biol Chem, 266, 14593-14596. 
[83] Enouf, J., Bredoux, R., Papp, B., Djaffar, I., et al. (1992) Human platelets express the SERCA2-
b isoform of Ca (2+)-transport ATPase. Biochem J 1, 135-140. 
[84] El-Daher, S. S., Patel, Y., Siddiqua, A., Hassock, S., et al. (2000) Distinct localization and 
function of (1, 4, 5) IP (3) receptor subtypes and the (1, 3, 4, 5) IP (4) receptor GAP1 (IP4BP) in 
highly purified human platelet membranes. Blood 95, 3412-3422. 
[85] Varga-Szabo, D, Braun, A., Nieswandt, B. (2009) Calcium signaling in platelets. J Thromb 
Haemost, 7, 1057-1066. 
[86] Sage, S. O., Yamoah, E. H., Heemskerk, J. W. (2000) The roles of P(2X1) and P(2TAC) 
receptors in ADP-evoked calcium signalling in human platelets. Cell Calcium 28, 119-126. 
[87] Hassock, S. R., Zhu, M. X., Trost, C., Flockerzi, V., et al. (2002) Expression and role of TRPC 
proteins in human platelets: evidence that TRPC6 forms the store independent calcium entry 
channel. Blood 100, 2801-2811. 
[88] Muik, M., Frischauf, I., Derler, I., Fahrner, M., et al. (2008) Dynamic coupling of the putative 
coiled-coil domain of ORAI1 with STIM1 mediates ORAI1 channel activation. J Biol Chem 283, 
8014-8022. 
[89] Prakriya, M.,  Lewis, R. S. (2003) CRAC channels: activation, permeation, and the search for a 
molecular identity. Cell Calcium 33, 311-21. 
[90] Roos, J., DiGregorio, P. J., Yeromin, A. V., Ohlsen, K., et al. (2005) STIM1, an essential and 
conserved component of store-operated Ca2+ channel function. J Cell Biol 169, 435-445. 
[91] Liou, J., Kim, M. L., Heo, W. D., Jones, J. T., et al. (2005) STIM is a Ca2+ sensor essential for 
Ca2+ store-depletion-triggered Ca2+ influx. Curr Biol 15, 1235-1241. 
[92] Zhang, S. L., Yu, Y., Roos, J., Kozak, J. A., et al. (2005) STIM1 is a Ca2+ sensor that activates 
CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature 437, 902-
905. 
[93] Feske, S., Gwack, Y., Prakriya, M., Srikanth, S., et al. (2006) A mutation in Orai1 causes 
immune deficiency by abrogating CRAC channel function. Nature 441, 179-185. 
[94] Prakriya, M., Feske, S., Gwack, Y., Srikanth, S., et al. (2006) Orai1 is an essential pore subunit 
of the CRAC channel. Nature 443, 230-233. 
[95] Stathopulos, P. B., Mitsuhiko, I. (2010) Partial unfolding and oligomerization of stromal 
interaction molecules as an initiation mechanism of store operated calcium entry. Biochem Cell 
Biol 88, 175-183. 
[96] Bergmeier, W., Stefanini, L. (2009) Novel molecules in calcium signaling in platelets. J Thromb 
Haemost 7, 187-190. 
Literature 
   
134 
[97] Grosse, J., Braun, A., Varga-Szabo, D., Beyersdorf, N., et al. (2007) An EF hand mutation in 
Stim1 causes premature platelet activation and bleeding in mice. J Clin Invest 117, 3540-3550. 
[98] Stathopulos, P. B., Zheng, L., Li, G. Y., Plevin, M. J., et al. (2008) Structural and mechanistic 
insights into STIM1-mediated initiation of store-operated calcium entry. Cell 135, 110-122. 
[99] Cai, X., Cookson, M. (2007) Molecular evolution and functional divergence of the Ca2+ sensor 
protein in store-operated Ca2+ entry: stromal interaction molecule. PLoS One 2, e609. 
[100] Tolhurst, G., Carter, R. N., Amisten, S., Holdich, J. P., et al. (2008) Expression profiling and 
electrophysiological studies suggest a major role for Orai1 in the store-operated Ca2+ influx 
pathway of platelets and megakaryocytes. Platelets 19, 308-313. 
[101] Braun, A., Varga-Szabo, D., Kleinschnitz, C., Pleines, I., et al. (2009) Orai1 (CRACM1) is the 
platelet SOC channel and essential for pathological thrombus formation. Blood 113, 2056-2063. 
[102] Lis, A., Peinelt, C., Beck, A., Parvez, S., et al. (2007) CRACM1, CRACM2, and CRACM3 are 
store-operated Ca2+ channels with distinct functional properties. Curr Biol 17, 794-800. 
[103] Roberts-Thomson, S. J., Peters, A. A., Grice, D. M., Monteith, G. P. (2010) ORAI-mediated 
calcium entry: Mechanism and roles, diseases and pharmacology. Pharmacology & 
Therapeutics 127, 121-130. 
[104] Ji, W., Xu, P., Li, Z., Lu, J., et al. (2008) Functional stoichiometry of the unitary calcium-release-
activated calcium channel. Proc Natl Acad Sci USA 105, 13668-13673. 
[105] Penna, A., Demuro, A., Yeromin, A. V., Zhang, S. L., et al. (2008) The CRAC channel consists 
of a tetramer formed by Stim-induced dimerization of Orai dimers. Nature 456, 116-120. 
[106] Maruyama, Y., Ogura, T., Mio, K., Kato, K., et al. (2009) Tetrameric Orai1 is a teardrop-shaped 
molecule with a long, tapered cytoplasmic domain. J Biol Chem 284, 13676-13685. 
[107] Wu, M. M., Buchanan, J., Luik, R. M., Lewis, R. S. (2006) Ca2+ store depletion causes STIM1 
to accumulate in ER regions closely associated with the plasma membrane. J Cell Biol 174, 
803-813. 
[108] Xu, P., Lu, J., Li, Z., Yu, X., et al. (2006) Aggregation of STIM1 underneath the plasma 
membrane induces clustering of Orai1. Biochem Biophys Res Commun 350, 969-976. 
[109] Várnai, P., Tóth, B., Tóth, D. J., Hunyady, L., et al. (2007) Visualization and manipulation of 
plasma membrane-endoplasmic reticulum contact sites indicates the presence of additional 
molecular components within the STIM1-Orai1 complex. J Biol Chem 282, 29678-29690. 
[110] Muik, M., Fahrner, M., Derler, I., Schindl, R., et al. (2009) A cytosolic homomerization and a 
modulatory domain within STIM1 C terminus determine coupling to ORAI1 channels. J Biol 
Chem 284, 8421-8426. 
[111] Park, C. Y., Hoover, P. J., Mullins, F. M., Bachhawat, P., et al. (2009) STIM1 clusters and 
activates CRAC channels via direct binding of a cytosolic domain to Orai1. Cell 136, 876-890. 
[112] Markham, K., Bai, Y., Schmitt-Ulms, G. (2007) Co-immunoprecipitations revisited: an update on 
experimental concepts and their implementation for sensitive interactome investigations of 
endogenous proteins. Anal Bioanal Chem 389, 461-473. 
[113] Kaboord, B., Perr, M. (2008) Isolation of proteins and protein complexes by 
immunoprecipitation. Methods Mol Biol 424, 349-364. 
Literature 
   
135 
[114] Miernyk, J. A., Thelen, J. J. (2008) Biochemical approaches for discovering protein-protein 
interactions. Plant J 53, 597-609. 
[115] Nisnevitch, M., Firer, M. A. (2001) The solid phase in affinity chromatography: strategies for 
antibody attachment. J Biochem Biophys Methods 49, 467-480. 
[116] Turková, J. (1999) Oriented immobilization of biologically active proteins as a tool for revealing 
protein interactions and function. J Chromatogr B Biomed Sci Appl 722, 11-31. 
[117] Sisson, T. H., Castor, C. W. (1990) An improved method for immobilizing IgG antibodies on 
protein A-agarose. J Immunol Methods 127, 215-220. 
[118] Ford, C. F., Suominen, I., Glatz, C. E. (1991) Fusion tails for the recovery and purification of 
recombinant proteins. Protein Expr Purif 2, 95-107. 
[119] Waugh, D. S. (2005) Making the most of affinity tags. Trends Biotechnol 23, 316-320. 
[120] Arnau, J., Lauritzen, C., Petersen, G. E., Pedersen, J. (2006) Current strategies for the use of 
affinity tags and tag removal for the purification of recombinant proteins. Protein Expr Purif 48, 
1-13. 
[121] Lee, W. C., Lee, K. H. (2004) Applications of affinity chromatography in proteomics. Anal 
Biochem 324, 1-10. 
[122] Azarkan, M., Huet, J., Baeyens-Volant, D., Looze, Y., et al. (2007) Affinity chromatography: a 
useful tool in proteomics studies. J Chromatogr B Analyt Technol Biomed Life Sci 849, 81-90. 
[123] Muronetz, V. I., Sholukh, M., Korpela, T. (2001) Use of protein-protein interactions in affinity 
chromatography. J Biochem Biophys Methods 49, 29-47. 
[124] Kellogg, D. R., Moazed, D. (2002) Protein- and immunoaffinity purification of multiprotein 
complexes. Methods Enzymol 351, 172-83. 
[125] Terpe, K. (2003) Overview of tag protein fusions: from molecular and biochemical fundamentals 
to commercial systems. Appl Microbiol Biotechnol, 60, 523-533. 
[126] Harper, S., Speicher, D. W. (2011) Purification of proteins fused to glutathione S-transferase. 
Methods Mol Biol 681, 259-280. 
[127] Xu, X., Song, Y., Li, Y., Chang, J., et al. (2010) The tandem affinity purification method: an 
efficient system for protein complex purification and protein interaction identification. Protein 
Expr Purif 72, 149-156. 
[128] Gaberc-Porekar, V., Menart, V. (2001) Perspectives of immobilized-metal affinity 
chromatography. J Biochem Biophys Methods 49, 335-360. 
[129] Block, H., Maertens, B., Spriestersbach, A., Brinker, N., et al. (2009) Immobilized-metal affinity 
chromatography (IMAC): a review. Methods Enzymol, 463, 439-473. 
[130] Brymora, A., Valova, V. A, Robinson, P. J. (2004) Protein-protein interactions identified by pull-
down experiments and mass spectrometry. Curr Protoc Cell Biol 17.5. 
[131] Guan, H., Kiss-Toth, E. (2008) Advanced technologies for studies on protein interactomes. Adv 
Biochem Eng Biotechnol 110, 1-24. 
[132] Mori, S., Barth, H. G. (1999) Size exclusion chromatography. 1st edn. Springer Verlag, Berlin, 
4ff. 
Literature 
   
136 
[133] Lottspeich, F., Engels, J. W. (2006) Bioanalytik. 2nd edn. Spektrum Akademischer Verlag, 
Elsevier GmbH, München, 231ff. 
[134] Graves, P. R., Haystead, T. A. (2002) Molecular biologist’s guide to proteomics. Microbiol Mol 
Biol Rev 66, 39-63. 
[135] Perkins, D. N., Pappin, D. J., Creasy, D. M., Cottrell, J. S. (1999) Probability-based protein 
identification by searching sequence databases using mass spectrometry data. Electrophoresis 
20, 3551-3567. 
[136] Martens, L., van Damme, P., van Damme, J., Staes, A., et al. (2005) The human platelet 
proteome mapped by peptide-centric proteomics: a functional protein profile. Proteomics 5, 
3193-3204. 
[137] Schütte, H., Kula, M. R. (1990) Pilot- and process-scale techniques for cell disruption. 
Biotechnol Appl Biochem 12, 599-620. 
[138] Benov, L., Al-Ibraheem, J. (2002) Disrupting Escherichia coli: a comparison of methods. J 
Biochem Mol Biol 35, 428-431. 
[139] Vediyappan, G., Bikandi, J., Braley, R., Chaffin, W. L. (2000) Cell surface proteins of Candida 
albicans: preparation of extracts and improved detection of proteins. Electrophoresis 21, 956-
961. 
[140] Naglak, T. J., Hettwer, D. J., Wang, H. Y. (1990) Chemical permeabilization of cells for 
intracellular product release. Bioprocess Technol 9, 177-205. 
[141] Falconer, R. J., O'Neill, B. K., Middelberg, A. P. (1998) Chemical treatment of Escherichia coli. 
II. Direct extraction of recombinant protein from cytoplasmic inclusion bodies in intact cells. 
Biotechnol Bioeng 57, 381-386. 
[142] Linke, D. (2009) Detergents: an overview. Methods Enzymol 463, 603-617. 
[143] Shapiro, A. L. Vinuela, E., Maizel, J.V. jr. (1967) Molecular weight estimation of polypeptide 
chains by electrophoresis in SDS-polyacrylamide gels. Biochem Biophys Res Commun 28, 815-
820. 
[144] Rabilloud, T. (1999) Solubilization of proteins in 2-D electrophoresis. Methods Mol Biol 112, 9-
19. 
[145] O'Farrell, P.H. (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 
250, 4007-4021. 
[146] Görg, A., Weiss, W., Dunn, M. J. (2004) Current two-dimensional electrophoresis technology for 
proteomics. Proteomics 4, 3665-3685. 
[147] Steinberg, T. H. (2009) Protein gel staining methods: an introduction and overview. Methods 
Enzymol 463, 541-563. 
[148] Barrett, A. J., Rawlings, N. D. (1995) Families and clans of serine peptidases. Arch Biochem 
Biophys 318, 247-250. 
[149] Olsen, J. V., Ong, S. E., Mann, M. (2004) Trypsin cleaves exclusively C-terminal to arginine and 
lysine residues. Mol Cell Proteomics 3, 608-614. 
[150] Cleland, W. W. (1964) Dithiothreitol, a new protective reagent for SH groups. Biochemistry 3, 
480-482. 
Literature 
   
137 
[151] Voet D., Voet J.G. (2004) Biochemistry. 3rd. edn. John Wiley and Sons Inc., Hoboken, 133. 
[152] Mitulovic, G., Mechtler, K. (2006) HPLC techniques for proteomics analysis - a short overview of 
latest developments. Brief Funct Genomic Proteomic 5, 49-60. 
[153] Peng, J., Gygi, S. P. (2001) Proteomics: the move to mixtures. J Mass Spectrom 36, 1083-1091. 
[154] Lottspeich, F., Engels, J. W. (2006) Bioanalytik. 2nd edn. Spektrum Akademischer Verlag, 
Elsevier GmbH, München, 217. 
[155] Voet D., Voet J.G. (2004) Biochemistry. 3rd. edn. John Wiley and Sons Inc., Hoboken, 134. 
[156] Lottspeich, F., Engels, J. W. (2006) Bioanalytik. 2nd edn. Spektrum Akademischer Verlag, 
Elsevier GmbH, München, 223 ff. 
[157] Gruber, K. A., Stein, S., Brink, L., Radhakrishnan, A., et al. (1976) Fluorometric assay of 
vasopressin and oxytocin: a general approach to the assay of peptides in tissues. Proc Natl 
Acad Sci USA 73, 1314-1318. 
[158] von Hagen, J. (2008) Proteomics sample preparation. 1st edn. Wiley-VCH Verlag GmbH & Co 
KGaA, Weinheim, 56. 
[159] Wolters, D. A., Washburn, M. P., Yates, J. R. 3rd (2001) An automated multidimensional protein 
identification technology for shotgun proteomics. Anal Chem 73, 5683-5690. 
[160] Fournier, M. L., Gilmore, J. M., Martin-Brown, S. A., Washburn, M. P. (2007) Multidimensional 
separation-based shotgun proteomics. Chem Rev 107, 3654-3686. 
[161] Banks, J. F. Jr., Quinn, J. P., Whitehouse, C. M. (1994) LC/ESI-MS determination of proteins 
using conventional liquid chromatography and ultrasonically assisted electrospray. Anal Chem 
66, 3688-3695. 
[162] Robertson, D. H., Hurst, J. L., Bolgar, M. S., Gaskell, S. J., et al. (1997) Molecular heterogeneity 
of urinary proteins in wild house mouse populations. Rapid Commun Mass Spectrom 11, 786-
790. 
[163] Karas, M., Hillenkamp, F. (1988) Laser desorption ionization of proteins with molecular masses 
exceeding 10,000 daltons. Anal Chem 60, 2299-2301 
[164] Beavis, R. C., Chait, B. T. (1996) Matrix-assisted laser desorption ionization mass-spectrometry 
of proteins. Methods Enzymol 270, 519-551. 
[165] Sickmann, A., Mreyen, M., Meyer, H. E. (2003) Mass spectrometry – a key technology in 
proteome research. Adv Biochem Eng Biotechnol 83, 141-176. 
[166] Marshall, A. G., Hendrickson, C. L. (2002) Fourier transform ion cyclotron resonance detection: 
principles and experimental configurations. Int J Mass Spectrom 215, 59. 
[167] Scigelova, M., Makarov, A. (2006) Orbitrap mass analyzer - overview and applications in 
proteomics. Proteomics 6, 16-21. 
[168] Makarov, A., Denisov, E., Lange, O., Horning, S. (2006) Dynamic range of mass accuracy in 
LTQ Orbitrap hybrid mass spectrometer. J Am Soc Mass Spectrom 17, 977-982. 
[169] Makarov, A., Denisov, E., Kholomeev, A., Balschun, W., et al. (2006) Performance evaluation of 
a hybrid linear ion trap/orbitrap mass spectrometer. Anal Chem 78, 2113-2120.  
[170] Matsuura, S., Umebayashi, S., Okuyama, C., Oba, K., et al. (1985) Characteristics of the newly 
developed MCP and its assembly. IEEE Trans 32, 350. 
Literature 
   
138 
[171] Dubois, F., Knochenmuss, R., Zenobi, R., Brunelle, A., et al. (1999) A comparison between ion-
to-photon and microchannel plate detectors. Rapid Commun Mass Spectrom 13, 786-791. 
[172] Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., et al. (1989) Electrospray ionization for mass 
spectrometry of large biomolecules. Science 246, 64-71. 
[173] Siethoff, C., Lohaus, C., Meyer H. E. (1999) Microcharacterization of proteins. 2nd edn. VCH-
Wiley Verlagsgesellschaft, Weinheim, 245-273. 
[174] Dole, M., Mack, L. L., Hines, R. L., Mobley, R. C., et al. (1968) Molecular beams of macroions. J 
Chem Phys 49, 2240-2249. 
[175] Schmelzeisen-Redeker, G., Bütfering, L., Röllgen, F. W. (1989) Desolvation of ions and 
molecules in thermospray mass spectrometry. Int J Mass Spectrom Ion Processes 90, 139-150. 
[176] Iribarne, J. V, Thomson, B. A. (1976) On the evaporation of small ions from charged droplets. J 
Phys Chem 64, 2287-2293. 
[177] Smith, R. D., Loo, J. A., Edmonds, C. G., Barinaga, C. J., et al. (1990) New developments in 
biochemical mass spectrometry: electrospray ionization. Anal Chem 62, 882-899. 
[178] Schaefer, H., Chervet, J. P., Bunse, C., Joppich, C., et al. (2004) A peptide preconcentration 
approach for nano-high-performance liquid chromatography to diminish memory effects. 
Proteomics 4, 2541-2544. 
[179] Niessen, W. M., Tinke, A. (1995) Liquid chromatography-mass spectrometry. General principles 
and instrumentation. J Chromatography 703, 37-57. 
[180] Lottspeich, F., Engels, J. W. (2006) Bioanalytik. 2nd edn. Spektrum Akademischer Verlag, 
Elsevier GmbH, München, 357 ff. 
[181] de Hoffmann, E. (1996) Tandem mass spectrometry: A primer. J Mass Spectrom 31, 129-137. 
[182] Siethoff, C., Lohaus, C., Meyer H. E. (1999) Microcharacterization of proteins. 2nd edn. VCH-
Wiley Verlagsgesellschaft, Weinheim, 252. 
[183] Stafford, G. C., Kelley, P. E., Syka, J. E. P., Reynolds, W. E., et al. (1984) Recent improvements 
in and analytical applications of advanced ion trap technology. Int J Mass Spectrom 60, 85-98. 
[184] Lottspeich, F., Engels, J. W. (2006) Bioanalytik. 2nd edn. Spektrum Akademischer Verlag, 
Elsevier GmbH, München, 361. 
[185] Douglas, D. J., Frank, A. J., Mao, D. (2005) Linear ion traps in mass spectrometry. Mass 
Spectrom Rev 24, 1-29. 
[186] Schwartz, J. C., Senko, M. W., Syka, J. E. P. (2002) A two-dimensional quadrupole ion trap 
mass spectrometer. J Am Soc Mass Spectrom 13, 659-669. 
[187] Roepsdorff, P., Fohlmann, J. (1984) Proposal for common nomenclature for sequence ions in 
mass spectra of peptides. Biomed Mass Spectrom 11, 601. 
[188] Biemann, K. (1992) Mass spectrometry of peptides and proteins. Annu Rev Biochem 61, 977-
1010. 
[189] Steen, H., Mann, M. (2004) The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol Cell 
Biol 5, 699-711. 
Literature 
   
139 
[190] Eng, J. K., McCormack, A. L., Yates, J. R. 3rd. (1994) An approach to correlate tandem mass 
spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass 
Spectrom 5, 976-989. 
[191] Geer, L. Y., Markey, S. P., Kowalak, J. A., Wagner, L., et al.  (2004) Open mass spectrometry 
search algorithm. J Proteome Res 3, 958-964. 
[192] Kapp, E., Schütz, F. (2007) Overview of tandem mass spectrometry (MS/MS) database search 
algorithms. Curr Protoc Protein Sci 49, 25.2.1-25.2.19. 
[193] Craig, R., Beavis, R. C. (2004) TANDEM: Matching proteins with tandem mass spectra. 
Bioinformatics 20, 1466-1467. 
[194] Sadygov, R. G., Cociorva, D., Yates, J. R. 3rd (2004) Large-scale database searching using 
tandem mass spectra: looking up the answer in the back of the book. Nat Methods 1, 195-202. 
[195] Cagney, G., Amiri, S., Premawaradena, T., Lindo, M., et al. (2003) In silico proteome analysis to 
facilitate proteomics experiments using mass spectrometry. Proteome Sci 13, 5. 
[196] Stephan, C., Reidegeld, K. A., Hamacher, M., van Hall, A., et al. (2006) Automated reprocessing 
pipeline for searching heterogeneous mass spectrometric data of the HUPO Brain Proteome 
Project pilot phase. Proteomics 6, 5015-5029. 
[197] Elias, J. E., Haas, W., Faherty, B. K., Gygi, S. P. (2005) Comparative evaluation of mass 
spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2, 667-675. 
[198] Elias, J. E., Gygi, S. P. (2007) Target-decoy search strategy for increased confidence in large-
scale protein identifications by mass spectrometry. Nat Methods 4, 207-214. 
[199] Benz, P. M., Blume, C., Moebius, J., Oschatz, C., et al. (2008) Cytoskeleton assembly at 
endothelial cell-cell contacts is regulated by alpha II-spectrin-VASP complexes. J Cell Biol 180, 
205-219. 
[200] Blum, H., Beier, H., Gross, H. J. (1987) Improved silver staining of plant proteins, RNA and DNA 
in polyacrylamide gels. Electrophoresis 8, 93-99. 
[201] Lakey, A., Labeit, S., Gautel, M., Ferguson, C., et al. (1993) Kettin, a large modular protein in 
the Z-disc of insect muscles. EMBO J 12, 2863-2871. 
[202] DuVerle, D. A., Ono, Y., Sorimachi, H., Mamitsuka, H. (2011) Calpain cleavage prediction using 
multiple kernel learning. PLoS One 6, e19035, 1-9. 
[203] Haffner, C., Jarchau, T., Reinhard, M., Hoppe, J., et al. (1995) Molecular cloning, structural 
analysis and functional expression of the proline-rich focal adhesion and microfilament-
associated protein VASP. EMBO J 14, 19-27. 
[204] Herwald, H., Dedio, J., Kellner, R., Loos, M., et al. (1996) Isolation and characterization of the 
kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol 
Chem 271, 13040-13047. 
[205] Benz, P. M.,  Feller, S. M., Sickmann, A., Walter, U., et al. (2008) Prostaglandin-induced VASP 
phosphorylation controls αII-spectrin breakdown in apoptotic cells. Int Immunopharmacol 8, 319-
324. 
[206] Novy, R., Drott, D., Yaeger, K., Mierendorf, R. (2001) Overcoming the codon bias of E.coli for 
enhanced protein expression. InNovations 12, 1-3. 
Literature 
   
140 
[207] Phizicky, E. M., Fields, S. (1995) Protein-protein interactions: methods for detection and 
analysis. Microbiol Rev 59, 94-123. 
[208] Debeljak, N., Feldman, L., Davis, K. L., Komel, R., et al. (2006) Variability in the 
immunodetection of His-tagged recombinant proteins. Anal Biochem 359, 216-223. 
[209] Lehman, W., Hatch, V., Korman, V., Rosol M., et al. (2000) Tropomyosin and actin isoforms 
modulate the localization of tropomyosin strands on actin filaments. J Mol Biol 302, 593-606. 
[210] Ono, S., Ono K. (2002) Tropomyosin inhibits ADF/cofilin-dependent actin filament dynamics. J 
Cell Biol 156, 1065-1076. 
[211] Sun, H. Q., Yamamoto, M., Mejillano, M., Yin, H. L. (1999) Gelsolin, a multifunctional actin 
regulatory protein. J Biol Chem 274, 33179-33182. 
[212] Weber, A., Pennise, C. R., Babcock, G. G., Fowler, V. M. (1994) Tropomodulin caps the pointed 
ends of actin filaments. J Cell Biol 127, 1627-1635. 
[213] Bauer, K., Kratzer, M., Otte, M., de Quintana, K. L., et al. (2000) Human CLP36, a PDZ-domain 
and LIM-domain protein, binds to alpha-actinin-1 and associates with actin filaments and stress 
fibers in activated platelets and endothelial cells. Blood 96, 4236-4245. 
[214] Vallenius, T., Luukko, K., Makela, T. P. (2000) CLP-36 PDZ-LIM protein associates with 
nonmuscle alpha-actinin-1 and alpha-actinin-4. J Biol Chem 275, 11100-11105. 
[215] Chakrabarti, A., Kelkar, D. A., Chattopadhyay, A. (2006) Spectrin organization and dynamics: 
new insights. Biosci Rep 26, 369-386. 
[216] Burn, P., Kupfer, A., Singer, S. J. (1988) Dynamic membrane-cytoskeletal interactions: specific 
association of integrin and talin arises in vivo after phorbol ester treatment of peripheral blood 
lymphocytes. Proc Natl Acad Sci USA 85, 497-501. 
[217] Escolar, G., Diaz-Ricart, M., White, J. G. (1995) Talin does not associate exclusively with alpha 
2b beta 3 integrin in activated human platelets. J Lab Clin Med 125, 597-607. 
[218] Peng, X., Nelson, E. S., Maiers, J. L., DeMali, K. A. (2011) New insights into vinculin function 
and regulation. Int Rev Cell Mol Biol 287, 191-231. 
[219] Nakamura, F., Pudas, R., Heikkinen, O., Permi, P., et al. (2006) The structure of the GPIb-
filamin A complex. Blood 107, 1925-1932. 
[220] Andrews, R. K., López, J. A., Berndt, M. C. (1997) Molecular mechanisms of platelet adhesion 
and activation. Int J Biochem Cell Biol 29, 91-105. 
[221] Calvete, J. J. (1995) On the structure and function of platelet integrin alpha IIb beta 3, the 
fibrinogen receptor. Proc Soc Exp Biol Med 208, 346-360. 
[222] Shattil, S. J. (1999) Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, 
and sideways. Thromb Haemost 82, 318-325. 
[223] Lefort, C. T., Rossaint, J., Moser, M., Petrich, B. G., et al. (2012) Distinct roles for talin-1 and 
kindlin-3 in LFA-1 extension and affinity regulation. Blood, Epub ahead of print. 
[224] Wu, C. (2004) The PINCH-ILK-parvin complexes: assembly, functions and regulation. Biochim 
Biophys Acta 1692, 55-62. 
[225] Wickström, S. A., Lange, A., Montanez, E., Fässler, R. (2010) The ILK/PINCH/parvin complex: 
the kinase is dead, long live the pseudokinase! EMBO J 29, 281-291. 
Literature 
   
141 
[226] Huang, M. M., Bolen, J. B., Barnwell, J. W., Shattil, S. J., et al. (1991) Membrane glycoprotein IV 
(CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human 
platelets. Proc Natl Acad Sci USA 88, 7844-7848. 
[227] Zheng, M., Cheng, H., Banerjee, I., Chen, J. (2010) ALP/Enigma PDZ-LIM domain proteins in 
the heart. J Mol Cell Biol 2, 96-102. 
[228] Harris, B. Z., Lim, W. A. (2001) Mechanism and role of PDZ domains in signaling complex 
assembly. J Cell Sci 114, 3219-3231. 
[229] Long, J. F., Tochio, H., Wang, P., Fan, J. S., et al. (2003) Supramodular structure and 
synergistic target binding of the N-terminal tandem PDZ domains of PSD-95. J Mol Biol 327, 
203-214. 
[230] Jani, K., Schock, F. (2007) Zasp is required for the assembly of functional integrin adhesion 
sites. J Cell Biol 179, 1583-1597. 
[231] Kadrmas, J. L., Beckerle, M. C. (2004) The LIM domain: from the cytoskeleton to the nucleus. 
Nat Rev Mol Cell Biol 5, 920-931. 
[232] Schaffar, G., Taniguchi, J., Brodbeck, T., Meyer, A. H., et la. (2008) LIM-only protein 4 interacts 
directly with the repulsive guidance molecule A receptor Neogenin. J Neurochem 107, 418-431. 
[233] Ponting, C. P., Phillips, C. (1995) DHR domains in syntrophins, neuronal NO synthases and 
other intracellular proteins. Trends Biochem Sci 20, 102-103. 
[234] Jemth, P., Gianni, S. (2007) PDZ domains: folding and binding. Biochemistry 46, 8701-8708. 
[235] Gill, G. N. (1995) The enigma of LIM domains. Structure 3, 1285-1289. 
[236] Zhang, Y., Tu, Y., Zhao, J., Chen, K., et al. (2009) Reversion-induced LIM interaction with Src 
reveals a novel Src inactivation cycle. J Cell Biol 184, 785-792. 
[237] Vallenius, T., Makela, T. P (2002) Clik1: a novel kinase targeted to actin stress fibers by the 
CLP-36 PDZ-LIM protein. J Cell Sci 115, 2067-2073. 
[238] Kuroda, S., Tokunaga, C., Kiyohara, Y., Higuchi, O., et al. (1996) Protein-protein interaction of 
zinc finger LIM domains with protein kinase C. J Biol Chem 271, 31029-31032. 
[239] Cuppen, E., Gerrits, H., Pepers, B., Wieringa, B., et al. (1998) PDZ motifs in PTP-BL and RIL 
bind to internal protein segments in the LIM domain protein RIL. Mol Biol Cell 9, 671-683. 
[240] Wu, R.Y., Gill, G. N. (1994) LIM domain recognition of a tyrosine-containing tight turn. J Biol 
Chem 269, 25085-25090. 
[241] Xia, H., Winokur, S. T., Kuo, W. L., Altherr, M. R., et al. (1997). Actinin associated LIM protein: 
identification of a domain interaction between PDZ and spectrin-like repeat motifs. J Cell Biol 
139, 507-515. 
[242] Te Velthuis, A. J., Bagowski, C. P (2007) PDZ and LIM domain-encoding genes: molecular 
interactions and their role in development. Scientific World Journal 7, 1470-1492. 
[243] Kotaka, M., Ngai, S. M., Carcia-Barcelo, M., Tsui, S. K. W., et al. (1999) Characterization of the 
human 36-kDa carboxyl terminal LIM domain protein (hCLIM1). J Cell Biochem 72, 279-285. 
[244] Meyer, S. C., Zuerbig, S., Cunningham, C. C., Hartwig, J. H., et al. (1997) Identification of the 
region in actin-binding protein that binds to the cytoplasmic domain of glycoprotein IB alpha. J 
Biol Chem 272, 2914-2919. 
Literature 
   
142 
[245] Feng, S., Reséndiz, J. C., Lu, X., Kroll, M. H. (2003) Filamin A binding to the cytoplasmic tail of 
glycoprotein Ib alpha regulates von Willebrand factor-induced platelet activation. Blood 102, 
2122-2129. 
[246] Williamson, D., Pikovski, I., Cranmer, S. L., Mangin, P., et al. (2002) Interaction between platelet 
glycoprotein Ib alpha and filamin-1 is essential for glycoprotein Ib/ IX receptor anchorage at high 
shear. J Biol Chem 277, 2151-2159. 
[247] Yap, C. L., Hughan, S. C., Cranmer, S. L., Nesbitt, W. S., et al. (2000) Synergistic adhesive 
interactions and signaling mechanisms operating between platelet glycoprotein Ib/ IX and 
integrin alpha IIb beta 3: studies in human platelets and transfected Chinese hamster ovary 
cells. J Biol Chem 275, 41377-41388. 
[248] Solum, N. O., Clemetson, K. J. (2005) The discovery and characterization of platelet GPIb. J 
Thromb Haemost 3, 1125-1132. 
[249] Podlubnaya, Z. A., Tskhovrebova, L. A., Zaalishtsbvili, M. M., Stefanenko, G. A. (1975) 
Electronmicroscopic study of alpha-actinin. J Mol Biol 92, 357-359. 
[250] Djinovic-Carugo, K., Young, P., Gaute l. M., Saraste, M. (1999) Structure of the alpha-actinin 
rod: molecular basis for cross-linking of actin filaments. Cell 98, 537-546. 
[251] Mimura, N., Asano, A. (1986) Isolation and characterization of a conserved actin-binding domain 
from rat hepatic actinogelin, rat skeletal muscle, and chicken gizzard alpha-actinins. J Biol Chem 
261, 10680-10687. 
[252] Otey, C. A., Pavalko, F. M., Burridge, K. (1990) An interaction between alpha-actinin and the 
beta 1 integrin subunit in vitro. J Cell Biol 111, 721-729. 
[253] Morgan, A. J., Jacob, R. (1994) Ionomycin enhances Ca2+ influx by stimulating store-regulated 
cation entry and not by a direct action at the plasma membrane. Biochem J 300, 665-672. 
[254] Azam, M., Andrabi, S. S., Sahr, K. E., Kamath, L., et al. (2001) Disruption of the mouse mu-
calpain gene reveals an essential role in platelet function. Mol Cell Biol. 21, 2213-20. 
[255] Croall, D. E., DeMartino, G. N. (1991) Calcium-activated neutral protease (calpain) system: 
structure, function, and regulation. Physiol Rev 71, 813-847. 
[256] Suzuki, K., Sorimachi, H., Yoshizawa, T., Kinbara, K., et al. (1995) Calpain: novel family 
members, activation, and physiologic function. Biol Chem Hoppe Seyler 376, 523-529. 
[257] Croce, K., Flaumenhaft, R., Rivers, M., Furie, B., et al. (1999) Inhibition of calpain blocks platelet 
secretion, aggregation, and spreading. J Biol Chem 274,36321-36327. 
[258] Potter, D. A., Tirnauer, J. S., Janssen, R., Croall, D. E., et al. (1998) Calpain regulates actin 
remodeling during cell spreading. J Cell Biol 141, 647-662. 
[259] Hayashi, M., Suzuki, H., Kawashima, S., Saido, T. C., et al. (1999) The behavior of calpain-
generated N- and C-terminal fragments of talin in integrin-mediated signaling pathways. Arch 
Biochem Biophys 371, 133-141. 
[260] Nieswandt, B., Watson, S. P. (2003) Platelet-collagen interaction: is GPVI the central receptor? 
Blood 102, 449-461. 
Literature 
   
143 
[261] Tsuji, M., Ezumi, Y., Arai, M., Takayama, H. (1997) A novel association of Fc receptor gamma-
chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J 
Biol Chem 272, 23528-23531. 
[262] Gibbins, J. M., Okuma, M., Farndale, R., Barnes, M., et al. (1997) Glycoprotein VI is the 
collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor 
gamma-chain. FEBS Lett 413, 255-259. 
[263] Suzuki-Inoue, K., Tulasne, D., Shen, Y., Bori-Sanz, T., et al. (2002) Association of Fyn and Lyn 
with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem 277, 
21561-21566. 
[264] Watson, S. P., Auger, J. M., McCarty, O. J., Pearce, A. C. (2005) GPVI and integrin alpha IIb 
beta 3 signaling in platelets. J Thromb Haemost 3, 1752-1762. 
[265] Hassock, S. R., Zhu, M. X., Trost, C., Flockerzi, V., et al. (2002) Expression and role of TRPC 
proteins in human platelets: evidence that TRPC6 forms the store-independent calcium entry 
channel. Blood 100, 2801-2811. 
[266] Ramanathan, G., Gupta, S., Thielmann, I., Pleines, I., et al. (2011) Defective diacylglycerol-
induced Ca(2+) entry but normal agonist-induced activation responses in TRPC6-deficient 
mouse platelets. J Thromb Haemost, doi: 10.1111/ j.1538-7836.2011.04596.x. 
[267] Gupta, S., Braun, A., Morowski, M., Premsler, T., et al. (2012) CLP36 is a negative regulator of 
GPVI signaling in platelets. Circulation Research, currently under submission. 
Appendix 
   
144 
7 Appendix 
 
7.1 Vector maps 
7.1.1 pcDNA3.1/V5-HisA and lacZ 
 
MCS: 
 
 
 
 
 
based on the Invitrogen user manuals 
 
 
V5-HisA 
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7.1.2 pGEX 6p1 
 
MCS: 
 
 
 
 
based on the GE Healthcare user manuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGEX 6p1 
4.9 kb 
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7.1.3 pQE-30 
 
MCS: 
 
 
 
based on the Qiagen user manuals 
 
 
 
 
 
 
 
 
 
 
 
 
pQE-30 
3.5 kb 
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7.2 Applied full-length nt-sequences 
7.2.1 Homo sapiens vasodilator-stimulated phosphoprotein (VASP), mRNA 
NCBI reference sequence: NM_003370.3 
Length 2298 nt. The coding sequence is marked in yellow. 
        1 tgtgggtgcg gggagtggaa ttttggaacg aaatgtaacg aagagaagta cagtagtaag 
       61 agtaacactg tagccgccac cggcaagggg tgcgcgctgg ggagcggacg ctgcatcccc 
      121 tttctgctgc aggaacctct catcagaccg cctgagggaa gcggcgcccg gagacccgcc 
      181 ccggcccggt ccacattctc cccaggaagc cggactctat ggggcgggac cctgggggag 
      241 cctgagccga gcccggagcc agccccgaac ccctgaacct ccagccaggg gcgccccggg 
      301 agcagccagc ccgtgggcga gccgcccgcc cgccgagcag ccatgagcga gacggtcatc 
      361 tgttccagcc gggccactgt gatgctttat gatgatggca acaagcgatg gctccctgct 
      421 ggcacgggtc cccaggcctt cagccgcgtc cagatctacc acaaccccac ggccaattcc 
      481 tttcgcgtcg tgggccggaa gatgcagccc gaccagcagg tggtcatcaa ctgtgccatc 
      541 gtccggggtg tcaagtataa ccaggccacc cccaacttcc atcagtggcg cgacgctcgc 
      601 caggtctggg gcctcaactt cggcagcaag gaggatgcgg cccagtttgc cgccggcatg 
      661 gccagtgccc tagaggcgtt ggaaggaggt gggccccctc cacccccagc acttcccacc 
      721 tggtcggtcc cgaacggccc ctccccggag gaggtggagc agcagaaaag gcagcagccc 
      781 ggcccgtcgg agcacataga gcgccgggtc tccaatgcag gaggcccacc tgctcccccc 
      841 gctgggggtc cacccccacc accaggacct ccccctcctc caggtccccc cccaccccca 
      901 ggtttgcccc cttcgggggt cccagctgca gcgcacggag cagggggagg accaccccct 
      961 gcaccccctc tcccggcagc acagggccct ggtggtgggg gagctggggc cccaggcctg 
     1021 gccgcagcta ttgctggagc caaactcagg aaagtcagca agcaggagga ggcctcaggg 
     1081 gggcccacag cccccaaagc tgagagtggt cgaagcggag gtgggggact catggaagag 
     1141 atgaacgcca tgctggcccg gagaaggaaa gccacgcaag ttggggagaa aacccccaag 
     1201 gatgaatctg ccaatcagga ggagccagag gccagagtcc cggcccagag tgaatctgtg 
     1261 cggagaccct gggagaagaa cagcacaacc ttgccaagga tgaagtcgtc ttcttcggtg 
     1321 accacttccg agacccaacc ctgcacgccc agctccagtg attactcgga cctacagagg 
     1381 gtgaaacagg agcttctgga agaggtgaag aaggaattgc agaaagtgaa agaggaaatc 
     1441 attgaagcct tcgtccagga gctgaggaag cggggttctc cctgaccaca gggacccaga 
     1501 agacccgctt ctcctttccg cacacccggc ctgtcaccct gctttccctg cctctacttg 
     1561 acttggaatt ggctgaagac tacacaggaa tgcatcgttc ccactcccca tcccacttgg 
     1621 aaaactccaa gggggtgtgg cttccctgct cacacccaca ctggctgctg attggctggg 
     1681 gaggcccccg cccttttctc cctttggtcc ttcccctctg ccatcccctt ggggccggtc 
     1741 cctctgctgg ggatgcacca atgaacccca caggaagggg gaaggaagga gggaatttca 
     1801 cattcccttg ttctagattc actttaacgc ttaatgcctt caaagttttg gtttttttaa 
     1861 gaaaaaaaaa tatatatata tttgggtttt gggggaaaag ggaaattttt ttttctcttt 
     1921 ggttttgata aaatgggatg tgggagtttt taaatgctat agccctgggc ttgccccatt 
     1981 tggggcagct atttaagggg aggggatgtc tcaccgggct gggggtgaga tatcccccca 
     2041 ccccagggac tccccttccc tctggctcct tccccttttc tatgaggaaa taagatgctg 
     2101 taactttttg gaacctcagt tttttgattt tttatttggg taggttttgg ggtccaggcc 
     2161 atttttttta ccccttggag gaaataagat gagggagaaa ggagaagggg aggaaacttc 
     2221 tcccctccca ccttcacctt tagcttcttg aaaatgggcc cctgcagaat aaatctgcca 
     2281 gtttttataa aaaaaaaa 
 
7.2.2 Homo sapiens stromal interaction molecule 1 (STIM1), mRNA 
NCBI reference sequence: NM_003156.3 
Length 4062 nt. The coding sequence is marked in yellow. 
        1 ctggacctgg gcaccgccag ccgcctgggc acgggactgg gcgggggcgc tgacctcggc 
       61 ctaggaggcc caggatcccg gagacgcccg cgccctcagg accctgcggg tcgcacgccc 
      121 tccccagctt ctgctgctcg ccgctcttcg gcagggcgag gtcaggtgcc cccttctcgc 
      181 ctctcttctc ttctcttctc ttcctcctcc acttctgtgc ccgcggagac tccggccgcc 
      241 cccttccgca ggggtgtagt aatctgcgga gctgacagca gccccgcagc caccctgccc 
      301 gaagtctccg gaagcggcac gagctcaggc cgccgcagcc ccggcggacc cactgttgga 
      361 cctgaggagc cagccctcct cccgcaccca aacttggagc acttgacctt tggctgttgg 
      421 agggggcagg ctcgcgggtg gctggacagc tgcggagccg cgagggcatc ttgcctggag 
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      481 accgtcggct gcactcccgg gctcctggct ttgcctctgg gatcccgagg tgtccacatc 
      541 agacgcatgt tgactgagac ctagagtcat ggatgtatgc gtccgtcttg ccctgtggct 
      601 cctctgggga ctcctcctgc accagggcca gagcctcagc catagtcaca gtgagaaggc 
      661 gacaggaacc agctcggggg ccaactctga ggagtccact gcagcagagt tttgccgaat 
      721 tgacaagccc ctgtgtcaca gtgaggatga gaaactcagc ttcgaggcag tccgtaacat 
      781 ccacaaactg atggacgatg atgccaatgg tgatgtggat gtggaagaaa gtgatgagtt 
      841 cctgagggaa gacctcaatt accatgaccc aacagtgaaa cacagcacct tccatggtga 
      901 ggataagctc atcagcgtgg aggacctgtg gaaggcatgg aagtcatcag aagtatacaa 
      961 ttggaccgtg gatgaggtgg tacagtggct gatcacatat gtggagctgc ctcagtatga 
     1021 ggagaccttc cggaagctgc agctcagtgg ccatgccatg ccaaggctgg ctgtcaccaa 
     1081 caccaccatg acagggactg tgctgaagat gacagaccgg agtcatcggc agaagctgca 
     1141 gctgaaggct ctggatacag tgctctttgg gcctcctctc ttgactcgcc ataatcacct 
     1201 caaggacttc atgctggtgg tgtctatcgt tattggtgtg ggcggctgct ggtttgccta 
     1261 tatccagaac cgttactcca aggagcacat gaagaagatg atgaaggact tggaggggtt 
     1321 acaccgagct gagcagagtc tgcatgacct tcaggaaagg ctgcacaagg cccaggagga 
     1381 gcaccgcaca gtggaggtgg agaaggtcca tctggaaaag aagctgcgcg atgagatcaa 
     1441 ccttgctaag caggaagccc agcggctgaa ggagctgcgg gagggtactg agaatgagcg 
     1501 gagccgccaa aaatatgctg aggaggagtt ggagcaggtt cgggaggcct tgaggaaagc 
     1561 agagaaggag ctagaatctc acagctcatg gtatgctcca gaggcccttc agaagtggct 
     1621 gcagctgaca catgaggtgg aggtgcaata ttacaacatc aagaagcaaa atgctgagaa 
     1681 gcagctgctg gtggccaagg agggggctga gaagataaaa aagaagagaa acacactctt 
     1741 tggcaccttc cacgtggccc acagctcttc cctggatgat gtagatcata aaattctaac 
     1801 agctaagcaa gcactgagcg aggtgacagc agcattgcgg gagcgcctgc accgctggca 
     1861 acagatcgag atcctctgtg gcttccagat tgtcaacaac cctggcatcc actcactggt 
     1921 ggctgccctc aacatagacc ccagctggat gggcagtaca cgccccaacc ctgctcactt 
     1981 catcatgact gacgacgtgg atgacatgga tgaggagatt gtgtctccct tgtccatgca 
     2041 gtcccctagc ctgcagagca gtgttcggca gcgcctgacg gagccacagc atggcctggg 
     2101 atctcagagg gatttgaccc attccgattc ggagtcctcc ctccacatga gtgaccgcca 
     2161 gcgtgtggcc cccaaacctc ctcagatgag ccgtgctgca gacgaggctc tcaatgccat 
     2221 gacttccaat ggcagccacc ggctgatcga gggggtccac ccagggtctc tggtggagaa 
     2281 actgcctgac agccctgccc tggccaagaa ggcattactg gcgctgaacc atgggctgga 
     2341 caaggcccac agcctgatgg agctgagccc ctcagcccca cctggtggct ctccacattt 
     2401 ggattcttcc cgttctcaca gccccagctc cccagaccca gacacaccat ctccagttgg 
     2461 ggacagccga gccctgcaag ccagccgaaa cacacgcatt ccccacctgg ctggcaagaa 
     2521 ggctgtggct gaggaggata atggctctat tggcgaggaa acagactcca gcccaggccg 
     2581 gaagaagttt cccctcaaaa tctttaagaa gcctcttaag aagtaggcag gatggggtgg 
     2641 cagtaaaggg acagcttgtc cttccctggg tgttctgtct ctccttccct cccttccttc 
     2701 aagataactg gccccaagag tggggcatgg gaagggctgg tccaggggtc tgggcactgt 
     2761 acatacctgc cccctcatcc ttgggtcctt cattattatt tattaactga ccaccatggc 
     2821 ctgcctgccc tgcctccgtc ccaaccatgg gctgctgctg tcactccctc tccacttcag 
     2881 tgcatgtctt agttgctgtt ccctcagctc ccagctccac ctctggggtt cagcttctgt 
     2941 ctctgctgtc ccagttttga ggtttggttt cttgtttctg tctcttgctt tcgggctcct 
     3001 ccctcccacc actccccaac ttcccctagc agttgcaggg aagataggac gagtagcttc 
     3061 tgacatgtgt gcctcagatc tgttccaccc cactcacagt ggttctgttt gctccagact 
     3121 ggggctaggg cctaatcttt gaagtttgtt ctttggtatt gatgtgggtc agaaggagcc 
     3181 tcatcctaat ctcactcagg cctccaggga tccatggggg agtgaaacca attctcagag 
     3241 aacaacccac cagagacttt taaagagagg ccaggcttgg gaatgggttg ggagaggcat 
     3301 ctgttcattg gagcatgagt ggatgccaga actgtaggtt ataaggcagt cactttttct 
     3361 ctctactccc acccacacct gcctccctct tacccctgct cccccacact gcaggaggat 
     3421 ttgtctctaa gaggtgctgc cccaaagctc cccaagcatc aatactccta gggctcagga 
     3481 caagtggctc ccctggccag gagagccaca gccatgatac agggctctta tggagccctg 
     3541 gagttgttgg gcaaggatgc tgtcattttt tgaaccaaaa gacaaacagg ttaaaaggaa 
     3601 aaaaagtaat ctgaatttcc caagtgccta cgctgcatat tccccttgtt agatcccatt 
     3661 ttcatgttac tttgtagcct tggccagagg ctcaaaaagg acacaaccag tttggggaag 
     3721 gggtggctaa ggaagatggt ataggtgaag gcggctgtgt gaccactttc ccccaccctt 
     3781 cccaccctct agacaactct ctcccttacc tgtttttgct atggctgtaa aggtattttt 
     3841 cctctgcccc actccctgcc atacctttat cctgggatcc tattttgggc ctggggtggg 
     3901 tatacctggg gctggtctta ggagggtgct aggctgcaga ctgccttgta ctccctggac 
     3961 accctcaaat ggggttttct gtgttatttc ataaaattct ttgaagtcca ataaagcatg 
     4021 taggagattt taaccactaa aaaaaaaaaa aaaaaaaaaa aa 
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7.2.3 Homo sapiens PDZ and LIM domain 1 (PDLIM1), mRNA 
NCBI reference sequence: NM_020992.2 
Length 1462 nt. The coding sequence is marked in yellow. 
 1 gcccgcgccg cgccgctctt tctccgacag ctgccggggg tgccctgcaa gctgttccgc 
       61 gcgtcctgcc cgtctgtccc cgcgggtcgt cgcccgccac agccgcgcca tgaccaccca 
      121 gcagatagac ctccagggcc cggggccgtg gggcttccgc ctcgtgggcg gcaaggactt 
      181 cgagcagcct ctcgccattt cccgggtcac tcctggaagc aaggcggctc tagctaattt 
      241 atgtattgga gatgtaatca cagccattga tggggaaaat actagcaata tgacacactt 
      301 ggaagctcag aacagaatca aaggctgcac agacaacttg actctcactg tagccagatc 
      361 tgaacataaa gtctggtctc ctctggtgac ggaggaaggg aagcgtcatc catacaagat 
      421 gaatttagcc tctgaacccc aggaggtcct gcacatagga agcgcccaca accgaagtgc 
      481 catgcccttt accgcctcgc ctgcctccag cactactgcc agggtcatca caaaccagta 
      541 caacaaccca gctggcctct actcttctga aaatatctcc aacttcaaca atgccctgga 
      601 gtcaaagact gctgccagcg gggtggaggc gaacagcaga cccttagacc atgctcagcc 
      661 tccaagcagc cttgtcatcg acaaagaatc tgaagtttac aagatgcttc aggagaaaca 
      721 ggagttgaat gagcccccga aacagtccac gtctttcttg gttttgcagg aaatcctgga 
      781 gtctgaagaa aaaggggatc ccaacaagcc ctcaggattc agaagtgtta aagctcctgt 
      841 cactaaagtg gctgcgtcga ttggaaatgc tcagaagttg cctatgtgtg acaaatgtgg 
      901 cactgggatt gttggtgtgt ttgtgaagct gcgggaccgt caccgccacc ctgagtgtta 
      961 tgtgtgcact gactgtggca ccaacctgaa acagaagggc catttctttg tggaggatca 
     1021 aatctactgt gagaagcatg cccgggagcg agtcacacca cctgagggtt atgaagtggt 
     1081 cactgtgttc cccaagtgag ccagcagatc tgaccactgt tctccagcag gcctctgctg 
     1141 cagctttttc tctcagtgtt ctggccctct cctctcttga aagttctctg cttactttgg 
     1201 ttttccctct gcttgtaaaa cattgagtcc cctccctgcc ttggttaatt gactcacacc 
     1261 agctgtgcga tgcccgcttt tacaattaaa ggaaaactgt tttgttcagt gtcaccttgt 
     1321 cagcaacact gtgtcccttc gccccaccgt tcttctctgc tgcatttgga catcagccaa 
     1381 atttgaaccc aatcaaatat aacgtgtctg acactgattt tgtttttact caataaatgt 
     1441 atagactaca aaaaaaaaaa aa 
 
7.2.4 Mus musculus stromal interaction molecule 1 (Stim1), mRNA 
NCBI reference sequence: NM_009287.4 
Length 3609 nt. The coding sequence is marked in yellow. 
        1 cccgggcctg gcccgtgcgc gtccgcctgc tgcaccgggg caccaggagc cgcagaggta 
       61 ccggacccgg cgggggcgct gacctcggcc taggagtctt aggatcccgg agacatccgt 
      121 gtctgctggg gcctgtaggt cgcacgccga agccctagct gctgaggctc accgctgttt 
      181 ctcggggcga ggtcaggtgc cccccttctc tcctctcttc tctccctccc ccacctcagt 
      241 gcgggcggga gattctgccc gcctcctccc gcaggggtgc agcaggctgc ggagctgaca 
      301 gcggccccgc agccaccctg ctcaaactct ccggaagcag atagagctca ggccgccgcc 
      361 gcagccccgg cggacctaca gttggaccgg agactccgat ccttctgcgt ccaaacttgg 
      421 ggcacttgac cttcgcttat cggaggaggt aagcccgcag gtggctggac agctgcggcg 
      481 ccgcgagggc atcttgcttt ggaaccgtcg gctgcactcc ctgactctgg gatttgcttc 
      541 tgggatccaa aggtgtctac agcaggcgca tgttgactga gacctaccgt catggatgtg 
      601 tgcgcccgtc ttgccctgtg gcttctttgg gggctccttc tgcatcaggg ccagagtctc 
      661 agccatagtc acagtgaaaa gaatacagga gctagctccg gggcgacttc tgaagagtct 
      721 accgaagcag agttttgccg aattgacaag cccctgtgcc acagtgagga tgagaagctc 
      781 agctttgagg ccgtccgaaa catccataag ctgatggatg acgatgccaa tggtgatgtg 
      841 gatgtggaag aaagtgatga gttcctaagg gaagacctca attaccatga cccaacagtg 
      901 aaacatagca ccttccatgg tgaggataag cttatcagcg tggaggacct gtggaaggcg 
      961 tggaagtcat cagaagtgta caactggact gtggatgagg tgatacagtg gctcattacg 
     1021 tatgtggagc tgccacagta tgaggaaacc ttccggaagt tgcagcttac tggccacgcc 
     1081 atgccaaggc tagcagtaac caacaccacc atgacaggga ctgtactgaa gatgacagat 
     1141 cggagccaca ggcagaagct gcagctgaag gccctggaca cagtgctgtt tgggcctcct 
     1201 ctcttgactc ggcataatca cctgaaggac ttcatgctgg tggtgtctat cgttattggt 
     1261 gtgggtggct gctggtttgc ctatatccag aaccgttact ctaaggagca catgaagaaa 
     1321 atgatgaagg atctggaagg gttacaccgg gctgagcaga gtctgcatga ccttcaggaa 
     1381 aggctgcaca aggcccagga ggagcaccga actgtggaag tagagaaggt ccacctggag 
Appendix 
   
150 
     1441 aagaagctgc gagatgagat caaccttgcc aagcaggaag ctcagcggct gaaggagctg 
     1501 agggagggta ctgagaatga gaggagccgt caaaaatatg ctgaggaaga gctggagcag 
     1561 gttcgggagg ccttgaggaa agcagagaag gagctggaat cacacagctc atggtatgct 
     1621 cctgaggccc tgcagaagtg gctgcagctg acccatgagg tggaggtgca gtactacaac 
     1681 atcaagaagc aaaatgcaga gaggcagctg ctggtggcca aggagggggc tgagaaaata 
     1741 aaaaagaaga gaaacacgct ttttggtacc ttccatgtgg cccacagctc ttccctggat 
     1801 gatgtggatc ataaaatcct aactgctaag caagctctga gtgaggtgac agcggcactg 
     1861 agggagcgcc tgcaccggtg gcagcagatc gagatcctct gcggtttcca gattgtcaat 
     1921 aaccccggca tccactcctt ggtggctgct ctcaacatcg accccagctg gatgggcagc 
     1981 acccgcccta accccgccca cttcatcatg actgacgatg tggatgacat ggatgaggag 
     2041 attgtgtcgc ccttgtccat gcagtccccc agcctgcaga gcagtgtccg gcagcgcctg 
     2101 acggagccac agcttggcct gggatctcag agggatttga cccattccga ttcggagtcc 
     2161 tccctccaca tgagtgaccg ccagcgtgtg gcccccaagc ctcctcagat gggccgtgct 
     2221 gcagatgaag ctctcaatgc catgccttcc aatggcagcc atcggctgat tgagggggtc 
     2281 catccaggat ctctggtgga gaaactgcct gacagccctg ctctggccaa gaagacattt 
     2341 atggcgttga accatggcct agacaaggcc cacagcctga tggagctgaa cccctcagtc 
     2401 ccacctggtg gctccccact tttggattct tcccattctc ttagccccag ttccccagac 
     2461 ccagacacgc catctccagt tggggacaac cgagctctgc agggtagccg aaacacacga 
     2521 attccccact tggctggcaa gaaggcaatg gctgaggagg ataatggttc cattggtgag 
     2581 gagacagact ccagtccagg caggaagaag tttcctctca aaatttttaa gaagcctctt 
     2641 aagaagtagg cagactaggg tggtagtgtt gagacagcct gtccttccct gggtcttctg 
     2701 ccttcacctc ccttcctttc tttgcaatat ctggctccta gagtggggca cagaggggct 
     2761 ggcccaaggg cctgggcact gtacatatct gccctgctca tccttggtcc ttcatcatta 
     2821 tttattaact gaccaccatg gcctgcctgt cgggaaaccc ttccacccat gggctgctgc 
     2881 tgtcacatct tctccacttc agtgcatgtc ttagttgctc ttccctcagt tcccactcca 
     2941 cttttggggt ccagcttctg tctctgctgt cccagttttg aggtttggtt tttgtttctg 
     3001 tctcctgctt tcaggctcct ctctcccatt actccccaac gatcctagca gttgtgggga 
     3061 agataggagg agtaacttct gacacctgta cctcagatct gttcatccta ctcacagcca 
     3121 ttctgcctac cccagactgg gccacggtcc tgatctctgg ggtttgttct atggaagtgt 
     3181 ggtagactgg agggaacctc atcctggagc tcctttggat ctccagggct ccattcaggg 
     3241 agtggaacca actcccaggg aacaagtcac cagagtttta aagagagacc aggcttgtga 
     3301 ttgatgggag agacttctcc cagttggagg atgagtagat gccaaagctg tgggctgtaa 
     3361 ggcagttgcc atttctctct tgccctgccc acacctgcct tcctcttacc tctgctcccc 
     3421 tatattgcag gagtgtatct cttaagaggt gctgccctga agctccccat cagcatcagc 
     3481 actactgggg ctcagggcaa ctggctcccc tggctatggg agccacagtc atgacacagg 
     3541 gctcttgtgg agccctgggc aaggatgtta tatttgaacc aaaagacaaa cagttttaaa 
     3601 ataaaaaaa 
 
7.2.5 Mus musculus PDZ and LIM domain 1 (elfin) (Pdlim1), mRNA 
NCBI reference sequence: NM_016861.4 
Length 1524 nt. The coding sequence is marked in yellow. 
 1 ggggctgcag cgacgcggcc ggggcggatc tgtccccgcc ctcgctcgcg accccgcccg 
       61 tcccaggatc tcccaactcc cgccgcgcgc tctttctccg acagctgctc cgggagcccc 
      121 gcgcgccgtg cagttctgtg ccttgcctgt ctgtcccttc cgattgtgcc tagcgatgac 
      181 cacccagcag attgttctcc agggcccggg tccctggggt ttccgcctcg tgggcggcaa 
      241 ggacttcgaa caacctctcg ccatttcccg ggtcactccc ggaagcaagg ctgctatagc 
      301 gaatttatgt attggagatt taatcacagc catcgatggg gaagatacca gcagcatgac 
      361 acacttggaa gctcagaaca aaatcaaggg ctgcgcagac aacatgacgc tcacagtatc 
      421 caggtctgaa cagaagattt ggtctcctct agtgaccgag gaggggaaac gtcatcccta 
      481 caagatgaat ttagcgtcgg aaccccaaga agtcctgcac ataggaagtg cccacaaccg 
      541 aagtgccatg ccatttactg cctcacctgc tcccagcacc cgggtcatca caaaccagta 
      601 caacagccca actggcctct actcatccga aaacatctct aacttcaaca atgctgtgga 
      661 gtcgaagacc tcagccagtg gggaggaggc gaacagcagg cccgtggttc agcctcatcc 
      721 ctccggcagc cttatcattg acaaggactc tgaagtttac aagatgcttc aggagaagca 
      781 agaattaaac gagcccccca aacagtccac atccttcctg gttctgcagg agatcctgga 
      841 gtcagatggg aaaggggatc ccaacaagcc atcaggattt agaagtgtta aagctccagt 
      901 caccaaagtg gctgcatctg ttggaaatgc tcagaagctg cccatctgtg acaaatgtgg 
      961 aactggtatt gttggtgtgt ttgtgaagct gagggatcac catcgccacc ctgaatgcta 
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     1021 tgtgtgcacc gactgtggca tcaacctgaa acagaagggc catttctttg tagaggatca 
     1081 gatctactgt gaaaagcatg cccgggagcg ggtcactccg cctgagggct acgatgtggt 
     1141 cacagtgttc cgcgagtgat ggagaggacc tgccctgtct actgccctcc agccagcctg 
     1201 ctgcacctgg ttctcggaat attctggctc tctcctccct gacagtcctg tgcttactta 
     1261 gtgttagtca tgcgcaataa acattgggtt tcgtctgggc tgactgactc ccactggcag 
     1321 ggtgacatct gcttttatat tattgggaga tggttttgtc cctgtccctt cacccacacc 
     1381 tcaatgcacc ttcttcactt ggagtcttct ctgctgcaaa tggacattgg tccattggaa 
     1441 ctaagccaaa tgtagtatct ctgatgttac ttggttttac ttaataaatt tagactttaa 
     1501 agcaaaaaaa aaaaaaaaaa aaaa 
 
7.3 Applied full-length aa-sequences 
7.3.1 Homo sapiens vasodilator-stimulated phosphoprotein (VASP), protein 
UniProtKB/ Swiss-Prot Acc.Nr.: P50552. Length 380 aa; MW 39,830 Da 
        10         20         30         40         50         60  
MSETVICSSR ATVMLYDDGN KRWLPAGTGP QAFSRVQIYH NPTANSFRVV GRKMQPDQQV  
        70         80         90        100        110        120  
VINCAIVRGV KYNQATPNFH QWRDARQVWG LNFGSKEDAA QFAAGMASAL EALEGGGPPP  
       130        140        150        160        170        180  
PPALPTWSVP NGPSPEEVEQ QKRQQPGPSE HIERRVSNAG GPPAPPAGGP PPPPGPPPPP  
       190        200        210        220        230        240  
GPPPPPGLPP SGVPAAAHGA GGGPPPAPPL PAAQGPGGGG AGAPGLAAAI AGAKLRKVSK  
       250        260        270        280        290        300  
QEEASGGPTA PKAESGRSGG GGLMEEMNAM LARRRKATQV GEKTPKDESA NQEEPEARVP  
       310        320        330        340        350        360  
AQSESVRRPW EKNSTTLPRM KSSSSVTTSE TQPCTPSSSD YSDLQRVKQE LLEEVKKELQ  
       370        380  
KVKEEIIEAF VQELRKRGSP  
 
7.3.2 Homo sapiens stromal interaction molecule 1 (STIM1), protein 
UniProtKB/ Swiss-Prot Acc.Nr.: Q13586. Length 685 aa; MW 77,423 Da 
        10         20         30         40         50         60  
MDVCVRLALW LLWGLLLHQG QSLSHSHSEK ATGTSSGANS EESTAAEFCR IDKPLCHSED  
        70         80         90        100        110        120  
EKLSFEAVRN IHKLMDDDAN GDVDVEESDE FLREDLNYHD PTVKHSTFHG EDKLISVEDL  
       130        140        150        160        170        180  
WKAWKSSEVY NWTVDEVVQW LITYVELPQY EETFRKLQLS GHAMPRLAVT NTTMTGTVLK  
       190        200        210        220        230        240  
MTDRSHRQKL QLKALDTVLF GPPLLTRHNH LKDFMLVVSI VIGVGGCWFA YIQNRYSKEH  
       250        260        270        280        290        300  
MKKMMKDLEG LHRAEQSLHD LQERLHKAQE EHRTVEVEKV HLEKKLRDEI NLAKQEAQRL  
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       310        320        330        340        350        360  
KELREGTENE RSRQKYAEEE LEQVREALRK AEKELESHSS WYAPEALQKW LQLTHEVEVQ  
       370        380        390        400        410        420  
YYNIKKQNAE KQLLVAKEGA EKIKKKRNTL FGTFHVAHSS SLDDVDHKIL TAKQALSEVT  
       430        440        450        460        470        480  
AALRERLHRW QQIEILCGFQ IVNNPGIHSL VAALNIDPSW MGSTRPNPAH FIMTDDVDDM  
       490        500        510        520        530        540  
DEEIVSPLSM QSPSLQSSVR QRLTEPQHGL GSQRDLTHSD SESSLHMSDR QRVAPKPPQM  
       550        560        570        580        590        600  
SRAADEALNA MTSNGSHRLI EGVHPGSLVE KLPDSPALAK KALLALNHGL DKAHSLMELS  
       610        620        630        640        650        660  
PSAPPGGSPH LDSSRSHSPS SPDPDTPSPV GDSRALQASR NTRIPHLAGK KAVAEEDNGS  
       670        680  
IGEETDSSPG RKKFPLKIFK KPLKK  
 
7.3.3 Homo sapiens PDZ and LIM domain 1 (PDLIM1), protein 
UniProtKB/ Swiss-Prot Acc.Nr.: O00151. Length 329 aa; MW 36,072 Da 
        10         20         30         40         50         60  
MTTQQIDLQG PGPWGFRLVG GKDFEQPLAI SRVTPGSKAA LANLCIGDVI TAIDGENTSN  
        70         80         90        100        110        120  
MTHLEAQNRI KGCTDNLTLT VARSEHKVWS PLVTEEGKRH PYKMNLASEP QEVLHIGSAH  
       130        140        150        160        170        180  
NRSAMPFTAS PASSTTARVI TNQYNNPAGL YSSENISNFN NALESKTAAS GVEANSRPLD  
       190        200        210        220        230        240  
HAQPPSSLVI DKESEVYKML QEKQELNEPP KQSTSFLVLQ EILESEEKGD PNKPSGFRSV  
       250        260        270        280        290        300  
KAPVTKVAAS IGNAQKLPMC DKCGTGIVGV FVKLRDRHRH PECYVCTDCG TNLKQKGHFF  
       310        320  
VEDQIYCEKH ARERVTPPEG YEVVTVFPK  
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7.3.4 Mus musculus stromal interaction molecule 1 (Stim1), protein 
UniProtKB/ Swiss-Prot Acc.Nr.: P70302. Length 685 aa; MW 77,567 Da 
        10         20         30         40         50         60  
MDVCARLALW LLWGLLLHQG QSLSHSHSEK NTGASSGATS EESTEAEFCR IDKPLCHSED  
        70         80         90        100        110        120  
EKLSFEAVRN IHKLMDDDAN GDVDVEESDE FLREDLNYHD PTVKHSTFHG EDKLISVEDL  
       130        140        150        160        170        180  
WKAWKSSEVY NWTVDEVIQW LITYVELPQY EETFRKLQLT GHAMPRLAVT NTTMTGTVLK  
       190        200        210        220        230        240  
MTDRSHRQKL QLKALDTVLF GPPLLTRHNH LKDFMLVVSI VIGVGGCWFA YIQNRYSKEH  
       250        260        270        280        290        300  
MKKMMKDLEG LHRAEQSLHD LQERLHKAQE EHRTVEVEKV HLEKKLRDEI NLAKQEAQRL  
       310        320        330        340        350        360  
KELREGTENE RSRQKYAEEE LEQVREALRK AEKELESHSS WYAPEALQKW LQLTHEVEVQ  
       370        380        390        400        410        420  
YYNIKKQNAE RQLLVAKEGA EKIKKKRNTL FGTFHVAHSS SLDDVDHKIL TAKQALSEVT  
       430        440        450        460        470        480  
AALRERLHRW QQIEILCGFQ IVNNPGIHSL VAALNIDPSW MGSTRPNPAH FIMTDDVDDM  
       490        500        510        520        530        540  
DEEIVSPLSM QSPSLQSSVR QRLTEPQLGL GSQRDLTHSD SESSLHMSDR QRVAPKPPQM  
       550        560        570        580        590        600  
GRAADEALNA MPSNGSHRLI EGVHPGSLVE KLPDSPALAK KTFMALNHGL DKAHSLMELN  
       610        620        630        640        650        660  
PSVPPGGSPL LDSSHSLSPS SPDPDTPSPV GDNRALQGSR NTRIPHLAGK KAMAEEDNGS  
       670        680  
IGEETDSSPG RKKFPLKIFK KPLKK  
 
7.3.5 Mus musculus PDZ and LIM domain 1 (elfin) (Pdlim1), protein 
UniProtKB/ Swiss-Prot Acc.Nr.: O70400. Length 327 aa; MW 35,774 Da 
        10         20         30         40         50         60  
MTTQQIVLQG PGPWGFRLVG GKDFEQPLAI SRVTPGSKAA IANLCIGDLI TAIDGEDTSS  
        70         80         90        100        110        120  
MTHLEAQNKI KGCADNMTLT VSRSEQKIWS PLVTEEGKRH PYKMNLASEP QEVLHIGSAH  
       130        140        150        160        170        180  
NRSAMPFTAS PAPSTRVITN QYNSPTGLYS SENISNFNNA VESKTSASGE EANSRPVVQP  
       190        200        210        220        230        240  
HPSGSLIIDK DSEVYKMLQE KQELNEPPKQ STSFLVLQEI LESDGKGDPN KPSGFRSVKA  
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       250        260        270        280        290        300  
PVTKVAASVG NAQKLPICDK CGTGIVGVFV KLRDHHRHPE CYVCTDCGIN LKQKGHFFVE  
       310        320  
DQIYCEKHAR ERVTPPEGYD VVTVFRE  
 
7.4 Sequencing data 
Full-length sequencing of VASP-deletion constructs in pcDNA3.1/V5-HisA vector was 
provided by GATC Biotech (Konstanz, Germany). Sequencing primers were T7-Fwd 
and BGH-Rev; the delivered nucleotide sequences were analyzed via the GATC 
Viewer software. 
 
Legend: 
VASP-starting sequence: ATGAGCGAGA 
VASP∆TD-ending:  TACTCG 
VASP∆FAB∆TD-ending: GGTCGAAGC 
V5-tag:    GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG 
His6-tag:   CATCATCATCATCATCATTGA         (His codons: ‘CAT’ or ‘CAC’) 
BamHI-restriction site:  GGATCC 
EcoRI-restriction site:  GAATTC 
 
7.4.1 Sequencing of VASP-AAA∆TD (in pcDNA3.1/V5-HisA) 
 
VASP-AAA∆TD, T7-Fwd-sequence: 
CGAGCTCGGATCCATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCA
ACAAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCACAACCCCACG
GCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTGGTCATCAACTGTGCCATCGT
CCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCATCAGTGGCGCGACGCTCGCCAGGTCTGGGGC
CTCAACTTCGGCAGCAAGGAGGATGCGGCCCAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGG
AAGGAGGTGGGCCCCCTCCACCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGA
GGTGGAGCAGCAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGCGAATGCAGG
AGGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCAGGTCCCCCC
CCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCAGGGGGAGGACCACCCCCT
G 
 
VASP-AAA∆TD, BGH-Rev-sequence (complementary): 
CACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCCCAGGCCTGG
CCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCGCGAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGC
CCCCAAAGCTGAGAGTGGTCGAAGCGGAGGTGGGGGACTCATGGAAGAGATGAACGCCATGCTGGCCCGG
AGAAGGAAAGCTGCGCAAGTTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGG
CCAGAGTCCCGGCCCAGAGTGAATCTGTGCGGAGACCCTGGGAGAAGAACAGCACAACCTTGCCAAGGAT
GAAGTCGTCTTCTTCGGTGACCACTTCCGAGACCCAACCCTGCACGCCCAGCTCCAGTGATTACTCGGAATT
CTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCTTCGAAGGTAAGCCTATCCCTAACC
CTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGA 
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VASP-AAA∆TD, sequence alignment with human VASP: 
 
Query:  human VASP 
Subject 1: VASP-AAA∆TD, T7-Fwd-sequence 
Length:  619 nt 
Score = 1109 bits (600), Expect = 0.0, Identities = 604/606 (99%), Gaps = 0/606 (0%) 
 
QUERY  1    ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  14   ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  73 
 
QUERY  61   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  74   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  133 
 
QUERY  121  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  134  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  193 
 
QUERY  181  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  194  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  253 
 
QUERY  241  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  254  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  313 
 
QUERY  301  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  314  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  373 
 
QUERY  361  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  374  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  433 
 
QUERY  421  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCTCCAATGCAGGA  480 
            |||||||||||||||||||||||||||||||||||||||||||||||| | ||||||||| 
SBJCT  434  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGCGAATGCAGGA  493 
        S157A (nt 469-471) 
 
QUERY  481  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  494  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  553 
 
QUERY  541  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  554  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  613 
 
QUERY  601  GGGGGA  606 
            |||||| 
SBJCT  614  GGGGGA  619 
 
 
Query:  human VASP 
Subject 2: VASP-AAA∆TD, BGH-Rev-sequence 
Length:  528 nt 
Score = 750 bits (406), Expect = 0.0, Identities = 416/419 (99%), Gaps = 2/419 (0%) 
 
QUERY  611   CACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCC  670 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1     CACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCC  60 
 
QUERY  671   CAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCAGC-AAGCAGGAGGAG  729 
             |||||||||||||||||||||||||||||||||||||||||||| || |||||||||||| 
SBJCT  61    CAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTC-GCGAAGCAGGAGGAG  119 
                 S239A (nt 715-717) 
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QUERY  730   GCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCGGAGGTGGGGGACTC  789 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  120   GCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCGGAGGTGGGGGACTC  179 
 
QUERY  790   ATGGAAGAGATGAACGCCATGCTGGCCCGGAGAAGGAAAGCCACGCAAGTTGGGGAGAAA  849 
             |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| 
SBJCT  180   ATGGAAGAGATGAACGCCATGCTGGCCCGGAGAAGGAAAGCCGCGCAAGTTGGGGAGAAA  239 
T278A (nt 832-834) 
 
QUERY  850   ACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGGCCAGAGTCCCGGCCCAGAGT  909 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  240   ACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGGCCAGAGTCCCGGCCCAGAGT  299 
 
QUERY  910   GAATCTGTGCGGAGACCCTGGGAGAAGAACAGCACAACCTTGCCAAGGATGAAGTCGTCT  969 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  300   GAATCTGTGCGGAGACCCTGGGAGAAGAACAGCACAACCTTGCCAAGGATGAAGTCGTCT  359 
 
QUERY  970   TCTTCGGTGACCACTTCCGAGACCCAACCCTGCACGCCCAGCTCCAGTGATTACTCGGA  1028 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  360   TCTTCGGTGACCACTTCCGAGACCCAACCCTGCACGCCCAGCTCCAGTGATTACTCGGA  418 
 
 
7.4.2 Sequencing of VASP-AAA∆FAB∆TD (in pcDNA3.1/V5-HisA) 
 
VASP-AAA∆FAB∆TD, T7-Fwd-sequence: 
CTTGGTACCGAGCTCGGATCCATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGAT
GATGGCAACAAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCACAA
CCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTGGTCATCAACTGTG
CCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCATCAGTGGCGCGACGCTCGCCAGGTC
TGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCCCAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGG
CGTTGGAAGGAGGTGGGCCCCCTCCACCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCC
GGAGGAGGTGGAGCAGCAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGCGAA
TGCAGGAGGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCAGGT
CCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCAGGGGGAGGACCA
CCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCCCAGGCCTGGCC
GCACTATTGCTGGAGCCAAACTCAGGAAAA 
 
VASP-AAA∆FAB∆TD, BGH-Rev-sequence (complementary): 
CAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCAGGGGGAG
GACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCCCAGGCC
TGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCGCGAAGCAGGAGGAGGCCTCAGGGGGGCCCAC
AGCCCCCAAAGCTGAGAGTGGTCGAAGCGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTA
GAGGGCCCTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATC
ACCATCACCATTGA 
 
VASP-AAA∆FAB∆TD, sequence alignment with human VASP: 
 
Query:  human VASP 
Subject 1: VASP-AAA∆FAB∆TD, T7-Fwd-sequence 
Length:  732 nt 
Score = 1295 bits (701), Expect = 0.0, Identities = 709/711 (99%), Gaps = 1/711 (0%) 
 
QUERY  1    ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  22   ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  81 
 
QUERY  61   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  82   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  141 
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QUERY  121  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  142  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  201 
 
QUERY  181  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  202  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  261 
 
QUERY  241  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  262  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  321 
 
QUERY  301  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  322  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  381 
 
QUERY  361  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  382  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  441 
 
QUERY  421  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCTCCAATGCAGGA  480 
            |||||||||||||||||||||||||||||||||||||||||||||||| | ||||||||| 
SBJCT  442  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGCGAATGCAGGA  501 
      S157A (nt 469-471) 
 
QUERY  481  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  502  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  561 
 
QUERY  541  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  562  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  621 
 
QUERY  601  GGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGA  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  622  GGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGA  681 
 
QUERY  661  GCTGGGGCCCCAGGCCTGGCCGCACTATTGCTGGAGCCAAACTCAGGAAA  711 
            |||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  682  GCTGGGGCCCCAGGCCTGGCCGCACTATTGCTGGAGCCAAACTCAGGAAA  731 
 
 
Query:  human VASP 
Subject 2: VASP-AAA∆FAB∆TD, BGH-Rev-sequence 
Length:  361 nt 
Score = 427 bits (231), Expect = 7e-124, Identities = 236/238 (99%), Gaps = 2/238 (0%) 
 
QUERY  539  CAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAG  598 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1    CAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAG  60 
 
QUERY  599  CAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGG  658 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  61   CAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGG  120 
 
QUERY  659  GAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCAGC-  717 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||  
SBJCT  121  GAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTC-GCG  179 
          S239A (nt 715-717) 
 
QUERY  718  AAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCG  775 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  180  AAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCG  237 
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7.4.3 Sequencing of VASP-DDE∆TD (in pcDNA3.1/V5-HisA) 
 
VASP-DDE∆TD, T7-Fwd-sequence: 
CTTGGTACCGAGCTCGGATCCATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGAT
GATGGCAACAAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCACAA
CCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTGGTCATCAACTGTG
CCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCATCAGTGGCGCGACGCTCGCCAGGTC
TGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCCCAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGG
CGTTGGAAGGAGGTGGGCCCCCTCCACCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCC
GGAGGAGGTGGAGCAGCAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGACAA
TGCAGGAGGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCAGGT
CCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCAGGGGGAGGACCA
CCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCCCAGGCCTGGCC
GCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCGACAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCC
CCAAAGCTGAGAGTGGTCGAAGCGGAGGTGGGGGACTCATGGAAGAGATGAACGCCATGCTGGCCCGGAG
AAGGAAAGCCGAGCAAGTTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGG 
 
VASP-DDE∆TD, BGH-Rev-sequence (complementary): 
CCTCCTCCAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCAG
GGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCC
CAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCGACAAGCAGGAGGAGGCCTCAGGGGG
GCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCGGAGGTGGGGGACTCATGGAAGAGATGAACGCCATG
CTGGCCCGGAGAAGGAAAGCCGAGCAAGTTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGG
AGCCAGAGGCCAGAGTCCCGGCCCAGAGTGAATCTGTGCGGAGACCCTGGGAGAAGAACAGCACAACCTT
GCCAAGGATGAAGTCGTCTTCTTCGGTGACCACTTCCGAGACCCAACCCTGCACGCCCAGCTCCAGTGATTA
CTCGGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCTTCGAAGGTAAGCCTA
TCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGA 
 
VASP-DDE∆TD, sequence alignment with human VASP: 
 
Query:  human VASP 
Subject 1: VASP-DDE∆TD, T7-Fwd-sequence 
Length:  910 nt 
Score = 1609 bits (871), Expect = 0.0, Identities = 885/891 (99%), Gaps = 4/891 (0%) 
 
QUERY  1    ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  22   ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  81 
 
QUERY  61   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  82   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  141 
 
QUERY  121  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  142  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  201 
 
QUERY  181  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  202  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  261 
 
QUERY  241  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  262  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  321 
 
QUERY  301  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  322  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  381 
 
QUERY  361  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  382  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  441 
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QUERY  421  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCTCCAATGCAGGA  480 
            ||||||||||||||||||||||||||||||||||||||||||||||||  |||||||||| 
SBJCT  442  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGACAATGCAGGA  501 
S157D (nt 469-471) 
 
QUERY  481  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  502  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  561 
 
QUERY  541  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  562  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  621 
 
QUERY  601  GGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGA  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  622  GGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGA  681 
 
QUERY  661  GCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTC-AGCAA  719 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| | ||| 
SBJCT  682  GCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCGA-CAA  740 
  S239D (nt 715-717) 
 
QUERY  720  GCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCGGAGG  779 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  741  GCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCGGAGG  800 
 
QUERY  780  TGGGGGACTCATGGAAGAGATGAACGCCATGCTGGCCCGGAGAAGGAAAGCC-ACGCAAG  838 
            |||||||||||||||||||||||||||||||||||||||||||||||||||| | ||||| 
SBJCT  801  TGGGGGACTCATGGAAGAGATGAACGCCATGCTGGCCCGGAGAAGGAAAGCCGA-GCAAG  859 
  T278E (nt 832-834) 
 
QUERY  839  TTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGG  889 
            ||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  860  TTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGG  910 
 
 
Query:  human VASP 
Subject 2: VASP-DDE∆TD, BGH-Rev-sequence 
Length:  620 nt 
Score = 896 bits (485), Expect = 0.0, Identities = 495/499 (99%), Gaps = 4/499 (0%) 
  
QUERY  532   CCTCCTCCAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCG  591 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1     CCTCCTCCAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCG  60 
 
QUERY  592   CACGGAGCAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGT  651 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  61    CACGGAGCAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGT  120 
 
QUERY  652   GGTGGGGGAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAA  711 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  121   GGTGGGGGAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAA  180 
 
QUERY  712   GTC-AGCAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCG  770 
             ||| | |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  181   GTCGA-CAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCG  239 
S239D (nt 715-717) 
 
QUERY  771   AAGCGGAGGTGGGGGACTCATGGAAGAGATGAACGCCATGCTGGCCCGGAGAAGGAAAGC  830 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  240   AAGCGGAGGTGGGGGACTCATGGAAGAGATGAACGCCATGCTGGCCCGGAGAAGGAAAGC  299 
 
QUERY  831   C-ACGCAAGTTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGG  889 
             | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  300   CGA-GCAAGTTGGGGAGAAAACCCCCAAGGATGAATCTGCCAATCAGGAGGAGCCAGAGG  358 
T278E (nt 832-834) 
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QUERY  890   CCAGAGTCCCGGCCCAGAGTGAATCTGTGCGGAGACCCTGGGAGAAGAACAGCACAACCT  949 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  359   CCAGAGTCCCGGCCCAGAGTGAATCTGTGCGGAGACCCTGGGAGAAGAACAGCACAACCT  418 
 
QUERY  950   TGCCAAGGATGAAGTCGTCTTCTTCGGTGACCACTTCCGAGACCCAACCCTGCACGCCCA  1009 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  419   TGCCAAGGATGAAGTCGTCTTCTTCGGTGACCACTTCCGAGACCCAACCCTGCACGCCCA  478 
 
QUERY  1010  GCTCCAGTGATTACTCGGA  1028 
             ||||||||||||||||||| 
SBJCT  479   GCTCCAGTGATTACTCGGA  497 
 
 
7.4.4 Sequencing of VASP-DDE∆FAB∆TD (in pcDNA3.1/V5-HisA) 
 
VASP-DDE∆FAB∆TD, T7-Fwd-sequence: 
CTTGGTACCGAGCTCGGATCCATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGAT
GATGGCAACAAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCACAA
CCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTGGTCATCAACTGTG
CCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCATCAGTGGCGCGACGCTCGCCAGGTC
TGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCCCAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGG
CGTTGGAAGGAGGTGGGCCCCCTCCACCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCC
GGAGGAGGTGGAGCAGCAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGACAA
TGCAGGAGGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCAGGT
CCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCAAGGGGGAGGACC
ACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGGAGCTGGGGCCCCAGGCCTGGC
CGCAGCTATTGCTGAAGCCAAACTCAGGAAAGTCGACAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCC
CCCAAAGCTGAGAGTGGTCGAAGCGAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGG
GCCCTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCA
TCACCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCC
TCCCCCGTGC 
 
VASP-DDE∆FAB∆TD, BGH-Rev-sequence (complementary): 
GCGGAACTTCCCCCTCCTCCAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAG
CGCACGGAGCAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGG
GAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGAAGCCAAACTCAGGAAAGTCGACAAGCAGGAGGA
GGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCGAATTCTGCAGATATCCAGCACAG
TGGCGGCCGCTCGAGTCTAGAGGGCCCTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCT
ACGCGTACCGGTCATCATCACCATCACCATTGA 
 
VASP-DDE∆FAB∆TD, sequence alignment with human VASP: 
 
Query:  human VASP 
Subject 1: VASP-DDE∆FAB∆TD, T7-Fwd-sequence 
Length:  998 nt 
Score = 1399 bits (757), Expect = 0.0, Identities = 773/777 (99%), Gaps = 3/777 (0%) 
 
QUERY  1    ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  22   ATGAGCGAGACGGTCATCTGTTCCAGCCGGGCCACTGTGATGCTTTATGATGATGGCAAC  81 
 
QUERY  61   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  82   AAGCGATGGCTCCCTGCTGGCACGGGTCCCCAGGCCTTCAGCCGCGTCCAGATCTACCAC  141 
 
QUERY  121  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  142  AACCCCACGGCCAATTCCTTTCGCGTCGTGGGCCGGAAGATGCAGCCCGACCAGCAGGTG  201 
 
QUERY  181  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  202  GTCATCAACTGTGCCATCGTCCGGGGTGTCAAGTATAACCAGGCCACCCCCAACTTCCAT  261 
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QUERY  241  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  262  CAGTGGCGCGACGCTCGCCAGGTCTGGGGCCTCAACTTCGGCAGCAAGGAGGATGCGGCC  321 
 
QUERY  301  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  322  CAGTTTGCCGCCGGCATGGCCAGTGCCCTAGAGGCGTTGGAAGGAGGTGGGCCCCCTCCA  381 
 
QUERY  361  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  382  CCCCCAGCACTTCCCACCTGGTCGGTCCCGAACGGCCCCTCCCCGGAGGAGGTGGAGCAG  441 
 
QUERY  421  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCTCCAATGCAGGA  480 
            ||||||||||||||||||||||||||||||||||||||||||||||||  |||||||||| 
SBJCT  442  CAGAAAAGGCAGCAGCCCGGCCCGTCGGAGCACATAGAGCGCCGGGTCGACAATGCAGGA  501 
S157D nt 469-471) 
 
QUERY  481  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  502  GGCCCACCTGCTCCCCCCGCTGGGGGTCCACCCCCACCACCAGGACCTCCCCCTCCTCCA  561 
 
QUERY  541  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  562  GGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGCAGCGCACGGAGCA  621 
 
QUERY  601  GGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGG  659 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  622  GGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCCTGGTGGTGGGGG  681 
 
QUERY  660  AGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTC-AGCA  718 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||| | || 
SBJCT  682  AGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAGGAAAGTCGA-CA  740 
  S239D (nt 715-717) 
 
QUERY  719  AGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCG  775 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  741  AGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTGGTCGAAGCG  797 
 
 
Query:  human VASP 
Subject 2: VASP-DDE∆FAB∆TD, BGH-Rev -sequence 
Length:  384 nt 
Score = 442 bits (239), Expect = 3e-128, Identities = 247/249 (98%), Gaps = 2/249 (0%) 
 
QUERY  528  TCCCCCTCCTCCAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGC  587 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  9    TCCCCCTCCTCCAGGTCCCCCCCCACCCCCAGGTTTGCCCCCTTCGGGGGTCCCAGCTGC  68 
 
QUERY  588  AGCGCACGGAGCAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCC  647 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  69   AGCGCACGGAGCAGGGGGAGGACCACCCCCTGCACCCCCTCTCCCGGCAGCACAGGGCCC  128 
 
QUERY  648  TGGTGGTGGGGGAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAG  707 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  129  TGGTGGTGGGGGAGCTGGGGCCCCAGGCCTGGCCGCAGCTATTGCTGGAGCCAAACTCAG  188 
 
QUERY  708  GAAAGTC-AGCAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTG  766 
            ||||||| | |||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  189  GAAAGTCGA-CAAGCAGGAGGAGGCCTCAGGGGGGCCCACAGCCCCCAAAGCTGAGAGTG  247 
S239D (nt 715-717) 
 
QUERY  767  GTCGAAGCG  775 
            ||||||||| 
SBJCT  248  GTCGAAGCG  256 
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7.5 Table 7.1: Data of the in vitro calpain in-solution digestion assay 
 
In silico vs in vitro determined calpain cleavage sites in human CLP36 protein. In vitro data were 
generated by in-solution digestion of recombinant human CLP36 via calpain-1 and calpain-2 (based 
on Lakey et al. [201]) and subsequent analysis on an LTQ-FT Ultra mass analyzer. MS data were 
searched for adjacent fragments fitting on either side of the indicated cleavage positions. In each 
case, the three fragments with the highest ion scores are displayed. In silico predicted yet non-
detected calpain cleavage sites, as well as unspecific fragmentation sites are shaded in grey. 
# in silico 
predicted site 
adjacent in vitro fragments as detected by 
LTQ-FT Ultra MS analysis 
ion score aa start-end 
1 Q9 Q.GPGPWGFRLVGGKDF.E 
Q.GPGPWGFRLV.G 
Q.GPGPWGFRLVGGKDF.E 
48 
55 
55 
010-024 
010-019 
010-024                    
2 F24 F.EQPLAISRVTPGSK.A 
F.EQPLAISRVTPGSK.A 
F.EQPLAISRVTPGSK.A 
Q.GPGPWGFRLVGGKDF.E   
Q.GPGPWGFRLVGGKDF.E   
Q.GPGPWGFRLVGGKDF.E   
39 
53 
59 
41 
48 
55 
025-038 
025-038 
025-038 
010-024 
010-024 
010-024               
3 R32 No   
4 V93 No   
5 H115 A.SEPQEVLH.I 
A.SEPQEVLH.I 
38 
47 
108-115 
108-115                
6 S123 E.PQEVLHIGSAHNRS.A 
A.SEPQEVLHIGSAHNRS.A   
A.SEPQEVLHIGSAHNRS.A   
S.AMPFTASPASSTT.A  
S.AMPFTASPASSTTARVIT.N 
S.AMPFTASPASSTTARVITNQY.N 
67 
89 
106 
77 
85 
93 
110-123 
108-123 
108-123               
124-136 
124-141 
124-144              
7 T128 T.ASPASSTTARVITN.Q     
T.ASPASSTTARVITNQY.N  
T.ASPASSTTARVITNQY.N   
52 
92 
96 
129-142 
129-144 
129-144                                  
8 T136 H.NRSAMPFTASPASSTT.A   
H.NRSAMPFTASPASSTT.A   
S.AMPFTASPASSTT.A   
T.ARVITNQYNNPAGLYSSE.N   
T.ARVITNQYNNPAGLYSSE.N   
T.ARVITNQYNNPAGLYSSENISNFNNALE.S 
70 
72 
77 
92 
98 
104 
121-136 
121-136 
124-136 
137-154 
137-154 
137-164 
9 V139 No   
10 T141 A.SPASSTTARVIT.N 
A.SPASSTTARVIT.N   
S.AMPFTASPASSTTARVIT.N   
T.NQYNNPAGLYSSENISNFNN.A   
T.NQYNNPAGLYSSENISNF.N   
T.NQYNNPAGLYSSENISNFN.N    
62 
70 
85 
97 
97 
100 
130-141 
130-141 
124-141 
142-161 
142-159   
142-160                                
11 Q143 F.TASPASSTTARVITNQ.Y   
A.SPASSTTARVITNQ.Y   
A.SPASSTTARVITNQ.Y   
78 
99 
107 
128-143 
130-143 
130-143                                        
12 Y144 S.AMPFTASPASSTTARVITNQY.N   
T.ASPASSTTARVITNQY.N   
F.TASPASSTTARVITNQY.N   
Y.NNPAGLYSSENISNFNNAL.E   
Y.NNPAGLYSSENISNFNNALE.S   
Y.NNPAGLYSSENISNFNNA.L   
93 
96 
98 
129 
132 
137 
124-144 
129-144 
128-144 
145-163  
145-164  
145-162                                          
13 Y151 Yes, yet also unspecific   
14 K166 Yes, yet also unspecific   
15 H181 K.TAASGVEANSRPLDH.A   
K.TAASGVEANSRPLDH.A   
K.TAASGVEANSRPLDH.A   
H.AQPPSSLVIDKESEVY.K   
74 
79 
96 
64 
167-181    
167-181 
167-181 
182-197 
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H.AQPPSSLVIDKESEVYK.M   
H.AQPPSSLVIDKESEVYK.M   
74 
78 
182-198 
182-198                                               
16 L217 L.NEPPKQSTSFL.V   41 207-217         
17 Q220 Yes, yet also unspecific   
18 R238 Q.EILESEEKGDPNKPSGFR.S   
Q.EILESEEKGDPNKPSGFR.S   
Q.EILESEEKGDPNKPSGFR.S 
47 
54 
58 
221-238  
221-238 
221-238                                        
19 K241 K.APVTKVAASIGNA.Q   
K.APVTKVAASIGN.A 
K.APVTKVAASIGN.A   
70 
71 
76 
242-254 
242-253 
242-253             
20 K246 R.SVKAPVTK.V   
K.VAASIGNAQK.L 
K.VAASIGNAQ.K     
K.VAASIGNAQ.K   
44 
63 
66 
69 
239-246 
247-256 
247-255     
247-255                      
21 A248 No   
22 R314 R.VTPPEGYEVVTVFPK.-   
R.VTPPEGYEVVTVFPK.-   
R.VTPPEGYEVVTVFPK.-   
75 
83 
93 
315-329 
315-329 
315-329                               
23 V315 No   
24 T325 A.RERVTPPEGYEVVT.V   
R.VTPPEGYEVVT.V   
R.VTPPEGYEVVT.V   
42 
42 
65 
312-325 
315-325   
315-325                      
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